Torsade B
de I
pointes I
ventricular B
tachycardia I
during O
low O
dose O
intermittent O
dobutamine O
treatment O
in O
a O
patient O
with O
dilated B
cardiomyopathy I
and O
congestive B
heart I
failure I
. O

The O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart B
failure I
secondary O
to O
dilated B
cardiomyopathy I
and O
absence O
of O
significant O
ventricular B
arrhythmias I
who O
developed O
QT B
prolongation I
and O
torsade B
de I
pointes I
ventricular B
tachycardia I
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O
5 O
mcg O
/ O
kg O
per O
min O
) O
dobutamine O
. O

After O
angiography O
by O
the O
venous O
route O
in O
patient O
n O
degree O
1 O
a O
biphasic O
reaction O
with O
an O
immediate O
reaction O
( O
dyspnea B
, O
loss B
of I
consciousness I
) O
and O
delayed O
macro B
- I
papular I
rash I
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
generalised O
sensation O
of O
heat O
, O
persistent O
pain B
at O
the O
site O
of O
injection O
immediately O
and O
a O
generalised O
macro O
- O
papular O
reaction O
after O
24 O
hours O
. O

Risk O
of O
transient O
hyperammonemic B
encephalopathy I
in O
cancer B
patients O
who O
received O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
with O
the O
complication O
of O
dehydration B
and O
infection B
. O

From O
1986 O
to O
1998 O
, O
29 O
cancer B
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic B
encephalopathy I
related O
to O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
were O
identified O
. O

None O
of O
the O
patients O
had O
decompensated O
liver B
disease I
. O

Onset O
of O
hyperammonemic B
encephalopathy I
varied O
from O
0 O
. O
5 O
to O
5 O
days O
( O
mean O
: O
2 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
days O
) O
after O
the O
initiation O
of O
chemotherapy O
. O

Among O
the O
32 O
episodes O
, O
26 O
( O
81 O
% O
) O
had O
various O
degrees O
of O
azotemia B
, O
18 O
( O
56 O
% O
) O
occurred O
during O
bacterial B
infections I
and O
14 O
( O
44 O
% O
) O
without O
infection B
occurred O
during O
periods O
of O
dehydration B
. O

Higher O
plasma O
ammonium O
levels O
and O
more O
rapid O
onset O
of O
hyperammonemia B
were O
seen O
in O
18 O
patients O
with O
bacterial B
infections I
( O
p O
= O
0 O
. O
003 O
and O
0 O
. O
0006 O
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
2600 O
or O
1800 O
mg O
/ O
m2 O
) O
of O
5 O
- O
FU O
( O
p O
= O
0 O
. O
0001 O
and O
< O
0 O
. O
0001 O
, O
respectively O
) O
. O

In O
conclusion O
, O
hyperammonemic B
encephalopathy I
can O
occur O
in O
patients O
receiving O
continuous O
infusion O
of O
5 O
- O
FU O
. O

Azotemia B
, O
body O
fluid O
insufficiency O
and O
bacterial B
infections I
were O
frequently O
found O
in O
these O
patients O
. O

Nociceptin O
/ O
orphanin O
FQ O
and O
nocistatin O
on O
learning B
and I
memory I
impairment I
induced O
by O
scopolamine O
in O
mice O
. O

The O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin O
/ O
orphanin O
FQ O
and O
nocistatin O
could O
modulate O
impairment B
of I
learning I
and I
memory I
induced O
by O
scopolamine O
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
Y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

Meloxicam O
- O
induced O
liver B
toxicity I
. O

We O
report O
the O
case O
of O
a O
female O
patient O
with O
rheumatoid B
arthritis I
who O
developed O
acute O
cytolytic O
hepatitis B
due O
to O
meloxicam O
. O

The O
acute O
cytolytic O
hepatitis B
occurred O
rapidly O
after O
meloxicam O
administration O
and O
was O
associated O
with O
the O
development O
of O
antinuclear O
antibodies O
suggesting O
a O
hypersensitivity B
mechanism O
. O

This O
first O
case O
of O
meloxicam O
related O
liver B
toxicity I
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
hepatic B
damage I
. O

Induction O
of O
apoptosis O
by O
remoxipride O
metabolites O
in O
HL60 O
and O
CD34 O
+ O
/ O
CD19 O
- O
human O
bone O
marrow O
progenitor O
cells O
: O
potential O
relevance O
to O
remoxipride O
- O
induced O
aplastic B
anemia I
. O

The O
antipsychotic O
agent O
, O
remoxipride O
[ O
( O
S O
) O
- O
( O
- O
) O
- O
3 O
- O
bromo O
- O
N O
- O
[ O
( O
1 O
- O
ethyl O
- O
2 O
- O
pyrrolidinyl O
) O
methyl O
] O
- O
2 O
, O
6 O
- O
dimethoxybenz O
amide O
] O
has O
been O
associated O
with O
acquired O
aplastic B
anemia I
. O

We O
propose O
that O
remoxipride O
and O
benzene O
may O
induce O
aplastic B
anemia I
via O
production O
of O
similar O
reactive O
metabolites O
and O
that O
the O
ability O
of O
NCQ436 O
and O
NCQ344 O
to O
induce O
apoptosis O
in O
HBMP O
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
aplastic B
anemia I
that O
has O
been O
associated O
with O
remoxipride O
. O

Prolonged O
left B
ventricular I
dysfunction I
occurs O
in O
patients O
with O
coronary B
artery I
disease I
after O
both O
dobutamine O
and O
exercise O
induced O
myocardial B
ischaemia I
. O

OBJECTIVE O
: O
To O
determine O
whether O
pharmacological O
stress O
leads O
to O
prolonged O
but O
reversible O
left B
ventricular I
dysfunction I
in O
patients O
with O
coronary B
artery I
disease I
, O
similar O
to O
that O
seen O
after O
exercise O
. O

SUBJECTS O
: O
10 O
patients O
with O
stable B
angina I
, O
angiographically O
proven O
coronary B
artery I
disease I
, O
and O
normal O
left O
ventricular O
function O
. O

CONCLUSIONS O
: O
In O
patients O
with O
coronary B
artery I
disease I
, O
dobutamine O
induced O
ischaemia B
results O
in O
prolonged O
reversible O
left B
ventricular I
dysfunction I
, O
presumed O
to O
be O
myocardial B
stunning I
, O
similar O
to O
that O
seen O
after O
exercise O
. O

Dobutamine O
induced O
ischaemia B
could O
therefore O
be O
used O
to O
study O
the O
pathophysiology O
of O
this O
phenomenon O
further O
in O
patients O
with O
coronary B
artery I
disease I
. O

BACKGROUND O
: O
The O
use O
of O
appetite O
suppressants O
in O
Europe O
has O
been O
associated O
with O
the O
development O
of O
primary B
pulmonary I
hypertension I
( O
PPH B
) O
. O

Clinical O
aspects O
of O
heparin O
- O
induced O
thrombocytopenia B
and O
thrombosis B
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

Heparin O
, O
first O
used O
to O
prevent O
the O
clotting O
of O
blood O
in O
vitro O
, O
has O
been O
clinically O
used O
to O
treat O
thrombosis B
for O
more O
than O
50 O
years O
. O

However O
, O
additional O
important O
untoward O
effects O
of O
heparin O
therapy O
include O
heparin O
- O
induced O
thrombocytopenia B
, O
heparin O
- O
associated O
osteoporosis B
, O
eosinophilia B
, O
skin B
reactions I
, O
allergic B
reactions I
other O
than O
thrombocytopenia B
, O
alopecia B
, O
transaminasemia O
, O
hyperkalemia B
, O
hypoaldosteronism B
, O
and O
priapism B
. O

A O
case O
of O
bilateral O
optic B
neuropathy I
in O
a O
patient O
on O
tacrolimus O
( O
FK506 O
) O
therapy O
after O
liver O
transplantation O
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
bilateral O
optic B
neuropathy I
in O
a O
patient O
receiving O
tacrolimus O
( O
FK O
506 O
, O
Prograf O
; O
Fujisawa O
USA O
, O
Inc O
, O
Deerfield O
, O
Illinois O
) O
for O
immunosuppression O
after O
orthotropic O
liver O
transplantation O
. O

RESULTS O
: O
The O
patient O
had O
episodic O
deterioration O
of O
vision O
in O
both O
eyes O
, O
with O
clinical O
features O
resembling O
ischemic B
optic I
neuropathies I
. O

Deterioration B
of I
vision I
occurred O
despite O
discontinuation O
of O
the O
tacrolimus O
. O

CONCLUSION O
: O
Tacrolimus O
and O
other O
immunosuppressive O
agents O
may O
be O
associated O
with O
optic B
nerve I
toxicity I
. O

Recent O
findings O
in O
a O
bipolar B
patient O
receiving O
maintenance O
lithium O
therapy O
who O
developed O
hypercalcemia B
and O
severe O
bradyarrhythmia B
prompted O
the O
authors O
to O
conduct O
a O
retrospective O
study O
of O
bipolar B
patients O
with O
lithium O
- O
associated O
hypercalcemia B
. O

Thus O
, O
two O
control O
groups O
were O
generated O
: O
group O
C1 O
, O
which O
included O
age O
- O
and O
sex O
- O
comparable O
lithium O
- O
treated O
bipolar B
normocalcemic O
patients O
, O
and O
group O
C2 O
, O
which O
included O
bipolar B
normocalcemic O
patients O
treated O
with O
anticonvulsant O
mood O
stabilizers O
. O

Patients O
with O
hypercalcemia B
resulting O
from O
medical O
diseases O
and O
bipolar B
patients O
with O
lithium O
- O
associated O
hypercalcemia B
had O
significantly O
higher O
frequencies O
of O
conduction O
defects O
. O

Patterns O
of O
sulfadiazine O
acute B
nephrotoxicity I
. O

Sulfadiazine O
acute B
nephrotoxicity I
is O
reviving O
specially O
because O
of O
its O
use O
in O
toxoplasmosis B
in O
HIV O
- O
positive O
patients O
. O

Under O
treatment O
with O
sulfadiazine O
they O
developed O
oliguria B
, O
abdominal B
pain I
, O
renal B
failure I
and O
showed O
multiple O
radiolucent O
renal B
calculi I
in O
echography O
. O

Phase O
2 O
trial O
of O
liposomal O
doxorubicin O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
platinum O
/ O
paclitaxel O
- O
refractory O
ovarian B
and I
fallopian I
tube I
cancers I
and O
primary O
carcinoma B
of I
the I
peritoneum I
. O

BACKGROUND O
: O
Several O
studies O
have O
demonstrated O
liposomal O
doxorubicin O
( O
Doxil O
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum O
- O
resistant O
ovarian B
cancer I
, O
with O
dose O
limiting O
toxicity B
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia B
( O
" O
hand B
- I
foot I
syndrome I
" O
) O
and O
stomatitis B
. O

METHODS O
AND O
MATERIALS O
: O
Patients O
with O
ovarian B
or I
fallopian I
tube I
cancers I
or O
primary O
peritoneal B
carcinoma I
with O
platinum O
/ O
paclitaxel O
- O
refractory O
disease O
( O
stable O
or O
progressive O
disease O
following O
treatment O
with O
these O
agents O
or O
previous O
objective O
response O
< O
3 O
months O
in O
duration O
) O
were O
treated O
with O
liposomal O
doxorubicin O
at O
a O
dose O
of O
40 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
. O

Six O
( O
12 O
% O
) O
and O
4 O
( O
8 O
% O
) O
patients O
experienced O
grade O
2 O
hand B
- I
foot I
syndrome I
and O
stomatitis B
, O
respectively O
( O
no O
episodes O
of O
grade O
3 O
) O
. O

One O
patient O
developed O
grade O
3 O
diarrhea B
requiring O
hospitalization O
for O
hydration O
. O

CONCLUSION O
: O
This O
modified O
liposomal O
doxorubicin O
regimen O
results O
in O
less O
toxicity B
( O
stomatitis B
, O
hand B
- I
foot I
syndrome I
) O
than O
the O
standard O
FDA O
- O
approved O
dose O
schedule O
. O

Definite O
, O
although O
limited O
, O
antineoplastic O
activity O
is O
observed O
in O
patients O
with O
well O
- O
defined O
platinum O
- O
and O
paclitaxel O
- O
refractory O
ovarian B
cancer I
. O

Efficacy O
of O
olanzapine O
in O
acute O
bipolar B
mania I
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
. O

BACKGROUND O
: O
We O
compared O
the O
efficacy O
and O
safety O
of O
olanzapine O
vs O
placebo O
for O
the O
treatment O
of O
acute O
bipolar B
mania I
. O

A O
total O
of O
115 O
patients O
with O
a O
DSM O
- O
IV O
diagnosis O
of O
bipolar B
disorder I
, O
manic B
or O
mixed O
, O
were O
randomized O
to O
olanzapine O
, O
5 O
to O
20 O
mg O
/ O
d O
( O
n O
= O
55 O
) O
, O
or O
placebo O
( O
n O
= O
60 O
) O
. O

CONCLUSION O
: O
Olanzapine O
demonstrated O
greater O
efficacy O
than O
placebo O
in O
the O
treatment O
of O
acute O
bipolar B
mania I
and O
was O
generally O
well O
tolerated O
. O

A O
case O
of O
isotretinoin B
embryopathy I
with O
bilateral O
anotia B
and O
Taussig B
- I
Bing I
malformation I
. O

We O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia B
and O
Taussig B
- I
Bing I
malformation I
) O
due O
to O
exposure O
to O
isotretinoin O
within O
the O
first O
trimester O
. O

The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
potential O
role O
for O
a O
selective O
alpha1 O
- O
adrenoceptor O
agonist O
in O
the O
treatment O
of O
urinary B
stress I
incontinence I
. O

Methoxamine O
evoked O
non O
- O
significant O
increases O
in O
MUP O
and O
diastolic O
blood O
pressure O
but O
caused O
a B
significant I
rise I
in I
systolic I
blood I
pressure I
and O
significant O
fall O
in O
heart O
rate O
at O
maximum O
dosage O
. O

Toleration O
of O
high O
doses O
of O
angiotensin O
- O
converting O
enzyme O
inhibitors O
in O
patients O
with O
chronic O
heart B
failure I
: O
results O
from O
the O
ATLAS O
trial O
. O

BACKGROUND O
: O
Treatment O
with O
angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
reduces O
mortality O
and O
morbidity O
in O
patients O
with O
chronic O
heart B
failure I
( O
CHF B
) O
, O
but O
most O
affected O
patients O
are O
not O
receiving O
these O
agents O
or O
are O
being O
treated O
with O
doses O
lower O
than O
those O
found O
to O
be O
efficacious O
in O
trials O
, O
primarily O
because O
of O
concerns O
about O
the O
safety O
and O
tolerability O
of O
these O
agents O
, O
especially O
at O
the O
recommended O
doses O
. O

We O
examined O
the O
occurrence O
of O
adverse O
events O
and O
the O
need O
for O
discontinuation O
and O
dose O
reduction O
during O
treatment O
, O
with O
a O
focus O
on O
hypotension B
and O
renal B
dysfunction I
. O

RESULTS O
: O
Of O
405 O
patients O
not O
previously O
receiving O
an O
ACE O
inhibitor O
, O
doses O
in O
only O
4 O
. O
2 O
% O
could O
not O
be O
titrated O
to O
the O
medium O
doses O
required O
for O
randomization O
because O
of O
symptoms O
possibly O
related O
to O
hypotension B
( O
2 O
. O
0 O
% O
) O
or O
because O
of O
renal B
dysfunction I
or O
hyperkalemia B
( O
2 O
. O
3 O
% O
) O
. O

Subgroups O
presumed O
to O
be O
at O
higher O
risk O
for O
ACE O
inhibitor O
intolerance O
( O
blood O
pressure O
, O
< O
120 O
mm O
Hg O
; O
creatinine O
, O
> O
or O
= O
132 O
. O
6 O
micromol O
/ O
L O
[ O
> O
or O
= O
1 O
. O
5 O
mg O
/ O
dL O
] O
; O
age O
, O
> O
or O
= O
70 O
years O
; O
and O
patients O
with O
diabetes B
) O
generally O
tolerated O
the O
high O
- O
dose O
strategy O
. O

Cocaine O
, O
ethanol O
, O
and O
cocaethylene O
cardiotoxity B
in O
an O
animal O
model O
of O
cocaine B
and I
ethanol I
abuse I
. O

OBJECTIVES O
: O
Simultaneous O
abuse B
of I
cocaine I
and I
ethanol I
affects O
12 O
million O
Americans O
annually O
. O

Their O
combined O
cardiac B
toxicity I
may O
be O
due O
to O
independent O
effects O
of O
each O
drug O
; O
however O
, O
they O
may O
also O
be O
due O
to O
cocaethylene O
( O
CE O
) O
, O
a O
cocaine O
metabolite O
formed O
only O
in O
the O
presence O
of O
ethanol O
. O

RESULTS O
: O
Two O
of O
eight O
dogs O
in O
the O
C O
+ O
E O
group O
experienced O
cardiovascular B
collapse I
. O

Peak O
CE O
levels O
were O
associated O
with O
a O
45 O
% O
( O
SD O
+ O
/ O
- O
22 O
% O
, O
95 O
% O
CI O
= O
22 O
% O
to O
69 O
% O
) O
decrease B
in I
cardiac I
output I
( O
p O
< O
0 O
. O
05 O
) O
, O
a O
56 O
% O
( O
SD O
+ O
/ O
- O
23 O
% O
, O
95 O
% O
CI O
= O
32 O
% O
to O
80 O
% O
) O
decrease O
in O
dP O
/ O
dt O
( O
max O
) O
( O
p O
< O
. O
006 O
) O
, O
and O
a O
23 O
% O
( O
SD O
+ O
/ O
- O
15 O
% O
, O
95 O
% O
CI O
= O
7 O
% O
to O
49 O
% O
) O
decrease O
in O
SVO O
( O
2 O
) O
( O
p O
< O
0 O
. O
025 O
) O
. O

Co O
- O
administration O
resulted O
in O
prolonged O
cardiac B
toxicity I
and O
was O
dysrhythmogenic O
. O

We O
describe O
a O
female O
patient O
with O
stable O
Parkinson B
' I
s I
disease I
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride O
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

A O
group O
of O
doctors O
in O
Boston O
warn O
that O
the O
protease O
inhibitor O
Viracept O
may O
cause O
an O
irregular B
heart I
beat I
, O
known O
as O
bradycardia B
, O
in O
people O
with O
HIV O
. O

Frequency O
of O
appearance O
of O
myeloperoxidase O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
in O
Graves B
' I
disease I
patients O
treated O
with O
propylthiouracil O
and O
the O
relationship O
between O
MPO O
- O
ANCA O
and O
clinical O
manifestations O
. O

OBJECTIVE O
: O
Myeloperoxidase O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
- O
positive O
vasculitis B
has O
been O
reported O
in O
patients O
with O
Graves B
' I
disease I
who O
were O
treated O
with O
propylthiouracil O
( O
PTU O
) O
. O

Nevertheless O
, O
there O
have O
been O
no O
studies O
on O
the O
temporal O
relationship O
between O
the O
appearance O
of O
MPO O
- O
ANCA O
and O
vasculitis B
during O
PTU O
therapy O
, O
or O
on O
the O
incidence O
of O
MPO O
- O
ANCA O
in O
untreated O
Graves B
' I
disease I
patients O
. O

Therefore O
, O
we O
sought O
to O
address O
these O
parameters O
in O
patients O
with O
Graves B
' I
disease I
. O

PATIENTS O
: O
We O
investigated O
102 O
untreated O
patients O
with O
hyperthyroidism B
due O
to O
Graves B
' I
disease I
for O
the O
presence O
of O
MPO O
- O
ANCA O
, O
and O
for O
the O
development O
vasculitis B
after O
starting O
PTU O
therapy O
. O

RESULTS O
: O
Before O
treatment O
, O
the O
MPO O
- O
ANCA O
titres O
of O
all O
102 O
untreated O
Graves B
' I
disease I
patients O
were O
within O
the O
reference O
range O
( O
below O
10 O
U O
/ O
ml O
) O
. O

In O
two O
of O
them O
, O
the O
MPO O
- O
ANCA O
titres O
transiently O
increased O
to O
12 O
. O
8 O
and O
15 O
. O
0 O
U O
/ O
ml O
, O
respectively O
, O
despite O
continued O
PTU O
therapy O
, O
but O
no O
vasculitic B
disorders I
developed O
. O

In O
the O
third O
patient O
, O
the O
MPO O
- O
ANCA O
titre O
increased O
to O
204 O
U O
/ O
ml O
and O
she O
developed O
a O
higher O
fever B
, O
oral B
ulcers I
and O
polyarthralgia B
, O
but O
the O
symptoms O
resolved O
2 O
weeks O
after O
stopping O
PTU O
therapy O
, O
and O
the O
MPO O
- O
ANCA O
titre O
decreased O
to O
20 O
. O
7 O
U O
/ O
ml O
by O
4 O
months O
after O
discontinuing O
PTU O
. O

CONCLUSIONS O
: O
PTU O
therapy O
may O
be O
related O
to O
the O
appearance O
of O
MPO O
- O
ANCA O
, O
but O
MPO O
- O
ANCA O
does O
not O
appear O
to O
be O
closely O
related O
to O
vasculitis B
. O

Prevalence O
of O
heart B
disease I
in O
asymptomatic O
chronic O
cocaine O
users O
. O

To O
determine O
the O
prevalence O
of O
heart B
disease I
in O
outpatient O
young O
asymptomatic O
chronic O
cocaine O
users O
, O
35 O
cocaine O
users O
and O
32 O
age O
- O
matched O
controls O
underwent O
resting O
and O
exercise O
electrocardiography O
( O
ECG O
) O
and O
Doppler O
echocardiography O
. O

Findings O
consistent O
with O
coronary B
artery I
disease I
were O
detected O
in O
12 O
( O
34 O
% O
) O
patients O
and O
3 O
( O
9 O
% O
) O
controls O
( O
p O
= O
0 O
. O
01 O
) O
. O

Finally O
, O
resting O
and O
peak O
exercise O
abnormal B
left I
ventricular I
filling I
was O
detected O
in O
38 O
and O
35 O
% O
of O
patients O
as O
compared O
to O
19 O
and O
9 O
% O
of O
controls O
, O
respectively O
( O
p O
= O
0 O
. O
11 O
and O
0 O
. O
02 O
, O
respectively O
) O
. O

We O
conclude O
that O
coronary B
artery I
or I
myocardial I
disease I
is O
common O
( O
38 O
% O
) O
in O
young O
asymptomatic O
chronic O
cocaine O
users O
. O

Phase O
2 O
early O
afterdepolarization O
as O
a O
trigger O
of O
polymorphic O
ventricular B
tachycardia I
in O
acquired O
long B
- I
QT I
syndrome I
: O
direct O
evidence O
from O
intracellular O
recordings O
in O
the O
intact O
left O
ventricular O
wall O
. O

PURPOSE O
: O
Prenatal O
cocaine O
exposure O
has O
been O
linked O
with O
subependymal O
hemorrhage B
and O
the O
formation O
of O
cysts B
that O
are O
detectable O
on O
cranial O
sonography O
in O
neonates O
born O
at O
term O
. O

We O
sought O
to O
determine O
if O
prenatal O
cocaine O
exposure O
increases O
the O
incidence O
of O
subependymal B
cysts I
in O
preterm B
infants I
. O

METHODS O
: O
We O
retrospectively O
reviewed O
the O
medical O
records O
and O
cranial O
sonograms O
obtained O
during O
a O
1 O
- O
year O
period O
on O
122 O
premature B
( I
< I
36 I
weeks I
of I
gestation I
) I
infants I
. O

The O
incidence O
of O
subependymal B
cysts I
in O
the O
117 O
remaining O
infants O
was O
14 O
% O
( O
16 O
of O
117 O
) O
. O

The O
incidence O
of O
subependymal B
cysts I
in O
infants O
exposed O
to O
cocaine O
prenatally O
was O
44 O
% O
( O
8 O
of O
18 O
) O
compared O
with O
8 O
% O
( O
8 O
of O
99 O
) O
in O
the O
unexposed O
group O
( O
p O
< O
0 O
. O
01 O
) O
. O

Thalidomide O
neuropathy B
in O
patients O
treated O
for O
metastatic O
prostate B
cancer I
. O

Sixty O
- O
seven O
men O
with O
metastatic O
androgen O
- O
independent O
prostate B
cancer I
in O
an O
open O
- O
label O
trial O
of O
oral O
thalidomide O
underwent O
neurologic O
examinations O
and O
nerve O
conduction O
studies O
( O
NCS O
) O
prior O
to O
and O
at O
3 O
- O
month O
intervals O
during O
treatment O
. O

The O
SNAP O
index O
can O
be O
used O
to O
monitor O
peripheral B
neuropathy I
, O
but O
not O
for O
early O
detection O
. O

Overexpression O
of O
copper O
/ O
zinc O
- O
superoxide O
dismutase O
protects O
from O
kanamycin O
- O
induced O
hearing B
loss I
. O

Fatty B
liver I
induced O
by O
tetracycline O
in O
the O
rat O
. O

Dose O
- O
response O
relationships O
, O
biochemical O
mechanisms O
, O
and O
sex O
differences O
in O
the O
experimental O
fatty B
liver I
induced O
by O
tetracycline O
were O
studied O
in O
the O
intact O
rat O
and O
with O
the O
isolated O
perfused O
rat O
liver O
in O
vitro O
. O

Depressed O
hepatic O
secretion O
of O
triglyceride O
accounted O
only O
for O
30 O
to O
50 O
% O
of O
accumulated O
hepatic O
triglyceride O
, O
indicating O
that O
additional O
mechanisms O
must O
be O
involved O
in O
the O
production O
of O
the O
triglyceride O
- O
rich O
fatty B
liver I
in O
response O
to O
tetracycline O
. O

Prednisone O
induces O
anxiety B
and O
glial O
cerebral O
changes O
in O
rats O
. O

OBJECTIVE O
: O
To O
assess O
whether O
prednisone O
( O
PDN O
) O
produces O
anxiety B
and O
/ O
or O
cerebral O
glial O
changes O
in O
rats O
. O

CONCLUSION O
: O
Subacute O
exposure O
to O
PDN O
induced O
anxiety B
and O
reactivity O
of O
microglia O
. O

Phase O
II O
study O
of O
carboplatin O
and O
liposomal O
doxorubicin O
in O
patients O
with O
recurrent O
squamous B
cell I
carcinoma I
of I
the I
cervix I
. O

BACKGROUND O
: O
The O
activity O
of O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
was O
tested O
in O
a O
Phase O
II O
study O
of O
patients O
with O
recurrent O
cervical B
carcinoma I
. O

METHODS O
: O
The O
combination O
of O
carboplatin O
( O
area O
under O
the O
concentration O
curve O
[ O
AUC O
] O
, O
5 O
) O
and O
liposomal O
doxorubicin O
( O
Doxil O
; O
starting O
dose O
, O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
was O
administered O
intravenously O
every O
28 O
days O
to O
37 O
patients O
with O
recurrent O
squamous B
cell I
cervical I
carcinoma I
to O
determine O
antitumor O
activity O
and O
toxicity B
profile O
. O

The O
main O
toxic O
effect O
was O
myelosuppression B
, O
with O
Grade O
3 O
and O
4 O
neutropenia B
in O
16 O
patients O
, O
anemia B
in O
12 O
patients O
, O
thrombocytopenia B
in O
11 O
patients O
, O
and O
neutropenic B
fever I
in O
3 O
patients O
. O

Grade O
> O
or O
= O
2 O
nonhematologic O
toxicity B
included O
nausea B
in O
17 O
patients O
, O
emesis B
in O
14 O
patients O
, O
fatigue B
in O
9 O
patients O
, O
mucositis B
and O
/ O
or O
stomatitis B
in O
8 O
patients O
, O
constipation B
in O
6 O
patients O
, O
weight B
loss I
in O
5 O
patients O
, O
hand B
- I
foot I
syndrome I
in O
2 O
patients O
, O
and O
skin B
reactions I
in O
3 O
patients O
. O

CONCLUSIONS O
: O
The O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
has O
modest O
activity O
in O
patients O
with O
recurrent O
cervical B
carcinoma I
. O

Levodopa O
- O
induced O
ocular B
dyskinesias I
in O
Parkinson B
' I
s I
disease I
. O

Levodopa O
- O
induced O
ocular B
dyskinesias I
are O
very O
uncommon O
. O

We O
report O
on O
a O
patient O
with O
leftward O
and O
upward O
deviations O
of O
gaze O
during O
the O
peak O
effect O
of O
levodopa O
, O
and O
hypothesize O
that O
a O
severe O
dopaminergic O
denervation O
in O
the O
caudate O
nucleus O
is O
needed O
for O
the O
appearance O
of O
these O
levodopa O
- O
induce O
ocular B
dyskinesias I
. O

Low B
back I
pain I
was O
also O
relieved O
by O
both O
drugs O
. O

Temocapril O
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin O
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular B
injury I
in O
chronic O
puromycin O
aminonucleoside O
nephrosis B
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril O
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
, O
reduced O
proteinuria B
, O
inhibited O
glomerular O
hypertrophy B
and O
prevented O
glomerulosclerosis B
in O
chronic O
puromycin O
aminonucleoside O
( O
PAN O
) O
- O
induced O
nephrotic B
rats O
. O

Temocapril O
did O
not O
attenuate O
proteinuria B
at O
8 O
days O
, O
but O
it O
did O
markedly O
lower O
it O
from O
weeks O
4 O
to O
20 O
. O

The O
glomerulosclerosis B
index O
( O
GSI O
) O
was O
6 O
. O
21 O
% O
at O
4 O
weeks O
and O
respectively O
25 O
. O
35 O
% O
and O
30 O
. O
49 O
% O
at O
14 O
and O
20 O
weeks O
in O
the O
PAN O
group O
. O

Hyponatremia B
and O
syndrome B
of I
inappropriate I
anti I
- I
diuretic I
hormone I
reported O
with O
the O
use O
of O
Vincristine O
: O
an O
over O
- O
representation O
of O
Asians O
? O

PURPOSE O
: O
This O
retrospective O
study O
used O
a O
pharmaceutical O
company O
' O
s O
global O
safety O
database O
to O
determine O
the O
reporting O
rate O
of O
hyponatremia B
and O
/ O
or O
syndrome B
of I
inappropriate I
secretion I
of I
anti I
- I
diuretic I
hormone I
( O
SIADH B
) O
among O
vincristine O
- O
treated O
patients O
and O
to O
explore O
the O
possibility O
of O
at O
- O
risk O
population O
subgroups O
. O

Approximately O
75 O
% O
of O
the O
patients O
were O
receiving O
treatment O
for O
leukemia B
or O
lymphoma B
. O

Early O
CY O
toxicity B
caused O
a O
typical O
haemorrhagic B
cystitis B
in O
both O
strains O
that O
was O
completely O
repaired O
in O
about O
7 O
- O
10 O
days O
. O

High O
- O
dose O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
in O
combination O
with O
three O
- O
weekly O
mitomycin O
C O
in O
the O
treatment O
of O
advanced O
gastric B
cancer I
. O

BACKGROUND O
: O
The O
24 O
- O
hour O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
and O
folinic O
acid O
( O
FA O
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric B
cancer I
( O
AGC B
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity B
. O

The O
worst O
toxicities B
( O
% O
) O
observed O
were O
( O
CTC O
- O
NCI O
1 O
/ O
2 O
/ O
3 O
) O
: O
leukopenia B
45 O
. O
5 O
/ O
18 O
. O
2 O
/ O
6 O
. O
1 O
, O
thrombocytopenia B
33 O
. O
3 O
/ O
9 O
. O
1 O
/ O
6 O
. O
1 O
, O
vomitus B
24 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
diarrhea B
36 O
. O
4 O
/ O
6 O
. O
1 O
/ O
3 O
. O
0 O
, O
stomatitis B
18 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
hand B
- I
foot I
syndrome I
12 O
. O
1 O
/ O
0 O
/ O
0 O
. O

Two O
patients O
developed O
hemolytic B
- I
uremic I
syndrome I
( O
HUS B
) O
. O

Persistent O
sterile O
leukocyturia B
is O
associated O
with O
impaired B
renal I
function I
in O
human B
immunodeficiency I
virus I
type I
1 I
- I
infected I
children O
treated O
with O
indinavir O
. O

DESIGN O
: O
A O
prospective O
study O
to O
monitor O
indinavir O
- O
related O
nephrotoxicity B
in O
a O
cohort O
of O
30 O
human B
immunodeficiency I
virus I
type I
1 I
- I
infected I
children O
treated O
with O
indinavir O
. O

The O
impairment B
of I
the I
renal I
function I
in O
these O
children O
occurred O
in O
the O
absence O
of O
clinical O
symptoms O
of O
nephrolithiasis B
. O

Outcomes O
included O
CK O
- O
MB O
MI B
( O
CK O
- O
MB O
> O
or O
= O
8 O
ng O
/ O
mL O
with O
a O
relative O
index O
[ O
( O
CK O
- O
MB O
x O
100 O
) O
/ O
total O
CK O
] O
> O
or O
= O
4 O
, O
cardiac B
death I
, O
and O
significant O
coronary B
disease I
( O
> O
or O
= O
50 O
% O
) O
. O

Sensitivities O
, O
specificities O
, O
and O
positive O
and O
negative O
likelihood O
ratios O
for O
predicting O
cardiac B
death I
or O
significant O
disease O
were O
high O
for O
both O
CK O
- O
MB O
MI B
and O
cTnI O
and O
were O
not O
significantly O
different O
. O

A O
50 O
- O
year O
- O
old O
patient O
admitted O
to O
our O
hospital O
for O
fever B
and O
acute B
renal I
failure I
. O

Before O
admission O
, O
he O
had O
been O
taking O
nicergoline O
and O
bendazac O
lysine O
due O
to O
retinal B
vein I
occlusion I
at O
ophthalmologic O
department O
. O

Thereafter O
, O
he O
experienced O
intermittent O
fever B
and O
skin B
rash I
. O

On O
admission O
, O
clinical O
symptoms O
( O
i O
. O
e O
. O
arthralgia B
and O
fever B
) O
and O
laboratory O
findings O
( O
i O
. O
e O
. O
eosinophilia B
and O
renal B
failure I
) O
suggested O
AIN B
, O
and O
which O
was O
confirmed O
by O
pathologic O
findings O
on O
renal O
biopsy O
. O

Neuroleptic B
malignant I
syndrome I
complicated O
by O
massive O
intestinal O
bleeding B
in O
a O
patient O
with O
chronic B
renal I
failure I
. O

A O
patient O
with O
chronic B
renal I
failure I
( O
CRF B
) O
developed O
neuroleptic B
malignant I
syndrome I
( O
NMS B
) O
after O
administration O
of O
risperidone O
and O
levomepromazine O
. O

Similar O
results O
were O
obtained O
in O
seizure B
- O
induced O
breakdown O
of O
BBB O
. O

Carvedilol O
protects O
against O
doxorubicin O
- O
induced O
mitochondrial O
cardiomyopathy B
. O

Several O
cytopathic O
mechanisms O
have O
been O
suggested O
to O
mediate O
the O
dose O
- O
limiting O
cumulative O
and O
irreversible O
cardiomyopathy B
caused O
by O
doxorubicin O
. O

Recent O
evidence O
indicates O
that O
oxidative O
stress O
and O
mitochondrial B
dysfunction I
are O
key O
factors O
in O
the O
pathogenic O
process O
. O

It O
is O
concluded O
that O
this O
protection O
by O
carvedilol O
against O
both O
the O
structural O
and O
functional O
cardiac O
tissue O
damage O
may O
afford O
significant O
clinical O
advantage O
in O
minimizing O
the O
dose O
- O
limiting O
mitochondrial B
dysfunction I
and O
cardiomyopathy B
that O
accompanies O
long O
- O
term O
doxorubicin O
therapy O
in O
cancer B
patients O
. O

All O
adenosine O
receptor O
agonists O
significantly O
decreased B
the I
locomotor I
activity I
in O
mice O
, O
and O
the O
effects O
were O
dose O
- O
dependent O
. O

Amiodarone O
and O
the O
risk O
of O
bradyarrhythmia B
requiring O
permanent O
pacemaker O
in O
elderly O
patients O
with O
atrial B
fibrillation I
and O
prior O
myocardial B
infarction I
. O

OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
amiodarone O
in O
patients O
with O
atrial B
fibrillation I
( O
AF B
) O
increases O
the O
risk O
of O
bradyarrhythmia B
requiring O
a O
permanent O
pacemaker O
. O

An O
open O
- O
label O
phase O
II O
study O
of O
low O
- O
dose O
thalidomide O
in O
androgen O
- O
independent O
prostate B
cancer I
. O

The O
antiangiogenic O
effects O
of O
thalidomide O
have O
been O
assessed O
in O
clinical O
trials O
in O
patients O
with O
various O
solid O
and O
haematological B
malignancies I
. O

We O
undertook O
an O
open O
- O
label O
study O
using O
thalidomide O
100 O
mg O
once O
daily O
for O
up O
to O
6 O
months O
in O
20 O
men O
with O
androgen O
- O
independent O
prostate B
cancer I
. O

Evidence O
of O
peripheral B
sensory I
neuropathy I
was O
found O
in O
nine O
of O
13 O
men O
before O
treatment O
. O

In O
the O
seven O
men O
who O
completed O
six O
months O
on O
thalidomide O
, O
subclinical O
evidence O
of O
peripheral B
neuropathy I
was O
found O
in O
four O
before O
treatment O
, O
but O
in O
all O
seven O
at O
repeat O
testing O
. O

The O
findings O
indicate O
that O
thalidomide O
may O
be O
an O
option O
for O
patients O
who O
have O
failed O
other O
forms O
of O
therapy O
, O
provided O
close O
follow O
- O
up O
is O
maintained O
for O
development O
of O
peripheral B
neuropathy I
. O

Central B
nervous I
system I
toxicity I
following O
the O
administration O
of O
levobupivacaine O
for O
lumbar O
plexus O
block O
: O
A O
report O
of O
two O
cases O
. O

BACKGROUND O
AND O
OBJECTIVES O
: O
Central B
nervous I
system I
and I
cardiac I
toxicity I
following O
the O
administration O
of O
local O
anesthetics O
is O
a O
recognized O
complication O
of O
regional O
anesthesia O
. O

We O
describe O
2 O
cases O
of O
grand B
mal I
seizures I
following O
accidental O
intravascular O
injection O
of O
levobupivacaine O
. O

Immediately O
after O
the O
administration O
of O
levobupivacaine O
0 O
. O
5 O
% O
with O
epinephrine O
2 O
. O
5 O
microgram O
/ O
mL O
, O
the O
patients O
developed O
grand B
mal I
seizures I
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine O
administration O
. O

Neither O
patient O
developed O
signs O
of O
cardiovascular B
toxicity I
. O

CONCLUSIONS O
: O
Although O
levobupivacaine O
may O
have O
a O
safer O
cardiac B
toxicity I
profile O
than O
racemic O
bupivacaine O
, O
if O
adequate O
amounts O
of O
levobupivacaine O
reach O
the O
circulation O
, O
it O
will O
result O
in O
convulsions B
. O

Plasma O
concentrations O
sufficient O
to O
result O
in O
central B
nervous I
system I
toxicity I
did O
not O
produce O
manifestations O
of O
cardiac B
toxicity I
in O
these O
2 O
patients O
. O

Anaesthetic O
complications O
associated O
with O
myotonia B
congenita I
: O
case O
study O
and O
comparison O
with O
other O
myotonic B
disorders I
. O

Myotonia B
congenita I
( O
MC B
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride O
channel O
function O
, O
which O
may O
cause O
sustained B
membrane I
depolarisation I
. O

We O
describe O
a O
previously O
healthy O
32 O
- O
year O
- O
old O
woman O
who O
developed O
a O
life O
- O
threatening O
muscle B
spasm I
and O
secondary O
ventilation O
difficulties O
following O
a O
preoperative O
injection O
of O
suxamethonium O
. O

The O
muscle B
spasms I
disappeared O
spontaneously O
and O
the O
surgery O
proceeded O
without O
further O
problems O
. O

When O
subsequently O
questioned O
, O
she O
reported O
minor O
symptoms O
suggesting O
a O
myotonic B
condition I
. O

Myotonia B
was O
found O
on O
clinical O
examination O
and O
EMG O
. O

We O
give O
a O
brief O
overview O
of O
ion B
channel I
disorders I
including O
malignant B
hyperthermia I
and O
their O
anaesthetic O
considerations O
. O

Vincristine O
was O
accidentally O
given O
intrathecally O
to O
a O
child O
with O
leukaemia B
, O
producing O
sensory B
and I
motor I
dysfunction I
followed O
by O
encephalopathy B
and O
death O
. O

Increased O
serum O
soluble O
Fas O
in O
patients O
with O
acute B
liver I
failure I
due O
to O
paracetamol O
overdose B
. O

BACKGROUND O
/ O
AIMS O
: O
Experimental O
studies O
have O
suggested O
that O
apoptosis O
via O
the O
Fas O
/ O
Fas O
Ligand O
signaling O
system O
may O
play O
an O
important O
role O
in O
the O
development O
of O
acute B
liver I
failure I
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
soluble O
form O
of O
Fas O
in O
patients O
with O
acute B
liver I
failure I
. O

METHODOLOGY O
: O
Serum O
levels O
of O
sFas O
( O
soluble O
Fas O
) O
were O
measured O
by O
ELISA O
in O
24 O
patients O
with O
acute B
liver I
failure I
and O
10 O
normal O
control O
subjects O
. O

Serum O
levels O
of O
tumor B
necrosis B
factor O
- O
alpha O
and O
interferon O
- O
gamma O
were O
also O
determined O
by O
ELISA O
. O

RESULTS O
: O
Serum O
sFas O
was O
significantly O
increased O
in O
patients O
with O
acute B
liver I
failure I
( O
median O
, O
26 O
. O
8 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
9 O
- O
52 O
. O
7 O
U O
/ O
mL O
) O
compared O
to O
the O
normal O
controls O
( O
median O
, O
8 O
. O
6 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
5 O
- O
12 O
. O
0 O
U O
/ O
mL O
, O
P O
< O
0 O
. O
0001 O
) O
. O

Levels O
were O
significantly O
greater O
in O
patients O
with O
acute B
liver I
failure I
due O
to O
paracetamol O
overdose B
( O
median O
, O
28 O
. O
7 O
U O
/ O
mL O
; O
range O
, O
12 O
. O
8 O
- O
52 O
. O
7 O
U O
/ O
mL O
, O
n O
= O
17 O
) O
than O
those O
due O
to O
non O
- O
A O
to O
E O
hepatitis B
( O
median O
, O
12 O
. O
5 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
9 O
- O
46 O
. O
0 O
U O
/ O
mL O
, O
n O
= O
7 O
, O
P O
< O
0 O
. O
01 O
) O
. O

CONCLUSIONS O
: O
The O
increased O
concentration O
of O
sFas O
in O
serum O
of O
patients O
with O
acute B
liver I
failure I
may O
reflect O
activation O
of O
Fas O
- O
mediated O
apoptosis O
in O
the O
liver O
and O
this O
together O
with O
increased O
tumor B
necrosis B
factor O
- O
alpha O
may O
be O
an O
important O
factor O
in O
liver O
cell O
loss O
. O

Bilateral O
subthalamic O
nucleus O
stimulation O
for O
Parkinson B
' I
s I
disease I
. O

High O
frequency O
stimulation O
of O
the O
subthalamic O
nucleus O
( O
STN O
) O
is O
known O
to O
ameliorate O
the O
signs O
and O
symptoms O
of O
advanced O
Parkinson B
' I
s I
disease I
. O

METHOD O
: O
Twenty O
- O
three O
patients O
suffering O
from O
severe O
Parkinson B
' I
s I
disease I
( O
Stages O
III O
- O
V O
on O
Hoehn O
and O
Yahr O
scale O
) O
and O
, O
particularly O
bradykinesia B
, O
rigidity B
, O
and O
levodopa O
- O
induced O
dyskinesias B
underwent O
bilateral O
implantation O
of O
electrodes O
in O
the O
STN O
. O

Preoperative O
and O
postoperative O
assessments O
of O
these O
patients O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
follow O
- O
up O
, O
in O
" O
on O
" O
and O
" O
off O
" O
drug O
conditions O
, O
was O
carried O
out O
using O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
, O
Hoehn O
and O
Yahr O
staging O
, O
England O
activities O
of O
daily O
living O
score O
and O
video O
recordings O
. O

RESULTS O
: O
After O
one O
year O
of O
electrical O
stimulation O
of O
the O
STN O
, O
the O
patients O
' O
scores O
for O
activities O
of O
daily O
living O
and O
motor O
examination O
scores O
( O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
parts O
II O
and O
III O
) O
off O
medication O
improved O
by O
62 O
% O
and O
61 O
% O
respectively O
( O
p O
< O
0 O
. O
0005 O
) O
. O

CONCLUSION O
: O
Bilateral O
subthalamic O
nucleus O
stimulation O
is O
an O
effective O
treatment O
for O
advanced O
Parkinson B
' I
s I
disease I
. O

The O
reduction O
in O
the O
levodopa O
dose O
is O
useful O
in O
controlling O
drug B
- I
induced I
dyskinesias I
. O

Acute B
renal I
failure I
occurring O
during O
intravenous O
desferrioxamine O
therapy O
: O
recovery O
after O
haemodialysis O
. O

A O
patient O
with O
transfusion O
- O
dependent O
thalassemia B
was O
undergoing O
home O
intravenous O
desferrioxamine O
( O
DFX O
) O
treatment O
by O
means O
of O
a O
totally O
implanted O
system O
because O
of O
his O
poor O
compliance O
with O
the O
nightly O
subcutaneous O
therapy O
. O

Due O
to O
an O
accidental O
malfunctioning O
of O
the O
infusion O
pump O
, O
the O
patient O
was O
inadvertently O
administered O
a O
toxic O
dosage O
of O
the O
drug O
which O
caused O
renal B
insufficiency I
. O

From O
the O
results O
obtained O
, O
haemodialysis O
can O
therefore O
be O
suggested O
as O
a O
useful O
therapy O
in O
rare O
cases O
of O
progressive O
acute B
renal I
failure I
caused O
by O
desferrioxamine O
. O

Ocular O
motility O
changes O
after O
subtenon O
carboplatin O
chemotherapy O
for O
retinoblastoma B
. O

BACKGROUND O
: O
Focal O
subtenon O
carboplatin O
injections O
have O
recently O
been O
used O
as O
a O
presumably O
toxicity B
- O
free O
adjunct O
to O
systemic O
chemotherapy O
for O
intraocular O
retinoblastoma B
. O

OBJECTIVE O
: O
To O
report O
our O
clinical O
experience O
with O
abnormal B
ocular I
motility I
in O
patients O
treated O
with O
subtenon O
carboplatin O
chemotherapy O
. O

METHODS O
: O
We O
noted O
abnormal B
ocular I
motility I
in O
10 O
consecutive O
patients O
with O
retinoblastoma B
who O
had O
received O
subtenon O
carboplatin O
. O

During O
ocular O
manipulation O
under O
general O
anesthesia O
, O
we O
assessed O
their O
eyes O
by O
forced O
duction O
testing O
, O
comparing O
ocular O
motility O
after O
tumor B
control O
with O
ocular O
motility O
at O
diagnosis O
. O

RESULTS O
: O
Limitation O
of O
ocular O
motility O
was O
detected O
in O
all O
12 O
eyes O
of O
10 O
patients O
treated O
for O
intraocular O
retinoblastoma B
with O
1 O
to O
6 O
injections O
of O
subtenon O
carboplatin O
as O
part O
of O
multimodality O
therapy O
. O

Ethambutol O
and O
optic B
neuropathy I
. O

PURPOSE O
: O
To O
demonstrate O
the O
association O
between O
ethambutol O
and O
optic B
neuropathy I
. O

METHOD O
: O
Thirteen O
patients O
who O
developed O
optic B
neuropathy I
after O
being O
treated O
with O
ethambutol O
for O
tuberculosis B
of I
the I
lung I
or I
lymph I
node I
at O
Siriraj O
Hospital O
between O
1997 O
and O
2001 O
were O
retrospectively O
reviewed O
. O

RESULTS O
: O
All O
patients O
had O
optic B
neuropathy I
between O
1 O
to O
6 O
months O
( O
mean O
= O
2 O
. O
9 O
months O
) O
after O
starting O
ethambutol O
therapy O
at O
a O
dosage O
ranging O
from O
13 O
to O
20 O
mg O
/ O
kg O
/ O
day O
( O
mean O
= O
17 O
mg O
/ O
kg O
/ O
day O
) O
. O

Of O
6 O
patients O
with O
irreversible O
visual B
impairment I
, O
4 O
patients O
had O
diabetes B
mellitus I
, O
glaucoma B
and O
a O
history O
of O
heavy O
smoking O
. O

CONCLUSION O
: O
Early O
recognition O
of O
optic B
neuropathy I
should O
be O
considered O
in O
patients O
with O
ethambutol O
therapy O
. O

A O
low O
dose O
and O
prompt O
discontinuation O
of O
the O
drug O
is O
recommended O
particularly O
in O
individuals O
with O
diabetes B
mellitus I
, O
glaucoma B
or O
who O
are O
heavy O
smokers O
. O

One O
woman O
, O
however O
, O
developed O
worsened O
psychiatric B
symptoms I
while O
taking O
bromocriptine O
, O
and O
it O
was O
discontinued O
. O

Intracerebroventricular O
injection O
of O
ethacrynic O
acid O
( O
50 O
% O
convulsive B
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
but O
suppressed O
the O
synthesis O
of O
gamma O
- O
aminobutyric O
acid O
and O
acetylcholine O
in O
mouse O
brain O
. O

Syndrome B
of I
inappropriate I
secretion I
of I
antidiuretic I
hormone I
after O
infusional O
vincristine O
. O

A O
77 O
- O
year O
- O
old O
woman O
with O
refractory O
multiple B
myeloma I
was O
treated O
with O
a O
4 O
- O
day O
continuous O
intravenous O
infusion O
of O
vincristine O
and O
doxorubicin O
and O
4 O
days O
of O
oral O
dexamethasone O
. O

Nine O
days O
after O
her O
second O
cycle O
she O
presented O
with O
lethargy B
and O
weakness B
associated O
with O
hyponatremia B
. O

Evaluation O
revealed O
the O
syndrome B
of I
inappropriate I
secretion I
of I
antidiuretic I
hormone I
, O
which O
was O
attributed O
to O
the O
vincristine O
infusion O
. O

Heart B
failure I
: O
to O
digitalise O
or O
not O
? O

In O
patients O
with O
atrial B
fibrillation I
digoxin O
is O
beneficial O
for O
ventricular O
rate O
control O
. O

For O
patients O
in O
sinus O
rhythm O
and O
heart B
failure I
the O
situation O
is O
less O
clear O
. O

Similar O
reductions O
occurred O
in O
standing O
blood O
pressure O
and O
there O
was O
no O
evidence O
of O
postural B
hypotension I
. O

Pure B
red I
cell I
aplasia I
, O
toxic B
dermatitis I
and O
lymphadenopathy B
in O
a O
patient O
taking O
diphenylhydantoin O
. O

A O
patient O
taking O
diphenylhydantoin O
for O
3 O
weeks O
developed O
a O
generalized O
skin B
rash I
, O
lymphadenopathy B
and O
pure B
red I
cell I
aplasia I
. O

Skin B
rash I
is O
a O
well O
- O
known O
complication O
of O
diphenylhydantoin O
treatment O
as O
is O
benign O
and O
malignant O
lymphadenopathy B
. O

Pure B
red I
cell I
aplasia I
associated O
with O
diphenylhydantoin O
medication O
has O
been O
reported O
in O
3 O
patients O
. O

In O
this O
patient O
the O
time O
relation O
between O
the O
ingestion O
of O
diphenylhydantoin O
and O
the O
occurrence O
of O
the O
skin B
rash I
, O
lymphadenopathy B
and O
pure B
red I
cell I
aplasia I
is O
very O
suggestive O
of O
a O
direct O
connection O
. O

Randomized O
clinical O
trials O
comparing O
VNR O
with O
other O
drugs O
in O
the O
treatment O
of O
cancer B
were O
searched O
in O
Medline O
, O
Embase O
, O
Evidence O
- O
based O
Medicine O
Reviews O
databases O
and O
the O
Cochrane O
library O
from O
1987 O
to O
2002 O
. O

Even O
if O
it O
did O
not O
reach O
statistical O
significance O
because O
of O
a O
few O
number O
of O
cases O
, O
the O
risk O
was O
lower O
in O
trials O
excluding O
patients O
with O
cardiac O
history O
, O
and O
seemed O
to O
be O
higher O
in O
trials O
including O
patients O
with O
pre O
- O
existing O
cardiac B
diseases I
. O

MRI O
findings O
of O
hypoxic O
cortical O
laminar O
necrosis B
in O
a O
child O
with O
hemolytic B
anemia I
crisis O
. O

We O
present O
magnetic O
resonance O
imaging O
findings O
of O
a O
5 O
- O
year O
- O
old O
girl O
who O
had O
a O
rapidly O
installing O
hemolytic B
anemia I
crisis O
induced O
by O
trimethoprim O
- O
sulfomethoxazole O
, O
resulting O
in O
cerebral B
anoxia I
leading O
to O
permanent O
damage O
. O

The O
natural O
history O
of O
Vigabatrin O
associated O
visual B
field I
defects I
in O
patients O
electing O
to O
continue O
their O
medication O
. O

PURPOSE O
: O
To O
determine O
the O
natural O
history O
of O
visual B
field I
defects I
in O
a O
group O
of O
patients O
known O
to O
have O
Vigabatrin O
- O
associated O
changes O
who O
elected O
to O
continue O
the O
medication O
because O
of O
good O
seizure B
control O
. O

Following O
already O
published O
methodology O
( O
Eye O
2002 O
; O
16 O
; O
567 O
- O
571 O
) O
monocular O
mean O
radial O
degrees O
( O
MRDs O
) O
to O
the O
I O
/ O
4e O
isopter O
on O
Goldmann O
perimetry O
was O
calculated O
for O
the O
right O
eye O
at O
the O
time O
of O
discovery O
of O
a O
visual B
field I
defect I
and O
again O
after O
not O
less O
than O
18 O
months O
follow O
- O
up O
. O

Only O
one O
patient O
demonstrated O
a O
deterioration B
in I
visual I
field I
during O
the O
study O
period O
and O
discontinued O
treatment O
. O

CONCLUSION O
: O
Established O
visual B
field I
defects I
presumed O
to O
be O
due O
to O
Vigabatrin O
therapy O
did O
not O
usually O
progress O
in O
spite O
of O
continuing O
use O
of O
the O
medication O
. O

These O
data O
give O
support O
to O
the O
hypothesis O
that O
the O
pathogenesis O
of O
Vigabatrin O
- O
associated O
visual B
field I
defects I
may O
be O
an O
idiosyncratic O
adverse O
drug O
reaction O
rather O
than O
dose O
- O
dependent O
toxicity B
. O

Induction O
of O
rosaceiform O
dermatitis B
during O
treatment O
of O
facial B
inflammatory I
dermatoses I
with O
tacrolimus O
ointment O
. O

BACKGROUND O
: O
Tacrolimus O
ointment O
is O
increasingly O
used O
for O
anti O
- O
inflammatory O
treatment O
of O
sensitive O
areas O
such O
as O
the O
face O
, O
and O
recent O
observations O
indicate O
that O
the O
treatment O
is O
effective O
in O
steroid O
- O
aggravated O
rosacea B
and O
perioral B
dermatitis I
. O

OBSERVATIONS O
: O
Six O
adult O
patients O
with O
inflammatory B
facial I
dermatoses I
were O
treated O
with O
tacrolimus O
ointment O
because O
of O
the O
ineffectiveness O
of O
standard O
treatments O
. O

In O
1 O
patient O
with O
eyelid O
eczema B
, O
rosaceiform O
periocular B
dermatitis I
gradually O
appeared O
after O
3 O
weeks O
of O
treatment O
. O

In O
1 O
patient O
with O
atopic B
dermatitis I
, O
telangiectatic O
and O
papular B
rosacea I
insidiously O
appeared O
after O
5 O
months O
of O
treatment O
. O

Intravascular O
hemolysis B
and O
acute B
renal I
failure I
following O
intermittent O
rifampin O
therapy O
. O

Renal B
failure I
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampin O
. O

Intravascular O
hemolysis B
leading O
to O
acute B
renal I
failure I
following O
rifampin O
therapy O
is O
extremely O
rare O
. O

Two O
patients O
with O
leprosy B
who O
developed O
hemolysis B
and O
acute B
renal I
failure I
following O
rifampin O
are O
reported O
. O

We O
visualize O
, O
for O
the O
first O
time O
, O
the O
profile O
of O
structural B
deficits I
in I
the I
human I
brain I
associated O
with O
chronic O
methamphetamine O
( O
MA O
) O
abuse O
. O

Studies O
of O
human O
subjects O
who O
have O
used O
MA O
chronically O
have O
revealed O
deficits O
in O
dopaminergic O
and O
serotonergic O
systems O
and O
cerebral O
metabolic B
abnormalities I
. O

Using O
magnetic O
resonance O
imaging O
( O
MRI O
) O
and O
new O
computational O
brain O
- O
mapping O
techniques O
, O
we O
determined O
the O
pattern O
of O
structural O
brain O
alterations O
associated O
with O
chronic O
MA O
abuse O
in O
human O
subjects O
and O
related O
these O
deficits O
to O
cognitive B
impairment I
. O

We O
used O
high O
- O
resolution O
MRI O
and O
surface O
- O
based O
computational O
image O
analyses O
to O
map O
regional O
abnormalities B
in I
the I
cortex I
, I
hippocampus I
, I
white I
matter I
, I
and I
ventricles I
in O
22 O
human O
subjects O
who O
used O
MA O
and O
21 O
age O
- O
matched O
, O
healthy O
controls O
. O

MRI O
- O
based O
maps O
suggest O
that O
chronic O
methamphetamine O
abuse O
causes O
a O
selective O
pattern O
of O
cerebral O
deterioration O
that O
contributes O
to O
impaired B
memory I
performance I
. O

Prominent O
white O
- O
matter O
hypertrophy B
may O
result O
from O
altered O
myelination O
and O
adaptive O
glial O
changes O
, O
including O
gliosis B
secondary O
to O
neuronal B
damage I
. O

These O
brain O
substrates O
may O
help O
account O
for O
the O
symptoms O
of O
MA O
abuse O
, O
providing O
therapeutic O
targets O
for O
drug O
- O
induced O
brain B
injury I
. O

Amiodarone O
induced O
hepatomegaly B
, O
hepatocyte O
microvesicular O
lipid O
accumulation O
, O
and O
a O
significant O
decrease O
in O
serum O
triglycerides O
and O
glucose O
. O

The O
absence O
of O
induction O
of O
these O
genes O
as O
well O
as O
hepatomegaly B
in O
PPARalpha O
knockout O
[ O
PPARalpha O
- O
/ O
- O
] O
mice O
indicated O
that O
the O
effects O
of O
amiodarone O
were O
dependent O
upon O
the O
presence O
of O
a O
functional O
PPARalpha O
gene O
. O

Compared O
to O
wild O
- O
type O
mice O
, O
treatment O
of O
PPARalpha O
- O
/ O
- O
mice O
with O
amiodarone O
resulted O
in O
an O
increased O
rate O
and O
extent O
of O
total O
body O
weight B
loss I
. O

The O
inability O
of O
amiodarone O
to O
directly O
activate O
either O
human O
or O
mouse O
PPARalpha O
transiently O
expressed O
in O
human O
HepG2 O
hepatoma B
cells O
indicates O
that O
the O
effects O
of O
amiodarone O
on O
the O
function O
of O
this O
receptor O
were O
indirect O
. O

Niacin O
extended O
- O
release O
/ O
lovastatin O
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia B
and O
mixed O
dyslipidemia B
. O

Primary O
end O
points O
were O
study O
compliance O
, O
increases O
in O
liver O
transaminases O
to O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
, O
and O
clinical O
myopathy B
. O

An O
increase O
of O
creatine O
phosphokinase O
to O
> O
5 O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0 O
. O
24 O
% O
of O
patients O
, O
and O
no O
cases O
of O
drug O
- O
induced O
myopathy B
were O
observed O
. O

Protective O
effect O
of O
Terminalia O
chebula O
against O
experimental O
myocardial B
injury I
induced O
by O
isoproterenol O
. O

Cardioprotective O
effect O
of O
ethanolic O
extract O
of O
Terminalia O
chebula O
fruits O
( O
500 O
mg O
/ O
kg O
body O
wt O
) O
was O
examined O
in O
isoproterenol O
( O
200 O
mg O
/ O
kg O
body O
wt O
) O
induced O
myocardial B
damage I
in O
rats O
. O

A O
case O
of O
postoperative O
anxiety B
due O
to O
low O
dose O
droperidol O
used O
with O
patient O
- O
controlled O
analgesia O
. O

The O
diagnosis O
of O
droperidol O
- O
induced O
psychological B
disturbance I
was O
not O
made O
straight O
away O
although O
on O
subsequent O
close O
questioning O
the O
patient O
gave O
a O
very O
clear O
history O
. O

Accurate O
patient O
history O
contributes O
to O
differentiating O
diabetes B
insipidus I
: O
a O
case O
study O
. O

The O
case O
discussed O
herein O
initially O
appeared O
to O
be O
neurogenic B
diabetes I
insipidus I
( O
DI B
) O
secondary O
to O
a O
traumatic B
brain I
injury I
. O

By O
combining O
information O
from O
the O
patient O
history O
, O
the O
physical O
examination O
, O
and O
radiologic O
and O
laboratory O
studies O
, O
the O
critical O
care O
team O
demonstrated O
that O
the O
patient O
had O
been O
self O
- O
treating O
his O
lithium O
- O
induced O
nephrogenic B
DI I
and O
developed O
neurogenic B
DI I
secondary O
to O
brain B
trauma I
. O

Factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B
. O

BACKGROUND O
AND O
AIM O
: O
Interferon O
and O
ribavirin O
combination O
therapy O
for O
chronic B
hepatitis I
C I
produces O
hemolytic B
anemia I
. O

This O
study O
was O
conducted O
to O
identify O
the O
factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B
. O

METHODS O
: O
Eighty O
- O
eight O
patients O
with O
chronic B
hepatitis I
C I
who O
received O
interferon O
- O
alpha O
- O
2b O
at O
a O
dose O
of O
6 O
MU O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin O
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

A O
hemoglobin O
concentration O
of O
< O
10 O
g O
/ O
dL O
was O
defined O
as O
ribavirin O
- O
induced O
anemia B
. O

RESULTS O
: O
Ribavirin O
- O
induced O
anemia B
occurred O
in O
18 O
( O
20 O
. O
5 O
% O
) O
patients O
during O
treatment O
. O

A O
2 O
g O
/ O
dL O
decrease O
in O
hemoglobin O
concentrations O
in O
patients O
with O
anemia B
was O
observed O
at O
week O
2 O
after O
the O
start O
of O
treatment O
. O

A O
significant O
relationship O
was O
observed O
between O
the O
rate O
of O
reduction O
of O
hemoglobin O
concentrations O
at O
week O
2 O
and O
the O
severity O
of O
anemia B
( O
P O
< O
0 O
. O
01 O
) O
. O

Oxidative O
damage O
precedes O
nitrative O
damage O
in O
adriamycin O
- O
induced O
cardiac O
mitochondrial B
injury I
. O

Our O
data O
showed O
ADR O
induced O
4HNE O
- O
protein O
adducts O
in O
mitochondria O
at O
the O
same O
time O
point O
as O
when O
mitochondrial B
injury I
initially O
appeared O
. O

These O
results O
document O
for O
the O
first O
time O
in O
vivo O
that O
mitochondrial B
oxidative I
damage I
precedes O
nitrative O
damage O
. O

The O
progressive O
nature O
of O
mitochondrial B
injury I
suggests O
that O
mitochondria O
, O
not O
other O
subcellular O
organelles O
, O
are O
the O
major O
site O
of O
intracellular O
injury O
. O

Sotalol O
- O
induced O
coronary B
spasm I
in O
a O
patient O
with O
dilated B
cardiomyopathy I
associated O
with O
sustained O
ventricular B
tachycardia I
. O

A O
54 O
- O
year O
- O
old O
man O
with O
severe O
left O
ventricular B
dysfunction I
due O
to O
dilated B
cardiomyopathy I
was O
referred O
to O
our O
hospital O
for O
symptomatic O
incessant O
sustained O
ventricular B
tachycardia I
( O
VT B
) O
. O

METHODS O
: O
The O
effect O
of O
pretreatment O
with O
trazodone O
on O
dexamphetamine O
- O
and O
apomorphine O
- O
induced O
oral B
stereotypies I
, O
on O
catalepsy B
induced O
by O
haloperidol O
and O
apomorphine O
( O
0 O
. O
05 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
on O
ergometrine O
- O
induced O
wet O
dog O
shake O
( O
WDS O
) O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
was O
studied O
in O
rats O
. O

Swallowing B
abnormalities I
and O
dyskinesia B
in O
Parkinson B
' I
s I
disease I
. O

Gastrointestinal B
abnormalities I
in O
Parkinson B
' I
s I
disease I
( O
PD B
) O
have O
been O
known O
for O
almost O
two O
centuries O
, O
but O
many O
aspects O
concerning O
their O
pathophysiology O
have O
not O
been O
completely O
clarified O
. O

Patients O
were O
asked O
about O
dysphagia B
and O
evaluated O
with O
the O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
Parts O
II O
and O
III O
and O
the O
Hoehn O
and O
Yahr O
scale O
. O

BACKGROUND O
: O
While O
the O
incidence O
of O
new O
- O
onset O
diabetes B
mellitus I
may O
be O
increasing O
in O
patients O
with O
schizophrenia B
treated O
with O
certain O
atypical O
antipsychotic O
agents O
, O
it O
remains O
unclear O
whether O
atypical O
agents O
are O
directly O
affecting O
glucose O
metabolism O
or O
simply O
increasing O
known O
risk O
factors O
for O
diabetes B
. O

Thirty O
- O
six O
nonobese O
subjects O
with O
schizophrenia B
or O
schizoaffective B
disorder I
, O
matched O
by O
body O
mass O
index O
and O
treated O
with O
either O
clozapine O
, O
olanzapine O
, O
or O
risperidone O
, O
were O
included O
in O
the O
analysis O
. O

Apparent O
risk O
factors O
for O
the O
development O
of O
mania B
or O
hypomania B
during O
fluoxetine O
pharmacotherapy O
in O
this O
population O
were O
the O
combination O
of O
attention B
- I
deficit I
hyperactivity I
disorder I
and O
affective O
instability O
; O
major O
depression B
with O
psychotic B
features O
; O
a O
family O
history O
of O
affective B
disorder I
, O
especially O
bipolar B
disorder I
; O
and O
a O
diagnosis O
of O
bipolar B
disorder I
. O

Acute B
renal I
insufficiency I
after O
high O
- O
dose O
melphalan O
in O
patients O
with O
primary B
systemic I
amyloidosis I
during O
stem O
cell O
transplantation O
. O

BACKGROUND O
: O
Patients O
with O
primary B
systemic I
amyloidosis I
( O
AL B
) O
have O
a O
poor O
prognosis O
. O

The O
authors O
have O
noted O
the O
development O
of O
acute B
renal I
insufficiency I
immediately O
after O
melphalan O
conditioning O
. O

Acute B
renal I
insufficiency I
( O
ARI B
) O
after O
high O
- O
dose O
melphalan O
was O
defined O
by O
a O
minimum O
increase O
of O
0 O
. O
5 O
mg O
/ O
dL O
( O
44 O
micromol O
/ O
L O
) O
in O
the O
serum O
creatinine O
level O
that O
is O
greater O
than O
50 O
% O
of O
baseline O
immediately O
after O
conditioning O
. O

Univariate O
analysis O
identified O
age O
, O
hypoalbuminemia B
, O
heavy O
proteinuria B
, O
diuretic O
use O
, O
and O
urine O
sediment O
score O
( O
> O
3 O
) O
as O
risk O
factors O
. O

CONCLUSION O
: O
The O
timing O
of O
renal B
injury I
strongly O
suggests O
melphalan O
as O
the O
causative O
agent O
. O

Ongoing O
tubular B
injury I
may O
be O
a O
prerequisite O
for O
renal B
injury I
by O
melphalan O
as O
evidenced O
by O
the O
active O
urinary O
sediment O
. O

Focal O
cerebral B
ischemia I
in O
rats O
: O
effect O
of O
phenylephrine O
- O
induced O
hypertension B
during O
reperfusion O
. O

After O
180 O
min O
of O
temporary O
middle B
cerebral I
artery I
occlusion I
in O
spontaneously O
hypertensive B
rats O
, O
the O
effect O
of O
phenylephrine O
- O
induced O
hypertension B
on O
ischemic B
brain I
injury I
and O
blood O
- O
brain O
barrier O
permeability O
was O
determined O
. O

Part O
A O
, O
for O
eight O
rats O
in O
each O
group O
brain B
injury I
was O
evaluated O
by O
staining O
tissue O
using O
2 O
, O
3 O
, O
5 O
- O
triphenyltetrazolium O
chloride O
and O
edema B
was O
evaluated O
by O
microgravimetry O
. O

Brain B
injury I
( O
percentage O
of O
the O
ischemic B
hemisphere I
) O
was O
less O
in O
the O
15 O
/ O
HTN B
group O
( O
16 O
+ O
/ O
- O
6 O
, O
mean O
+ O
/ O
- O
SD O
) O
versus O
the O
90 O
/ O
HTN B
group O
( O
30 O
+ O
/ O
- O
6 O
) O
, O
which O
was O
in O
turn O
less O
than O
the O
control O
group O
( O
42 O
+ O
/ O
- O
5 O
) O
. O

This O
study O
supports O
a O
hypothesis O
that O
during O
reperfusion O
, O
a O
short O
interval O
of O
hypertension B
decreases O
brain B
injury I
and O
edema B
; O
and O
that O
sustained O
hypertension B
increases O
the O
risk O
of O
vasogenic B
edema I
. O

People O
aged O
over O
75 O
in O
atrial B
fibrillation I
on O
warfarin O
: O
the O
rate O
of O
major O
hemorrhage B
and O
stroke B
in O
more O
than O
500 O
patient O
- O
years O
of O
follow O
- O
up O
. O

OBJECTIVES O
: O
To O
determine O
the O
incidence O
of O
major O
hemorrhage B
and O
stroke B
in O
people O
aged O
76 O
and O
older O
with O
atrial B
fibrillation I
on O
adjusted O
- O
dose O
warfarin O
who O
had O
been O
recently O
been O
admitted O
to O
hospital O
. O

PARTICIPANTS O
: O
Two O
hundred O
thirty O
- O
five O
patients O
aged O
76 O
and O
older O
admitted O
to O
a O
major O
healthcare O
network O
between O
July O
1 O
, O
2001 O
, O
and O
June O
30 O
, O
2002 O
, O
with O
atrial B
fibrillation I
on O
warfarin O
were O
enrolled O
. O

Safety O
of O
celecoxib O
in O
patients O
with O
adverse O
skin B
reactions I
to O
acetaminophen O
( O
paracetamol O
) O
and O
nimesulide O
associated O
or O
not O
with O
common O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
. O

The O
rate O
of O
adverse O
hypersensitivity B
reactions O
to O
these O
agents O
is O
generally O
low O
. O

OBJECTIVE O
: O
We O
evaluated O
the O
tolerability O
of O
CE O
in O
a O
group O
of O
patients O
with O
documented O
history O
of O
adverse O
cutaneous B
reactions I
to O
P O
and O
N O
associated O
or O
not O
to O
classic O
NSAIDs O
. O

METHODS O
: O
We O
studied O
9 O
patients O
with O
hypersensitivity B
to O
P O
and O
N O
with O
or O
without O
associated O
reactions O
to O
classic O
NSAIDs O
. O

The O
diagnosis O
of O
P O
and O
N O
- O
induced O
skin B
reactions I
was O
based O
in O
vivo O
challenge O
. O

The O
challenge O
was O
considered O
positive O
if O
one O
or O
more O
of O
the O
following O
appeared O
: O
erythema B
, O
rush O
or O
urticaria B
- O
angioedema B
. O

Only O
one O
patient O
developed O
a O
moderate O
angioedema B
of O
the O
lips O
. O

CONCLUSION O
: O
Only O
one O
hypersensitivity B
reaction O
to O
CE O
was O
documented O
among O
9 O
P O
and O
N O
- O
highly O
NSAIDs O
intolerant O
patients O
. O

Case O
- O
control O
study O
of O
regular O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
use O
and O
end B
- I
stage I
renal I
disease I
. O

BACKGROUND O
: O
Studies O
on O
the O
association O
between O
the O
long O
- O
term O
use O
of O
aspirin O
and O
other O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
and O
end B
- I
stage I
renal I
disease I
( O
ESRD B
) O
have O
given O
conflicting O
results O
. O

The O
risk O
of O
ESRD B
associated O
with O
aspirin O
was O
related O
to O
the O
cumulated O
dose O
and O
duration O
of O
use O
, O
and O
it O
was O
particularly O
high O
among O
the O
subset O
of O
patients O
with O
vascular O
nephropathy B
as O
underlying O
disease O
[ O
2 O
. O
35 O
( O
1 O
. O
17 O
- O
4 O
. O
72 O
) O
] O
. O

Two O
cases O
of O
amisulpride O
overdose B
: O
a O
cause O
for O
prolonged B
QT I
syndrome I
. O

Although O
some O
studies O
in O
experimental O
animals O
indicate O
clear O
pharmacological O
interactions O
between O
them O
, O
no O
studies O
have O
shown O
a O
specific O
interaction O
on O
anxiety B
responses O
. O

OBJECTIVES O
: O
The O
present O
study O
investigates O
the O
effects O
of O
nicotine O
on O
anxiety B
induced O
by O
caffeine O
and O
another O
anxiogenic O
drug O
, O
pentylenetetrazole O
, O
in O
mice O
. O

The O
elevated O
plus O
- O
maze O
( O
EPM O
) O
test O
was O
used O
to O
evaluate O
the O
effects O
of O
drugs O
on O
anxiety B
. O

Nicotine O
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
pretreatment O
blocked O
the O
caffeine O
- O
but O
not O
pentylenetetrazole O
- O
induced O
anxiety B
. O

CONCLUSIONS O
: O
Our O
results O
suggest O
that O
the O
antagonistic O
effect O
of O
nicotine O
on O
caffeine O
- O
induced O
anxiety B
is O
specific O
to O
caffeine O
, O
instead O
of O
a O
non O
- O
specific O
anxiolytic O
effect O
. O

BACKGROUND O
: O
Hormone O
therapy O
( O
HT O
) O
is O
widely O
used O
for O
controlling O
menopausal B
symptoms I
. O

It O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B
disease I
, O
osteoporosis B
and O
dementia B
in O
older O
women O
but O
the O
evidence O
supporting O
its O
use O
for O
these O
indications O
is O
largely O
observational O
. O

OBJECTIVES O
: O
To O
assess O
the O
effect O
of O
long O
- O
term O
HT O
on O
mortality O
, O
heart B
disease I
, O
venous B
thromboembolism I
, O
stroke B
, O
transient B
ischaemic I
attacks I
, O
breast B
cancer I
, O
colorectal B
cancer I
, O
ovarian B
cancer I
, O
endometrial B
cancer I
, O
gallbladder B
disease I
, O
cognitive O
function O
, O
dementia B
, O
fractures B
and O
quality O
of O
life O
. O

In O
relatively O
healthy O
women O
, O
combined O
continuous O
HT O
significantly O
increased O
the O
risk O
of O
venous B
thromboembolism I
or O
coronary O
event O
( O
after O
one O
year O
' O
s O
use O
) O
, O
stroke B
( O
after O
3 O
years O
) O
, O
breast B
cancer I
( O
after O
5 O
years O
) O
and O
gallbladder B
disease I
. O

Long O
- O
term O
oestrogen O
- O
only O
HT O
also O
significantly O
increased O
the O
risk O
of O
stroke B
and O
gallbladder B
disease I
. O

Overall O
, O
the O
only O
statistically O
significant O
benefits O
of O
HT O
were O
a O
decreased O
incidence O
of O
fractures B
and O
colon B
cancer I
with O
long O
- O
term O
use O
. O

Among O
women O
with O
cardiovascular B
disease I
, O
long O
- O
term O
use O
of O
combined O
continuous O
HT O
significantly O
increased O
the O
risk O
of O
venous B
thromboembolism I
. O

The O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B
thromboembolism I
in O
women O
taking O
combined O
continuous O
HT O
; O
their O
absolute O
risk O
remained O
very O
low O
. O

AUTHORS O
' O
CONCLUSIONS O
: O
HT O
is O
not O
indicated O
for O
the O
routine O
management O
of O
chronic B
disease I
. O

Drug B
- I
induced I
liver I
injury I
: O
an O
analysis O
of O
461 O
incidences O
submitted O
to O
the O
Spanish O
registry O
over O
a O
10 O
- O
year O
period O
. O

BACKGROUND O
& O
AIMS O
: O
Progress O
in O
the O
understanding O
of O
susceptibility O
factors O
to O
drug B
- I
induced I
liver I
injury I
( O
DILI B
) O
and O
outcome O
predictability O
are O
hampered O
by O
the O
lack O
of O
systematic O
programs O
to O
detect O
bona O
fide O
cases O
. O

The O
liver B
damage I
was O
characterized O
according O
to O
hepatocellular O
, O
cholestatic B
, O
and O
mixed O
laboratory O
criteria O
and O
to O
histologic O
criteria O
when O
available O
. O

Indeed O
, O
the O
incidence O
of O
liver O
transplantation O
and O
death O
in O
this O
group O
was O
11 O
. O
7 O
% O
if O
patients O
had O
jaundice B
at O
presentation O
, O
whereas O
the O
corresponding O
figure O
was O
3 O
. O
8 O
% O
in O
nonjaundiced O
patients O
( O
P O
< O
. O
04 O
) O
. O

Factors O
associated O
with O
the O
development O
of O
fulminant B
hepatic I
failure I
were O
female O
sex O
( O
OR O
= O
25 O
; O
95 O
% O
CI O
: O
4 O
. O
1 O
- O
151 O
; O
P O
< O
. O
0001 O
) O
, O
hepatocellular O
damage O
( O
OR O
= O
7 O
. O
9 O
; O
95 O
% O
CI O
: O
1 O
. O
6 O
- O
37 O
; O
P O
< O
. O
009 O
) O
, O
and O
higher O
baseline O
plasma O
bilirubin O
value O
( O
OR O
= O
1 O
. O
15 O
; O
95 O
% O
CI O
: O
1 O
. O
09 O
- O
1 O
. O
22 O
; O
P O
< O
. O
0001 O
) O
. O

CONCLUSIONS O
: O
Patients O
with O
drug O
- O
induced O
hepatocellular O
jaundice B
have O
11 O
. O
7 O
% O
chance O
of O
progressing O
to O
death O
or O
transplantation O
. O

Adriamycin O
in O
the O
cumulative O
dose O
of O
25 O
mg O
/ O
kg O
evoked O
fully O
developed O
cardiac B
toxicity I
. O

The O
aims O
of O
this O
study O
were O
to O
examine O
vancomycin O
( O
VCM O
) O
- O
induced O
oxidative O
stress O
that O
promotes O
production O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
and O
to O
investigate O
the O
role O
of O
erdosteine O
, O
an O
expectorant O
agent O
, O
which O
has O
also O
antioxidant O
properties O
, O
on O
kidney O
tissue O
against O
the O
possible O
VCM O
- O
induced O
renal B
impairment I
in O
rats O
. O

VCM O
administration O
to O
control O
rats O
significantly O
increased O
renal O
malondialdehyde O
( O
MDA O
) O
and O
urinary O
N O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
, O
a O
marker O
of O
renal B
tubular I
injury I
) O
excretion O
but O
decreased O
superoxide O
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
activities O
. O

There O
were O
a O
significant O
dilatation O
of O
tubular O
lumens O
, O
extensive O
epithelial O
cell O
vacuolization O
, O
atrophy B
, O
desquamation B
, O
and O
necrosis B
in O
VCM O
- O
treated O
rats O
more O
than O
those O
of O
the O
control O
and O
the O
erdosteine O
groups O
. O

It O
is O
concluded O
that O
oxidative O
tubular O
damage O
plays O
an O
important O
role O
in O
the O
VCM O
- O
induced O
nephrotoxicity B
and O
the O
modulation O
of O
oxidative O
stress O
with O
erdosteine O
reduces O
the O
VCM O
- O
induced O
kidney B
damage I
both O
at O
the O
biochemical O
and O
histological O
levels O
. O

The O
specific O
aim O
of O
this O
retrospective O
, O
observational O
study O
was O
to O
assess O
safety O
and O
efficacy O
of O
long O
- O
term O
( O
21 O
months O
/ O
patient O
) O
, O
open O
- O
label O
, O
gemfibrozil O
- O
lovastatin O
treatment O
in O
80 O
patients O
with O
primary O
mixed O
hyperlipidemia B
( O
68 O
% O
of O
whom O
had O
atherosclerotic B
vascular I
disease I
) O
. O

Does O
domperidone O
potentiate O
mirtazapine O
- O
associated O
restless B
legs I
syndrome I
? O

There O
is O
now O
evidence O
to O
suggest O
a O
central O
role O
for O
the O
dopaminergic O
system O
in O
restless B
legs I
syndrome I
( O
RLS B
) O
. O

Antiandrogenic O
therapy O
can O
cause O
coronary B
arterial I
disease I
. O

AIM O
: O
To O
study O
the O
change O
of O
lipid O
metabolism O
by O
antiandrogen O
therapy O
in O
patients O
with O
prostate B
cancer I
. O

MATERIALS O
AND O
METHODS O
: O
We O
studied O
with O
a O
2 O
. O
5 O
years O
follow O
- O
up O
the O
changes O
in O
plasma O
cholesterols O
( O
C O
) O
, O
triglycerides O
( O
TG O
) O
, O
lipoproteins O
( O
LP O
) O
, O
and O
apolipoproteins O
( O
Apo O
) O
B O
- O
100 O
, O
A O
- O
I O
, O
and O
A O
- O
II O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate B
cancer I
( O
stage O
: O
T1cN0M0 O
, O
Gleason O
score O
: O
2 O
- O
5 O
) O
during O
treatment O
with O
cyproterone O
acetate O
( O
CPA O
) O
without O

After O
a O
period O
of O
2 O
. O
5 O
years O
on O
CPA O
treatment O
, O
four O
patients O
out O
of O
twenty O
- O
four O
were O
found O
to O
be O
affected O
by O
coronary B
heart I
disease I
. O

CONCLUSIONS O
: O
Ischaemic O
coronary B
arteriosclerosis I
with O
an O
incidence O
rate O
of O
16 O
. O
6 O
% O
as O
caused O
by O
prolonged O
CPA O
therapy O
is O
mediated O
through O
changes O
in O
HDL O
cholesterol O
, O
Apo O
A O
- O
I O
and O
Apo O
A O
- O
II O
pro O
fi O
les O
, O
other O
than O
the O
well O
- O
known O
hyperglyceridemic B
effect I
caused O
by O
estrogen O
. O

The O
patient O
, O
who O
had O
unresectable O
colon B
cancer I
metastases O
to O
the O
liver O
and O
lung O
, O
was O
referred O
to O
us O
for O
chemotherapy O
from O
an O
affiliated O
hospital O
; O
he O
had O
no O
cardiac O
history O
. O

After O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
FU O
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial B
pain I
with O
right B
bundle I
branch I
block I
occurred O
concomitantly O
with O
a O
high O
serum O
FBAL O
concentration O
of O
1955 O
ng O
/ O
ml O
. O

Thereafter O
, O
no O
cardiac B
symptoms I
were O
observed O
. O

Hepatocellular B
carcinoma I
in O
Fanconi B
' I
s I
anemia I
treated O
with O
androgen O
and O
corticosteroid O
. O

The O
case O
of O
an O
11 O
- O
year O
- O
old O
boy O
is O
reported O
who O
was O
known O
to O
have O
Fanconi B
' I
s I
anemia I
for O
3 O
years O
and O
was O
treated O
with O
androgens O
, O
corticosteroids O
and O
transfusions O
. O

At O
autopsy O
peliosis B
and O
multiple O
hepatic B
tumors I
were O
found O
which O
histologically O
proved O
to O
be O
well O
- O
differentiated O
hepatocellular B
carcinoma I
. O

This O
case O
contributes O
to O
the O
previous O
observations O
that O
non O
- O
metastasizing O
hepatic B
neoplasms I
and O
peliosis B
can O
develop O
in O
patients O
with O
androgen O
- O
and O
corticosteroid O
- O
treated O
Fanconi B
' I
s I
anemia I
. O

DOX O
- O
induced O
cardiac B
damage I
presumably O
results O
from O
the O
formation O
of O
free O
radicals O
by O
DOX O
. O

Their O
cardiac O
tissues O
were O
processed O
for O
light O
microscopy O
, O
after O
which O
cardiomyocyte B
damage I
was O
evaluated O
according O
to O
Billingham O
( O
in O
Cancer B
Treat O
Rep O
62 O
( O
6 O
) O
: O
865 O
- O
872 O
, O
1978 O
) O
. O

Microscopic O
evaluation O
revealed O
that O
treatment O
with O
DOX O
alone O
induced O
significant O
cardiac B
damage I
in O
comparison O
to O
the O
saline O
control O
group O
( O
P O
< O
0 O
. O
001 O
) O
. O

Clinical O
evaluation O
of O
adverse O
effects O
during O
bepridil O
administration O
for O
atrial B
fibrillation I
and I
flutter I
. O

BACKGROUND O
: O
Bepridil O
hydrochloride O
( O
Bpd O
) O
has O
attracted O
attention O
as O
an O
effective O
drug O
for O
atrial B
fibrillation I
( O
AF B
) O
and O
atrial B
flutter I
( O
AFL B
) O
. O

Enhanced O
isoproterenol O
- O
induced O
cardiac B
hypertrophy I
in O
transgenic O
rats O
with O
low O
brain O
angiotensinogen O
. O

LV B
hypertrophy I
induced O
by O
Iso O
treatment O
was O
significantly O
higher O
in O
TGR O
than O
in O
SD O
rats O
( O
in O
g O
LV O
wt O
/ O
100 O
g O
body O
wt O
, O
0 O
. O
28 O
+ O
/ O
- O
0 O
. O
004 O
vs O
. O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
004 O
, O
respectively O
) O
. O

The O
greater O
LV B
hypertrophy I
in O
TGR O
rats O
was O
associated O
with O
more O
pronounced O
downregulation O
of O
beta O
- O
AR O
and O
upregulation O
of O
LV O
beta O
- O
AR O
kinase O
- O
1 O
mRNA O
levels O
compared O
with O
those O
in O
SD O
rats O
. O

These O
results O
indicate O
that O
TGR O
are O
more O
sensitive O
to O
beta O
- O
AR O
agonist O
- O
induced O
cardiac B
inotropic I
response O
and O
hypertrophy B
, O
possibly O
due O
to O
chronically O
low O
sympathetic O
outflow O
directed O
to O
the O
heart O
. O

Drug O
- O
induced O
long B
QT I
syndrome I
in O
injection O
drug O
users O
receiving O
methadone O
: O
high O
frequency O
in O
hospitalized O
patients O
and O
risk O
factors O
. O

BACKGROUND O
: O
Drug O
- O
induced O
long B
QT I
syndrome I
is O
a O
serious O
adverse O
drug O
reaction O
. O

Long B
QT I
syndrome I
can O
occur O
with O
low O
doses O
of O
methadone O
. O

Loss O
of O
endothelial O
cell O
- O
derived O
nitric O
oxide O
( O
NO O
) O
in O
hypertension B
is O
a O
hallmark O
of O
arterial B
dysfunction I
. O

Association O
of O
DRD2 O
polymorphisms O
and O
chlorpromazine O
- O
induced O
extrapyramidal B
syndrome I
in O
Chinese O
schizophrenic B
patients O
. O

AIM O
: O
Extrapyramidal B
syndrome I
( O
EPS B
) O
is O
most O
commonly O
affected O
by O
typical O
antipsychotic O
drugs O
that O
have O
a O
high O
affinity O
with O
the O
D2 O
receptor O
. O

The O
dopamine O
agonist O
significantly O
impaired B
novel I
word I
learning I
compared O
to O
placebo O
. O

Minocycline O
- O
induced O
vasculitis B
fulfilling O
the O
criteria O
of O
polyarteritis B
nodosa I
. O

A O
47 O
- O
year O
- O
old O
man O
who O
had O
been O
taking O
minocycline O
for O
palmoplantar B
pustulosis I
developed O
fever B
, O
myalgias B
, O
polyneuropathy B
, O
and O
testicular B
pain I
, O
with O
elevated O
C O
- O
reactive O
protein O
( O
CRP O
) O
. O

To O
our O
knowledge O
, O
this O
is O
the O
second O
case O
of O
minocycline O
- O
induced O
vasculitis B
satisfying O
the O
criteria O
. O

Intramuscular O
hepatitis B
B I
immune O
globulin O
combined O
with O
lamivudine O
in O
prevention O
of O
hepatitis B
B I
recurrence O
after O
liver O
transplantation O
. O

BACKGROUND O
: O
Combined O
hepatitis B
B I
immune O
globulin O
( O
HBIg O
) O
and O
lamivudine O
in O
prophylaxis O
of O
the O
recurrence O
of O
hepatitis B
B I
after O
liver O
transplantation O
has O
significantly O
improved O
the O
survival O
of O
HBsAg O
positive O
patients O
. O

This O
study O
was O
undertaken O
to O
evaluate O
the O
outcomes O
of O
liver O
transplantation O
for O
patients O
with O
hepatitis B
B I
virus O
( O
HBV O
) O
. O

METHODS O
: O
A O
retrospective O
chart O
analysis O
and O
a O
review O
of O
the O
organ O
transplant O
database O
identified O
51 O
patients O
( O
43 O
men O
and O
8 O
women O
) O
transplanted O
for O
benign O
HBV O
- O
related O
cirrhotic B
diseases I
between O
June O
2002 O
and O
December O
2004 O
who O
had O
survived O
more O
than O
3 O
months O
. O

We O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine O
acetate O
on O
a O
whole O
- O
animal O
model O
in O
which O
partial O
seizures B
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure B
patterns O
. O

In O
the O
animals O
treated O
with O
threshold O
doses O
of O
picrotoxin O
, O
the O
average O
number O
of O
seizures B
was O
2 O
. O
3 O
+ O
/ O
- O
1 O
. O
2 O
, O
and O
average O
seizure B
duration O
was O
39 O
. O
5 O
+ O
/ O
- O
8 O
. O
4s O
. O

Lower O
doses O
( O
3 O
and O
10mg O
/ O
kg O
) O
did O
not O
suppress O
seizures B
, O
however O
, O
after O
administration O
of O
10mg O
/ O
kg O
, O
significant O
reductions O
in O
seizures B
duration O
( O
24 O
. O
3 O
+ O
/ O
- O
6 O
. O
8s O
) O
and O
seizure B
number O
( O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
34 O
) O
were O
found O
. O

Acute B
renal I
failure I
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones O
. O

Nephropathy B
caused O
by O
Chinese O
herbs O
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic O
acids O
. O

We O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute B
renal I
failure I
following O
prolonged O
use O
of O
a O
proprietary O
Chinese O
herbal O
slimming O
pill O
that O
contained O
anthraquinone O
derivatives O
, O
extracted O
from O
Rhizoma O
Rhei O
( O
rhubarb O
) O
. O

The O
renal B
injury I
was O
probably O
aggravated O
by O
the O
concomitant O
intake O
of O
a O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
diclofenac O
. O

Spontaneous O
renal O
recovery O
occurred O
upon O
cessation O
of O
the O
slimming O
pills O
, O
but O
mild O
interstitial O
fibrosis B
and O
tubular O
atrophy B
was O
still O
evident O
histologically O
4 O
months O
later O
. O

Although O
a O
causal O
relationship O
between O
the O
use O
of O
an O
anthraquinone O
- O
containing O
herbal O
agent O
and O
renal B
injury I
remains O
to O
be O
proven O
, O
phytotherapy O
- O
associated O
interstitial O
nephropathy B
should O
be O
considered O
in O
patients O
who O
present O
with O
unexplained O
renal B
failure I
. O

Chloroacetaldehyde O
as O
a O
sulfhydryl O
reagent O
: O
the O
role O
of O
critical O
thiol O
groups O
in O
ifosfamide O
nephropathy B
. O

Chloroacetaldehyde O
( O
CAA O
) O
is O
a O
metabolite O
of O
the O
alkylating O
agent O
ifosfamide O
( O
IFO O
) O
and O
putatively O
responsible O
for O
renal B
damage I
following O
anti O
- O
tumor B
therapy O
with O
IFO O
. O

Therefore O
, O
urinary O
acidification O
could O
be O
an O
option O
to O
prevent O
IFO O
nephropathy B
in O
patients O
. O

The O
results O
provide O
new O
insight O
into O
the O
potential O
role O
of O
ectopic O
hilar O
granule O
cells O
in O
the O
pilocarpine O
model O
of O
temporal B
lobe I
epilepsy I
. O

A O
prospective O
, O
open O
- O
label O
trial O
of O
galantamine O
in O
autistic B
disorder I
. O

OBJECTIVE O
: O
Post O
- O
mortem O
studies O
have O
reported O
abnormalities O
of O
the O
cholinergic O
system O
in O
autism B
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
use O
of O
galantamine O
, O
an O
acetylcholinesterase O
inhibitor O
and O
nicotinic O
receptor O
modulator O
, O
in O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B
. O

METHODS O
: O
Thirteen O
medication O
- O
free O
children O
with O
autism B
( O
mean O
age O
, O
8 O
. O
8 O
+ O
/ O
- O
3 O
. O
5 O
years O
) O
participated O
in O
a O
12 O
- O
week O
, O
open O
- O
label O
trial O
of O
galantamine O
. O

CONCLUSION O
: O
In O
this O
open O
trial O
, O
galantamine O
was O
well O
- O
tolerated O
and O
appeared O
to O
be O
beneficial O
for O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B
, O
particularly O
aggression B
, O
behavioral B
dyscontrol I
, O
and O
inattention B
. O

METHOD O
: O
One O
hundred O
twelve O
subjects O
( O
70 O
% O
male O
; O
mean O
age O
= O
23 O
. O
3 O
years O
[ O
SD O
= O
5 O
. O
1 O
] O
) O
with O
first O
- O
episode O
schizophrenia B
( O
75 O
% O
) O
, O
schizophreniform B
disorder I
( O
17 O
% O
) O
, O
or O
schizoaffective B
disorder I
( O
8 O
% O
) O
were O
randomly O
assigned O
to O
treatment O
with O
olanzapine O
( O
2 O
. O
5 O
- O
20 O
mg O
/ O
day O
) O
or O
risperidone O
( O
1 O
- O
6 O
mg O
/ O
day O
) O
. O

Early O
paracentral O
visual B
field I
loss I
in O
patients O
taking O
hydroxychloroquine O
. O

Thirty O
- O
five O
patients O
( O
13 O
. O
4 O
% O
) O
had O
visual B
field I
abnormalities I
, O
which O
were O
attributed O
to O
hydroxychloroquine O
treatment O
in O
4 O
patients O
( O
1 O
. O
5 O
% O
) O
. O

CONCLUSIONS O
: O
The O
current O
study O
used O
a O
protocol O
of O
visual O
acuity O
and O
color O
vision O
assessment O
, O
funduscopy O
, O
and O
Humphrey O
10 O
- O
2 O
visual O
field O
testing O
and O
shows O
that O
visual B
field I
defects I
appeared O
before O
any O
corresponding O
changes O
in O
any O
other O
tested O
clinical O
parameters O
; O
the O
defects O
were O
reproducible O
and O
the O
test O
parameters O
were O
reliable O
. O

Peri O
- O
operative O
atrioventricular B
block I
as O
a O
result O
of O
chemotherapy O
with O
epirubicin O
and O
paclitaxel O
. O

A O
47 O
- O
year O
- O
old O
woman O
presented O
for O
mastectomy O
and O
immediate O
latissimus O
dorsi O
flap O
reconstruction O
having O
been O
diagnosed O
with O
carcinoma B
of I
the I
breast I
6 O
months O
previously O
. O

Second O
degree O
Mobitz O
type O
II O
atrioventricular B
block I
was O
diagnosed O
on O
electrocardiogram O
, O
and O
temporary O
transvenous O
ventricular O
pacing O
instituted O
in O
the O
peri O
- O
operative O
period O
. O

OBJECTIVES O
: O
The O
risk O
of O
acute B
myocardial I
infarction I
( O
AMI B
) O
with O
COX O
- O
2 O
inhibitors O
may O
offset O
their O
gastrointestinal O
( O
GI O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
NS O
) O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
. O

We O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
AMI B
and O
GI B
bleeding I
among O
elderly O
patients O
using O
COX O
- O
2 O
inhibitors O
, O
NS O
- O
NSAIDs O
and O
acetaminophen O
. O

CONCLUSION O
: O
Among O
non O
- O
users O
of O
aspirin O
, O
naproxen O
seemed O
to O
carry O
the O
highest O
risk O
for O
AMI B
/ O
GI B
bleeding I
. O

Quinine O
- O
induced O
arrhythmia B
in O
a O
patient O
with O
severe B
malaria I
. O

It O
was O
reported O
that O
there O
was O
a O
case O
of O
severe B
malaria I
patient O
with O
jaundice B
who O
presented O
with O
arrhythmia B
( O
premature B
ventricular I
contraction I
) O
while O
getting O
quinine O
infusion O
was O
reported O
. O

A O
man O
, O
25 O
years O
old O
, O
was O
admitted O
to O
hospital O
with O
high O
fever B
, O
chill B
, O
vomiting B
, O
jaundice B
. O

On O
admission O
, O
laboratory O
examination O
showed O
Plasmodium O
falciparum O
( O
+ O
+ O
+ O
+ O
) O
, O
total O
bilirubin O
8 O
. O
25 O
mg O
/ O
dL O
, O
conjugated O
bilirubin O
4 O
. O
36 O
mg O
/ O
dL O
, O
unconjugated O
bilirubin O
3 O
. O
89 O
mg O
/ O
dL O
, O
potassium O
3 O
. O
52 O
meq O
/ O
L O
Patient O
was O
diagnosed O
as O
severe B
malaria I
with O
jaundice B
and O
got O
quinine O
infusion O
in O
dextrose O
5 O
% O
500 O
mg O
/ O
8 O
hour O
. O

On O
the O
second O
day O
the O
patient O
had O
vomitus B
, O
diarrhea B
, O
tinnitus B
, O
loss B
of I
hearing I
. O

After O
30 O
hours O
of O
quinine O
infusion O
the O
patient O
felt O
palpitation B
and O
electrocardiography O
( O
ECG O
) O
recording O
showed O
premature B
ventricular I
contraction I
( O
PVC B
) O
> O
5 O
x O
/ O
minute O
, O
trigemini O
, O
constant O
type O
- O
- O
sinoatrial B
block I
, O
positive O
U O
wave O
. O

Administration O
of O
parenteral O
quinine O
must O
be O
done O
carefully O
and O
with O
good O
observation O
because O
of O
its O
pro O
- O
arrhythmic B
effect O
, O
especially O
in O
older O
patients O
who O
have O
heart B
diseases I
or O
patients O
with O
electrolyte B
disorder I
( O
hypokalemia B
) O
which O
frequently O
occurs O
due O
to O
vomiting B
and O
or O
diarrhea B
in O
malaria B
cases O
. O

Penicillamine O
- O
related O
lichenoid B
dermatitis I
and O
utility O
of O
zinc O
acetate O
in O
a O
Wilson B
disease I
patient O
with O
hepatic O
presentation O
, O
anxiety B
and O
SPECT O
abnormalities O
. O

Wilson B
' I
s I
disease I
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper O
metabolism O
with O
consequent O
copper O
accumulation O
and O
toxicity B
in O
many O
tissues O
and O
consequent O
hepatic B
, I
neurologic I
and I
psychiatric I
disorders I
. O

We O
report O
a O
case O
of O
Wilson B
' I
s I
disease I
with O
chronic B
liver I
disease I
; O
moreover O
, O
in O
our O
patient O
, O
presenting O
also O
with O
high O
levels O
of O
state O
anxiety B
without O
depression B
, O
99mTc O
- O
ECD O
- O
SPECT O
showed O
cortical O
hypoperfusion O
in O
frontal O
lobes O
, O
more O
marked O
on O
the O
left O
frontal O
lobe O
. O

During O
the O
follow O
- O
up O
of O
our O
patient O
, O
penicillamine O
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid B
dermatitis I
, O
and O
zinc O
acetate O
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side O
- O
effects O
. O

In O
our O
case O
the O
therapy O
with O
zinc O
acetate O
represented O
an O
effective O
treatment O
for O
a O
Wilson B
' I
s I
disease I
patient O
in O
which O
penicillamine O
- O
related O
side O
effects O
appeared O
. O

The O
safety O
of O
the O
zinc O
acetate O
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
Wilson B
' I
s I
disease I
. O

Since O
most O
of O
Wilson B
' I
s I
disease I
penicillamine O
- O
treated O
patients O
do O
not O
seem O
to O
develop O
this O
skin B
lesion I
, O
it O
could O
be O
conceivable O
that O
a O
specific O
genetic O
factor O
is O
involved O
in O
drug O
response O
. O

Further O
studies O
are O
needed O
for O
a O
better O
clarification O
of O
Wilson B
' I
s I
disease I
therapy O
, O
and O
in O
particular O
to O
differentiate O
specific O
therapies O
for O
different O
Wilson B
' I
s I
disease I
phenotypes O
. O

A O
dramatic O
drop B
in I
blood I
pressure I
following O
prehospital O
GTN O
administration O
. O

Several O
minutes O
after O
the O
GTN O
the O
patient O
experienced O
a O
sudden O
drop B
in I
blood I
pressure I
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine O
sulphate O
and O
a O
fluid O
challenge O
. O

Acute B
encephalopathy I
and O
cerebral B
vasospasm I
after O
multiagent O
chemotherapy O
including O
PEG O
- O
asparaginase O
and O
intrathecal O
cytarabine O
for O
the O
treatment O
of O
acute B
lymphoblastic I
leukemia I
. O

A O
7 O
- O
year O
- O
old O
girl O
with O
an O
unusual O
reaction O
to O
induction O
chemotherapy O
for O
precursor O
B O
- O
cell O
acute B
lymphoblastic I
leukemia I
( O
ALL B
) O
is O
described O
. O

The O
patient O
developed O
acute B
encephalopathy I
evidenced O
by O
behavioral O
changes O
, O
aphasia B
, O
incontinence B
, O
visual B
hallucinations I
, O
and O
right O
- O
sided O
weakness B
with O
diffuse O
cerebral B
vasospasm I
on O
magnetic O
resonance O
angiography O
after O
the O
administration O
of O
intrathecal O
cytarabine O
. O

OBJECTIVE O
: O
This O
study O
investigated O
the O
efficacy O
and O
tolerability O
of O
valsartan O
( O
VAL O
) O
or O
hydrochlorothiazide O
( O
HCTZ O
) O
- O
monotherapy O
and O
higher O
- O
dose O
combinations O
in O
patients O
with O
essential B
hypertension I
. O

Patients O
with O
essential B
hypertension I
( O
mean O
sitting O
diastolic O
BP O
[ O
MSDBP O
] O
, O
> O
or O
= O
95 O
mm O
Hg O
and O
< O
110 O
mm O
Hg O
) O
were O
randomized O
to O
1 O
of O
8 O
treatment O
groups O
: O
VAL O
160 O
or O
320 O
mg O
; O
HCTZ O
12 O
. O
5 O
or O
25 O
mg O
; O
VAL O
/ O
HCTZ O
160 O
/ O
12 O
. O
5 O
, O
320 O
/ O
12 O
. O
5 O
, O
or O
320 O
/ O
25 O
mg O
; O
or O
placebo O
. O

Succimer O
chelation O
improves O
learning O
, O
attention O
, O
and O
arousal O
regulation O
in O
lead O
- O
exposed O
rats O
but O
produces O
lasting O
cognitive B
impairment I
in O
the O
absence O
of O
lead O
exposure O
. O

RESULTS O
: O
Pb O
exposure O
produced O
lasting O
impairments B
in I
learning I
, I
attention I
, I
inhibitory I
control I
, I
and I
arousal I
regulation I
, O
paralleling O
the O
areas O
of O
dysfunction O
seen O
in O
Pb O
- O
exposed O
children O
. O

In O
contrast O
, O
succimer O
treatment O
of O
rats O
not O
previously O
exposed O
to O
Pb O
produced O
lasting O
and O
pervasive O
cognitive B
and I
affective I
dysfunction I
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
Pb O
exposure O
regimen O
. O

CONCLUSIONS O
: O
These O
are O
the O
first O
data O
, O
to O
our O
knowledge O
, O
to O
show O
that O
treatment O
with O
any O
chelating O
agent O
can O
alleviate O
cognitive B
deficits I
due O
to O
Pb O
exposure O
. O

Caffeine O
challenge O
test O
in O
panic B
disorder I
and O
depression B
with O
panic B
attacks I
. O

Our O
aim O
was O
to O
observe O
if O
patients O
with O
panic B
disorder I
( O
PD B
) O
and O
patients O
with O
major B
depression I
with O
panic B
attacks I
( O
MDP B
) O
( O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental B
Disorders I
, O
Fourth O
Edition O
criteria O
) O
respond O
in O
a O
similar O
way O
to O
the O
induction O
of O
panic B
attacks I
by O
an O
oral O
caffeine O
challenge O
test O
. O

We O
randomly O
selected O
29 O
patients O
with O
PD B
, O
27 O
with O
MDP B
, O
25 O
with O
major B
depression I
without O
panic B
attacks I
( O
MD B
) O
, O
and O
28 O
healthy O
volunteers O
. O

In O
a O
randomized O
double O
- O
blind O
experiment O
performed O
in O
2 O
occasions O
7 O
days O
apart O
, O
480 O
mg O
caffeine O
and O
a O
caffeine O
- O
free O
( O
placebo O
) O
solution O
were O
administered O
in O
a O
coffee O
form O
and O
anxiety B
scales O
were O
applied O
before O
and O
after O
each O
test O
. O

A O
total O
of O
58 O
. O
6 O
% O
( O
n O
= O
17 O
) O
of O
patients O
with O
PD B
, O
44 O
. O
4 O
% O
( O
n O
= O
12 O
) O
of O
patients O
with O
MDP B
, O
12 O
. O
0 O
% O
( O
n O
= O
3 O
) O
of O
patients O
with O
MD B
, O
and O
7 O
. O
1 O
% O
( O
n O
= O
2 O
) O
of O
control O
subjects O
had O
a O
panic B
attack I
after O
the O
480 O
- O
mg O
caffeine O
challenge O
test O
( O
chi O
( O
2 O
) O
( O
3 O
) O
= O
16 O
. O
22 O
, O
P O
= O
. O
001 O
) O
. O

No O
panic B
attack I
was O
observed O
after O
the O
caffeine O
- O
free O
solution O
intake O
. O

Our O
data O
suggest O
that O
there O
is O
an O
association O
between O
panic B
attacks I
, O
no O
matter O
if O
associated O
with O
PD B
or O
MDP B
, O
and O
hyperreactivity O
to O
an O
oral O
caffeine O
challenge O
test O
. O

BACKGROUND O
AND O
AIM O
OF O
THE O
STUDY O
: O
Undersized O
mitral O
annuloplasty O
( O
MAP O
) O
is O
effective O
in O
patients O
with O
dilated B
cardiomyopathy I
and O
functional O
mitral B
regurgitation I
( O
MR B
) O
since O
, O
as O
well O
as O
addressing O
the O
MR B
, O
the O
MAP O
may O
also O
reshape O
the O
dilated O
left O
ventricular O
( O
LV O
) O
base O
. O

The O
study O
aim O
was O
to O
identify O
these O
benefits O
in O
a O
canine O
model O
of O
acute O
heart B
failure I
. O

Acute O
heart B
failure I
was O
induced O
by O
propranolol O
and O
volume O
loading O
after O
weaning O
from O
cardiopulmonary O
bypass O
; O
an O
absence O
of O
MR B
was O
confirmed O
by O
echocardiography O
. O

Data O
were O
acquired O
at O
baseline O
, O
after O
induction O
of O
acute O
heart B
failure I
, O
and O
after O
MAP O
. O

CONCLUSION O
: O
The O
data O
acquired O
suggest O
that O
isolated O
MAP O
may O
have O
certain O
benefits O
on O
LV O
dimension O
/ O
function O
in O
acute O
heart B
failure I
, O
even O
in O
the O
absence O
of O
MR B
. O

However O
, O
further O
investigations O
are O
warranted O
in O
a O
model O
of O
chronic O
heart B
failure I
. O

Piperacillin O
/ O
tazobactam O
- O
induced O
seizure B
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

We O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end B
- I
stage I
renal I
disease I
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor B
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion B
, O
and O
2 O
episodes O
of O
generalized O
tonic B
- I
clonic I
seizure I
( O
GTCS B
) O
after O
5 O
doses O
of O
piperacillin O
/ O
tazobactam O
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis B
with O
secondary B
infection I
. O

Brain O
magnetic O
resonance O
imaging O
did O
not O
demonstrate O
acute O
infarction B
and O
organic B
brain I
lesions I
. O

Frequency O
of O
transient O
ipsilateral O
vocal B
cord I
paralysis I
in O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

Twelve O
patients O
( O
43 O
% O
) O
were O
found O
to O
have O
intraoperative O
ipsilateral O
vocal B
cord I
paralysis I
. O

There O
were O
no O
significant O
differences O
in O
operating O
time O
or O
volume O
or O
frequency O
of O
anesthetic O
administration O
in O
patients O
with O
temporary O
vocal B
cord I
paralysis I
compared O
with O
those O
without O
. O

CONCLUSION O
: O
Local O
anesthesia O
led O
to O
temporary O
ipsilateral O
vocal B
cord I
paralysis I
in O
almost O
half O
of O
these O
patients O
. O

In O
patients O
with O
preoperative O
contralateral O
vocal B
cord I
paralysis I
, O
surgery O
under O
general O
anesthesia O
should O
be O
considered O
. O

Impaired B
fear I
recognition I
in O
regular O
recreational O
cocaine O
users O
. O

RESULTS O
: O
There O
were O
no O
group O
differences O
in O
psychopathology O
or O
" O
eyes O
task O
" O
performance O
, O
but O
the O
RC O
group O
, O
who O
otherwise O
had O
similar O
illicit O
substance O
use O
histories O
to O
the O
OC O
group O
, O
exhibited O
impaired B
fear I
recognition I
accuracy O
compared O
to O
the O
OC O
and O
CN O
groups O
. O

The O
selective O
deficit B
in I
fear I
recognition I
accuracy O
manifested O
by O
the O
RC O
group O
cannot O
be O
explained O
by O
the O
subacute O
effects O
of O
cocaine O
, O
or O
ecstasy O
, O
because O
recent O
and O
less O
recent O
users O
of O
these O
drugs O
within O
this O
group O
were O
similarly O
impaired O
. O

Possible O
parallels O
between O
RC O
users O
and O
psychopaths B
with O
respect O
to O
impaired B
fear I
recognition I
, O
amygdala B
dysfunction I
, O
and O
etiology O
are O
discussed O
. O

Damage B
of I
substantia I
nigra I
pars I
reticulata I
during O
pilocarpine O
- O
induced O
status B
epilepticus I
in O
the O
rat O
: O
immunohistochemical O
study O
of O
neurons O
, O
astrocytes O
and O
serum O
- O
protein O
extravasation O
. O

Additionally O
, O
in O
models O
of O
prolonged B
status I
epilepticus I
the O
pars O
reticulata O
of O
substantia O
nigra O
( O
SNR O
) O
suffers O
from O
a O
massive O
lesion O
which O
may O
arise O
from O
a O
massive O
metabolic B
derangement I
and O
hyperexcitation O
developing O
in O
the O
activated O
SNR O
. O

Nissl O
- O
staining O
and O
antibodies O
against O
the O
neuron O
- O
specific O
calcium O
- O
binding O
protein O
, O
parvalbumin O
, O
served O
to O
detect O
neuronal B
damage I
in O
SNR O
. O

Immunohistochemical O
staining O
for O
serum O
- O
albumin O
and O
immunoglobulins O
in O
brain O
tissue O
was O
taken O
as O
indicator O
of O
blood O
- O
brain O
barrier O
disturbances O
and O
vasogenic B
edema I
formation O
. O

By O
2 O
hours O
, O
parvalbumin O
- O
staining O
changed O
in O
the O
central O
SNR O
indicating O
neuronal B
damage I
, O
and O
Nissl O
- O
staining O
visualized O
some O
neuronal O
distortion O
. O

By O
6 O
h O
, O
vasogenic B
edema I
covered O
the O
lesioned B
SNR I
. O

In O
a O
further O
group O
of O
animals O
surviving O
1 O
to O
5 O
days O
, O
conventional O
paraffin O
- O
sections O
confirmed O
the O
neuronal O
and O
glial O
damage B
of I
SNR I
. O

Both O
cell O
elements O
may O
suffer O
in O
common O
from O
metabolic O
disturbance O
and O
neurotransmitter B
dysfunction I
as O
occur O
during O
massive O
status B
epilepticus I
. O

Neuroprotective O
effects O
of O
melatonin O
upon O
the O
offspring O
cerebellar O
cortex O
in O
the O
rat O
model O
of O
BCNU O
- O
induced O
cortical B
dysplasia I
. O

Cortical B
dysplasia I
is O
a O
malformation O
characterized O
by O
defects O
in O
proliferation O
, O
migration O
and O
maturation O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine O
- O
[ O
1 O
, O
3 O
- O
bis O
( O
2 O
- O
chloroethyl O
) O
- O
1 O
- O
nitrosoure O
] O
( O
BCNU O
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin O
upon O
cerebellar O
BCNU O
- O
induced O
cortical B
dysplasia I
, O
using O
histological O
and O
biochemical O
analyses O
. O

Histopathologically O
, O
typical O
findings O
were O
observed O
in O
the O
cerebella O
from O
the O
control O
groups O
, O
but O
the O
findings O
consistent O
with O
early O
embryonic O
development O
were O
noted O
in O
BCNU O
- O
exposed O
cortical B
dysplasia I
group O
. O

Corneal B
ulcers I
associated O
with O
aerosolized O
crack O
cocaine O
use O
. O

PURPOSE O
: O
We O
report O
4 O
cases O
of O
corneal B
ulcers I
associated O
with O
drug B
abuse I
. O

METHODS O
: O
Review O
of O
all O
cases O
of O
corneal B
ulcers I
associated O
with O
drug B
abuse I
seen O
at O
our O
institution O
from O
July O
2006 O
to O
December O
2006 O
. O

RESULTS O
: O
Four O
patients O
with O
corneal B
ulcers I
associated O
with O
crack O
cocaine O
use O
were O
reviewed O
. O

All O
corneal B
ulcers I
were O
cultured O
, O
and O
the O
patients O
were O
admitted O
to O
the O
hospital O
for O
intensive O
topical O
antibiotic O
treatment O
. O

Two O
patients O
needed O
a O
lateral O
tarsorrhaphy O
for O
persistent O
epithelial B
defects I
. O

CONCLUSIONS O
: O
Aerosolized O
crack O
cocaine O
use O
can O
be O
associated O
with O
the O
development O
of O
corneal B
ulcers I
. O

Topical O
0 O
. O
025 O
% O
capsaicin O
in O
chronic O
post B
- I
herpetic I
neuralgia I
: O
efficacy O
, O
predictors O
of O
response O
and O
long O
- O
term O
course O
. O

In O
order O
to O
evaluate O
the O
efficacy O
, O
time O
- O
course O
of O
action O
and O
predictors O
of O
response O
to O
topical O
capsaicin O
, O
39 O
patients O
with O
chronic O
post B
- I
herpetic I
neuralgia I
( O
PHN B
) O
, O
median O
duration O
24 O
months O
, O
were O
treated O
with O
0 O
. O
025 O
% O
capsaicin O
cream O
for O
8 O
weeks O
. O

Treatment O
effect O
was O
not O
dependent O
on O
patient O
' O
s O
age O
, O
duration O
or O
localization O
of O
PHN B
( O
trigeminal O
involvement O
was O
excluded O
) O
, O
sensory B
disturbance I
or O
pain B
character O
. O

Acute B
tubulo I
- I
interstitial I
nephritis I
( O
ATIN B
) O
is O
an O
important O
cause O
of O
acute B
renal I
failure I
resulting O
from O
a O
variety O
of O
insults O
, O
including O
immune O
complex O
- O
mediated O
tubulo B
- I
interstitial I
injury I
, O
but O
drugs O
such O
as O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
are O
a O
far O
more O
frequent O
cause O
. O

We O
report O
on O
a O
14 O
- O
year O
- O
old O
boy O
who O
developed O
acute B
renal I
failure I
2 O
weeks O
after O
aortic O
valve O
surgery O
. O

He O
was O
put O
on O
aspirin O
following O
surgery O
and O
took O
ibuprofen O
for O
fever B
for O
nearly O
a O
week O
prior O
to O
presentation O
. O

His O
renal O
recovery O
and O
disappearance O
of O
proteinuria B
took O
a O
year O
. O

Rifampicin O
- O
associated O
segmental O
necrotizing O
glomerulonephritis B
in O
staphylococcal B
endocarditis I
. O

Segmental O
necrotising O
glomerulonephritis B
has O
been O
reported O
as O
complication O
of O
rifampicin O
therapy O
in O
patients O
receiving O
treatment O
for O
tuberculosis B
. O

Changing O
epidemiology O
of O
infections B
such O
as O
infective B
endocarditis I
( O
IE B
) O
has O
led O
to O
an O
increase O
in O
the O
use O
of O
rifampicin O
for O
Staphylococcal B
infections I
. O

We O
describe O
a O
case O
of O
a O
patient O
with O
Staphylococcal B
IE I
who O
developed O
acute B
renal I
failure I
secondary O
to O
a O
segmental O
necrotising O
glomerulonephritis B
while O
being O
treated O
with O
rifampicin O
, O
and O
review O
the O
literature O
regarding O
this O
complication O
of O
rifampicin O
therapy O
. O

Rate O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
Iranian O
patients O
with O
chronic B
hepatitis I
B I
virus I
infection I
. O

BACKGROUND O
: O
Lamivudine O
is O
used O
for O
the O
treatment O
of O
chronic B
hepatitis I
B I
patients O
. O

Recent O
studies O
show O
that O
the O
YMDD O
motif O
mutants O
( O
resistant O
hepatitis B
B I
virus O
) O
occur O
as O
natural O
genome O
variability O
in O
lamivudine O
- O
untreated O
chronic B
hepatitis I
B I
patients O
. O

In O
this O
study O
we O
aimed O
to O
determine O
the O
rate O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
chronic B
hepatitis I
B I
patients O
in O
Iran O
. O

PATIENTS O
AND O
METHODS O
: O
A O
total O
of O
77 O
chronic B
hepatitis I
B I
patients O
who O
had O
not O
been O
treated O
with O
lamivudine O
were O
included O
in O
the O
study O
. O

CONCLUSION O
: O
Although O
the O
natural O
occurrence O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
patients O
with O
chronic B
hepatitis I
B I
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
Iranian O
lamivudine O
- O
untreated O
chronic B
hepatitis I
B I
patients O
. O

Branch O
retinal B
vein I
occlusion I
and O
fluoxetine O
. O

A O
case O
of O
branch O
retinal B
vein I
occlusion I
associated O
with O
fluoxetine O
- O
induced O
secondary O
hypertension B
is O
described O
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
bupivacaine O
stimulates O
COX O
- O
2 O
gene O
expression O
after O
tissue B
injury I
, O
which O
is O
associated O
with O
higher O
PGE2 O
production O
and O
pain B
after O
the O
local O
anesthetic O
effect O
dissipates O
. O

Previous O
studies O
have O
examined O
the O
expression O
and O
regulation O
of O
tyrosine O
kinase O
receptors O
( O
Trks O
) O
in O
micturition O
reflexes O
with O
urinary B
bladder I
inflammation I
. O

The O
present O
studies O
examine O
the O
expression O
and O
regulation O
of O
another O
receptor O
known O
to O
bind O
NGF O
, O
p75 O
( O
NTR O
) O
, O
after O
various O
durations O
of O
bladder B
inflammation I
induced O
by O
cyclophosphamide O
( O
CYP O
) O
. O

These O
studies O
demonstrate O
that O
p75 O
( O
NTR O
) O
expression O
in O
micturition O
reflexes O
is O
present O
constitutively O
and O
modified O
by O
bladder B
inflammation I
. O

The O
side O
effects O
of O
azathioprine O
include O
anemia B
, O
which O
has O
been O
attributed O
to O
bone O
marrow O
suppression O
. O

Alternatively O
, O
anemia B
could O
result O
from O
accelerated O
suicidal O
erythrocyte O
death O
or O
eryptosis O
, O
which O
is O
characterized O
by O
exposure O
of O
phosphatidylserine O
( O
PS O
) O
at O
the O
erythrocyte O
surface O
and O
by O
cell O
shrinkage O
. O

CONCLUSIONS O
: O
Azathioprine O
triggers O
suicidal O
erythrocyte O
death O
, O
an O
effect O
presumably O
contributing O
to O
azathioprine O
- O
induced O
anemia B
. O

Levetiracetam O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
suspected O
idiopathic B
epilepsy I
. O

OBJECTIVE O
: O
To O
assess O
pharmacokinetics O
, O
efficacy O
, O
and O
tolerability O
of O
oral O
levetiracetam O
administered O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
poorly O
controlled O
suspected O
idiopathic B
epilepsy I
. O

ANIMALS O
: O
12 O
cats O
suspected O
to O
have O
idiopathic B
epilepsy I
that O
was O
poorly O
controlled O
with O
phenobarbital O
or O
that O
had O
unacceptable O
adverse O
effects O
when O
treated O
with O
phenobarbital O
. O

Median O
seizure B
frequency O
prior O
to O
treatment O
with O
levetiracetam O
( O
2 O
. O
1 O
seizures B
/ O
mo O
) O
was O
significantly O
higher O
than O
median O
seizure B
frequency O
after O
initiation O
of O
levetiracetam O
treatment O
( O
0 O
. O
42 O
seizures B
/ O
mo O
) O
, O
and O
7 O
of O
10 O
cats O
were O
classified O
as O
having O
responded O
to O
levetiracetam O
treatment O
( O
ie O
, O
reduction O
in O
seizure B
frequency O
of O
> O
or O
= O
50 O
% O
) O
. O

CONCLUSIONS O
AND O
CLINICAL O
RELEVANCE O
: O
Results O
suggested O
that O
levetiracetam O
is O
well O
tolerated O
in O
cats O
and O
may O
be O
useful O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
idiopathic B
epilepsy I
. O

Elements O
common O
to O
these O
cases O
included O
a O
history O
of O
paranoid B
symptomatology O
and O
the O
concomitant O
occurrence O
of O
depressive B
and I
psychotic I
symptoms I
. O

Complicated O
depressive B
disorders I
( O
including O
atypicality O
of O
course O
and O
symptomatology O
, O
chronicity O
, O
psychosis B
, O
bipolarity O
, O
and O
secondary O
onset O
in O
the O
course O
of O
a O
primary O
psychosis B
) O
may O
present O
particular O
vulnerability O
to O
paranoid B
exacerbations O
associated O
with O
serotonin O
reuptake O
inhibitors O
. O

Spectrum O
of O
adverse O
events O
after O
generic O
HAART O
in O
southern O
Indian O
HIV B
- I
infected I
patients O
. O

To O
determine O
the O
incidence O
of O
clinically O
significant O
adverse O
events O
after O
long O
- O
term O
, O
fixed O
- O
dose O
, O
generic O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
use O
among O
HIV B
- I
infected I
individuals O
in O
South O
India O
, O
we O
examined O
the O
experiences O
of O
3154 O
HIV B
- I
infected I
individuals O
who O
received O
a O
minimum O
of O
3 O
months O
of O
generic O
HAART O
between O
February O
1996 O
and O
December O
2006 O
at O
a O
tertiary O
HIV O
care O
referral O
center O
in O
South O
India O
. O

The O
most O
common O
adverse O
events O
and O
median O
CD4 O
at O
time O
of O
event O
were O
rash B
( O
15 O
. O
2 O
% O
; O
CD4 O
, O
285 O
cells O
/ O
microL O
) O
and O
peripheral B
neuropathy I
( O
9 O
. O
0 O
% O
and O
348 O
cells O
/ O
microL O
) O
. O

Clinically O
significant O
anemia B
( O
hemoglobin O
< O
7 O
g O
/ O
dL O
) O
was O
observed O
in O
5 O
. O
4 O
% O
of O
patients O
( O
CD4 O
, O
165 O
cells O
/ O
microL O
) O
and O
hepatitis B
( O
clinical O
jaundice B
with O
alanine O
aminotransferase O
> O
5 O
times O
upper O
limits O
of O
normal O
) O
in O
3 O
. O
5 O
% O
of O
patients O
( O
CD4 O
, O
260 O
cells O
/ O
microL O
) O
. O

Women O
were O
significantly O
more O
likely O
to O
experience O
lactic B
acidosis I
, O
while O
men O
were O
significantly O
more O
likely O
to O
experience O
immune B
reconstitution I
syndrome I
( O
p O
< O
0 O
. O
05 O
) O
. O

Among O
the O
patients O
with O
1 O
year O
of O
follow O
- O
up O
, O
NVP O
therapy O
was O
significantly O
associated O
with O
developing O
rash B
and O
d4T O
therapy O
with O
developing O
peripheral B
neuropathy I
( O
p O
< O
0 O
. O
05 O
) O
. O

Thalidomide O
and O
sensory B
neurotoxicity I
: O
a O
neurophysiological O
study O
. O

BACKGROUND O
: O
Recent O
studies O
confirmed O
a O
high O
incidence O
of O
sensory B
axonal I
neuropathy I
in O
patients O
treated O
with O
different O
doses O
of O
thalidomide O
. O

The O
study O
' O
s O
aims O
were O
to O
measure O
variations O
in O
sural O
nerve O
sensory O
action O
potential O
( O
SAP O
) O
amplitude O
in O
patients O
with O
refractory O
cutaneous B
lupus I
erythematosus I
( O
CLE B
) O
treated O
with O
thalidomide O
and O
use O
these O
findings O
to O
identify O
the O
neurotoxic B
potential O
of O
thalidomide O
and O
the O
recovery O
capacity O
of O
sensory O
fibres O
after O
discontinuation O
of O
treatment O
. O

Amiodarone O
- O
related O
pulmonary B
mass I
and O
unique O
membranous B
glomerulonephritis I
in O
a O
patient O
with O
valvular B
heart I
disease I
: O
Diagnostic O
pitfall O
and O
new O
findings O
. O

Reported O
herein O
is O
an O
autopsy O
case O
of O
valvular B
heart I
disease I
, O
in O
a O
patient O
who O
developed O
a O
lung B
mass I
( O
1 O
. O
5 O
cm O
in O
diameter O
) O
and O
proteinuria B
( O
2 O
. O
76 O
g O
/ O
day O
) O
after O
treatment O
with O
amiodarone O
for O
a O
long O
time O
. O

The O
lung B
mass I
was O
highly O
suspected O
to O
be O
lung B
cancer I
on O
CT O
and O
positron O
emission O
tomography O
, O
but O
histologically O
the O
lesion O
was O
composed O
of O
lymphoplasmacytic O
infiltrates O
in O
alveolar O
walls O
and O
intra O
- O
alveolar O
accumulation O
of O
foamy O
macrophages O
containing O
characteristic O
myelinoid O
bodies O
, O
indicating O
that O
it O
was O
an O
amiodarone O
- O
related O
lesion O
. O

Autoimmune B
diseases I
, O
viral B
hepatitis I
, O
malignant O
neoplasms B
or O
other O
diseases O
with O
a O
known O
relationship O
to O
membranous B
glomerulonephritis I
were O
not O
found O
. O

The O
present O
case O
highlights O
the O
possibility O
that O
differential O
diagnosis O
between O
an O
amiodarone O
- O
related O
pulmonary B
lesion I
and O
a O
neoplasm B
can O
be O
very O
difficult O
radiologically O
, O
and O
suggests O
that O
membranous B
glomerulonephritis I
might O
be O
another O
possible O
complication O
of O
amiodarone O
treatment O
. O

Risk O
of O
coronary B
artery I
disease I
associated O
with O
initial O
sulphonylurea O
treatment O
of O
patients O
with O
type B
2 I
diabetes I
: O
a O
matched O
case O
- O
control O
study O
. O

AIMS O
: O
This O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary B
artery I
disease I
( O
CAD B
) O
associated O
with O
initial O
treatment O
of O
type B
2 I
diabetes I
with O
different O
sulphonylureas O
. O

METHODS O
: O
In O
type B
2 I
diabetic I
patients O
, O
cases O
who O
developed O
CAD B
were O
compared O
retrospectively O
with O
controls O
that O
did O
not O
. O

The O
20 O
- O
year O
risk O
of O
CAD B
at O
diagnosis O
of O
diabetes B
, O
using O
the O
UKPDS O
risk O
engine O
, O
was O
used O
to O
match O
cases O
with O
controls O
. O

CONCLUSIONS O
: O
Initiating O
treatment O
of O
type B
2 I
diabetes I
with O
glibenclamide O
or O
glipizide O
is O
associated O
with O
increased O
risk O
of O
CAD B
in O
comparison O
to O
gliclazide O
or O
glimepiride O
. O

Reduced O
progression O
of O
adriamycin O
nephropathy B
in O
spontaneously O
hypertensive B
rats O
treated O
by O
losartan O
. O

BACKGROUND O
: O
The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
antihypertensive O
effects O
of O
angiotensin O
II O
type O
- O
1 O
receptor O
blocker O
, O
losartan O
, O
and O
its O
potential O
in O
slowing O
down O
renal B
disease I
progression O
in O
spontaneously O
hypertensive B
rats O
( O
SHR O
) O
with O
adriamycin O
( O
ADR O
) O
nephropathy B
. O

RESULTS O
: O
Short O
- O
term O
losartan O
treatment O
, O
besides O
antihypertensive O
effect O
, O
improved O
glomerular O
filtration O
rate O
and O
ameliorated O
glomerulosclerosis B
resulting O
in O
decreased O
proteinuria B
. O

Prolonged O
treatment O
with O
losartan O
showed O
further O
reduction O
of O
glomerulosclerosis B
associated O
with O
reduced O
progression O
of O
tubular O
atrophy B
and O
interstitial B
fibrosis I
, O
thus O
preventing O
heavy O
proteinuria B
and O
chronic B
renal I
failure I
. O

Losartan O
reduced O
uraemia B
and O
increased O
urea O
clearance O
in O
advanced O
ADR O
nephropathy B
in O
SHR O
. O

Histological O
examination O
showed O
that O
losartan O
could O
prevent O
tubular O
atrophy B
, O
interstitial O
infiltration O
and O
fibrosis B
in O
ADR O
nephropathy B
. O

CONCLUSION O
: O
Losartan O
reduces O
the O
rate O
of O
progression O
of O
ADR O
- O
induced O
focal B
segmental I
glomerulosclerosis I
to O
end B
- I
stage I
renal I
disease I
in O
SHR O
. O

Persistent O
atrial O
fibrillation O
( O
7 O
. O
9 O
% O
vs O
2 O
. O
3 O
% O
, O
P O
= O
0 O
. O
020 O
) O
and O
renal B
failure I
( O
9 O
. O
7 O
% O
vs O
1 O
. O
7 O
% O
, O
P O
= O
0 O
. O
002 O
) O
were O
also O
more O
common O
in O
Group O
T O
, O
in O
the O
primary O
valve O
surgery O
subgroup O
. O

On O
the O
contrary O
, O
among O
primary O
coronary O
artery O
bypass O
surgery O
patients O
, O
there O
were O
more O
acute O
myocardial B
infarctions I
and O
renal B
dysfunction I
in O
Group O
A O
( O
5 O
. O
8 O
% O
vs O
2 O
. O
0 O
% O
, O
P O
= O
0 O
. O
027 O
; O
22 O
. O
5 O
% O
vs O
15 O
. O
2 O
% O
, O
P O
= O
0 O
. O
036 O
, O
respectively O
) O
. O

The O
biological O
properties O
of O
the O
optical O
isomers O
of O
propranolol O
and O
their O
effects O
on O
cardiac B
arrhythmias I
. O

Both O
isomers O
of O
propranolol O
were O
capable O
of O
preventing O
adrenaline O
- O
induced O
cardiac B
arrhythmias I
in O
cats O
anaesthetized O
with O
halothane O
, O
but O
the O
mean O
dose O
of O
( O
- O
) O
- O
propranolol O
was O
0 O
. O
09 O
+ O
/ O
- O
0 O
. O
02 O
mg O
/ O
kg O
whereas O
that O
of O
( O
+ O
) O
- O
propranolol O
was O
4 O
. O
2 O
+ O
/ O
- O
1 O
. O
2 O
mg O
/ O
kg O
. O

Topotecan O
is O
an O
attractive O
option O
as O
it O
exhibits O
growth O
inhibition O
of O
human O
glioma B
as O
well O
as O
brain O
penetration O
. O

CONCLUSION O
: O
Primary B
hyperparathyroidism I
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
side O
effect O
of O
long O
- O
term O
lithium O
therapy O
. O

Nonalcoholic B
fatty I
liver I
disease I
during O
valproate O
therapy O
. O

We O
report O
a O
case O
of O
nonalcoholic B
fatty I
liver I
disease I
( O
NAFLD B
) O
arising O
in O
a O
child O
who O
developed O
obesity B
during O
VPA O
treatment O
. O

After O
the O
withdrawal O
of O
VPA O
therapy O
, O
our O
patient O
showed O
a O
significant O
weight B
loss I
, O
a O
decrease O
of O
body O
mass O
index O
, O
and O
normalization O
of O
metabolic O
and O
endocrine O
parameters O
; O
moreover O
, O
ultrasound O
measurements O
showed O
a O
complete O
normalization O
. O

The O
present O
case O
suggests O
that O
obesity B
, O
hyperinsulinemia B
, O
insulin B
resistance I
, O
and O
long O
- O
term O
treatment O
with O
VPA O
may O
be O
all O
associated O
with O
the O
development O
of O
NAFLD B
; O
this O
side O
effect O
is O
reversible O
after O
VPA O
withdrawal O
. O

Carbimazole O
induced O
ANCA B
positive I
vasculitis I
. O

Antineutrophil B
cytoplasmic I
antibody I
( I
ANCA I
) I
- I
- I
associated I
vasculitis I
is O
a O
potentially O
life O
- O
threatening O
adverse O
effect O
of O
antithyroidmedications O
. O

We O
report O
a O
patient O
with O
Graves B
' I
disease I
who O
developed O
ANCA O
positive O
carbimazole O
induced O
vasculitis B
. O

The O
episode O
was O
characterized O
by O
a O
vasculitic B
skin B
rash I
associated O
with O
large O
joint O
arthritis B
, O
pyrexia B
and O
parotiditis B
but O
no O
renal O
or O
pulmonary O
involvement O
. O

To O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
ANCA O
positive O
carbimazole O
induced O
vasculitis B
case O
reported O
from O
India O
. O

BACKGROUND O
: O
Coronary B
heart I
disease I
and O
cerebrovascular B
disease I
are O
leading O
causes O
of O
death O
in O
the O
United O
States O
. O

Preventive O
Services O
Task O
Force O
( O
USPSTF O
) O
strongly O
recommended O
that O
clinicians O
discuss O
aspirin O
with O
adults O
who O
are O
at O
increased O
risk O
for O
coronary B
heart I
disease I
. O

STUDY O
SELECTION O
: O
English O
- O
language O
randomized O
, O
controlled O
trials O
( O
RCTs O
) O
; O
case O
- O
control O
studies O
; O
meta O
- O
analyses O
; O
and O
systematic O
reviews O
of O
aspirin O
versus O
control O
for O
the O
primary O
prevention O
of O
cardiovascular B
disease I
( O
CVD B
) O
were O
selected O
to O
answer O
the O
following O
questions O
: O
Does O
aspirin O
decrease O
coronary O
heart O
events O
, O
strokes B
, O
death O
from O
coronary O
heart O
events O
or O
stroke B
, O
or O
all O
- O
cause O
mortality O
in O
adults O
without O
known O
CVD B
? O

Does O
aspirin O
increase O
gastrointestinal B
bleeding I
or O
hemorrhagic B
strokes I
? O

The O
use O
of O
aspirin O
for O
primary O
prevention O
increases O
the O
risk O
for O
major O
bleeding B
events O
, O
primarily O
gastrointestinal B
bleeding I
events O
, O
in O
both O
men O
and O
women O
. O

Reducing O
harm O
associated O
with O
anticoagulation O
: O
practical O
considerations O
of O
argatroban O
therapy O
in O
heparin O
- O
induced O
thrombocytopenia B
. O

Argatroban O
is O
a O
hepatically O
metabolized O
, O
direct O
thrombin O
inhibitor O
used O
for O
prophylaxis O
or O
treatment O
of O
thrombosis B
in O
heparin O
- O
induced O
thrombocytopenia B
( O
HIT B
) O
and O
for O
patients O
with O
or O
at O
risk O
of O
HIT B
undergoing O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O

The O
US O
FDA O
- O
recommended O
argatroban O
dose O
in O
HIT B
is O
2 O
microg O
/ O
kg O
/ O
min O
( O
reduced O
in O
patients O
with O
hepatic B
impairment I
and O
in O
paediatric O
patients O
) O
, O
adjusted O
to O
achieve O
activated O
partial O
thromboplastin O
times O
( O
aPTTs O
) O
1 O
. O
5 O
- O
3 O
times O
baseline O
( O
not O
> O
100 O
seconds O
) O
. O

Contemporary O
experiences O
indicate O
that O
reduced O
doses O
are O
also O
needed O
in O
patients O
with O
conditions O
associated O
with O
hepatic O
hypoperfusion O
, O
e O
. O
g O
. O
heart B
failure I
, O
yet O
are O
unnecessary O
for O
renal B
dysfunction I
, O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B
. O

For O
PCI O
, O
argatroban O
has O
not O
been O
investigated O
in O
hepatically O
impaired O
patients O
; O
dose O
adjustment O
is O
unnecessary O
for O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B
, O
and O
lesser O
doses O
may O
be O
adequate O
with O
concurrent O
glycoprotein O
IIb O
/ O
IIIa O
inhibition O
. O

Rhabdomyolysis B
and O
brain O
ischemic B
stroke I
in O
a O
heroin O
- O
dependent O
male O
under O
methadone O
maintenance O
therapy O
. O

RESULTS O
: O
A O
33 O
- O
year O
- O
old O
man O
presented O
with O
rhabdomyolysis B
and O
cerebral O
ischemic B
stroke I
after O
intravenous O
heroin O
. O

In O
the O
ICU O
, O
we O
found O
rhabdomyolysis B
, O
acute B
renal I
failure I
and O
acute O
respiratory B
failure I
. O

After O
transfer O
to O
an O
internal O
ward O
, O
we O
noted O
aphasia B
and O
weakness B
of O
his O
left O
limbs O
. O

After O
MRI O
, O
we O
found O
cerebral B
ischemic I
infarction I
. O

CONCLUSION O
: O
Those O
using O
methadone O
and O
heroin O
simultaneously O
may O
increase O
risk O
of O
rhabdomyolysis B
and O
ischemic B
stroke I
. O

Hepatocellular O
oxidant O
stress O
following O
intestinal O
ischemia B
- O
reperfusion B
injury I
. O

Reperfusion O
of O
ischemic B
intestine O
results O
in O
acute O
liver B
dysfunction I
characterized O
by O
hepatocellular O
enzyme O
release O
into O
plasma O
, O
reduction O
in O
bile O
flow O
rate O
, O
and O
neutrophil O
sequestration O
within O
the O
liver O
. O

The O
pathophysiology O
underlying O
this O
acute O
hepatic B
injury I
is O
unknown O
. O

This O
study O
was O
undertaken O
to O
determine O
whether O
oxidants O
are O
associated O
with O
the O
hepatic B
injury I
and O
to O
determine O
the O
relative O
value O
of O
several O
indirect O
methods O
of O
assessing O
oxidant O
exposure O
in O
vivo O
. O

Rats O
were O
subjected O
to O
a O
standardized O
intestinal O
ischemia B
- O
reperfusion B
injury I
. O

There O
was O
no O
change O
in O
hepatic O
tissue O
total O
glutathione O
following O
intestinal O
ischemia B
- O
reperfusion B
injury I
. O

The O
intracerebroventricular O
( O
ICV O
) O
administration O
of O
ouabain O
( O
a O
Na O
( O
+ O
) O
/ O
K O
( O
+ O
) O
- O
ATPase O
inhibitor O
) O
in O
rats O
has O
been O
suggested O
to O
mimic O
some O
symptoms O
of O
human O
bipolar B
mania I
. O

Clinical O
studies O
have O
shown O
that O
bipolar B
disorder I
may O
be O
related O
to O
mitochondrial B
dysfunction I
. O

In O
conclusion O
, O
ouabain O
- O
induced O
mania B
- O
like O
behavior O
may O
provide O
a O
useful O
animal O
model O
to O
test O
the O
hypothesis O
of O
the O
involvement O
of O
oxidative O
stress O
in O
bipolar B
disorder I
. O

Liver O
transplantation O
for O
acutely O
ill O
patients O
with O
fulminant B
liver I
failure I
carries O
high O
intraoperative O
and O
immediate O
postoperative O
risks O
. O

These O
are O
increased O
with O
the O
presence O
of O
concomitant O
acute B
kidney I
injury I
( O
AKI B
) O
and O
intraoperative O
dialysis O
is O
sometimes O
required O
to O
allow O
the O
transplant O
to O
proceed O
. O

The O
derangements O
in O
the O
procoagulant O
and O
anticoagulant O
pathways O
during O
fulminant B
liver I
failure I
can O
lead O
to O
difficulties O
with O
anticoagulation O
during O
dialysis O
, O
especially O
when O
continued O
in O
the O
operating O
room O
. O

We O
report O
a O
case O
of O
a O
40 O
- O
year O
- O
old O
female O
with O
acetaminophen O
- O
induced O
fulminant B
liver I
failure I
with O
associated O
AKI B
who O
underwent O
intraoperative O
dialytic O
support O
during O
liver O
transplantation O
anticoagulated O
with O
citrate O
dialysate O
during O
the O
entire O
procedure O
. O

Citrate O
dialysate O
is O
a O
safe O
alternative O
for O
intradialytic O
support O
of O
liver O
transplantation O
in O
fulminant B
liver I
failure I
. O

Flecainide O
had O
been O
started O
2 O
weeks O
prior O
for O
atrial B
fibrillation I
. O

BACKGROUND O
: O
Treatment O
options O
are O
scarce O
in O
pretreated O
advanced O
non B
- I
small I
- I
cell I
lung I
cancer I
( O
NSCLC B
) O
patients O
. O

Analyses O
of O
markers O
associated O
with O
the O
mTOR O
pathway O
were O
carried O
out O
on O
archival O
tumor B
from O
a O
subgroup O
using O
immunohistochemistry O
( O
IHC O
) O
and O
direct O
mutation O
sequencing O
. O

Common O
> O
or O
= O
grade O
3 O
events O
were O
fatigue B
, O
dyspnea B
, O
stomatitis B
, O
anemia B
, O
and O
thrombocytopenia B
. O

Posttransplant O
anemia B
: O
the O
role O
of O
sirolimus O
. O

Posttransplant O
anemia B
is O
a O
common O
problem O
that O
may O
hinder O
patients O
' O
quality O
of O
life O
. O

A O
variety O
of O
factors O
have O
been O
identified O
that O
increase O
the O
risk O
of O
posttransplant O
anemia B
, O
of O
which O
the O
level O
of O
renal O
function O
is O
most O
important O
. O

Sirolimus O
, O
a O
mammalian O
target O
of O
rapamycin O
inhibitor O
, O
has O
been O
implicated O
as O
playing O
a O
special O
role O
in O
posttransplant O
anemia B
. O

This O
review O
considers O
anemia B
associated O
with O
sirolimus O
, O
including O
its O
presentation O
, O
mechanisms O
, O
and O
management O
. O

BACKGROUND O
: O
Most O
patients O
presenting O
to O
emergency O
departments O
( O
EDs O
) O
with O
cocaine O
- O
associated O
chest B
pain I
are O
admitted O
for O
at O
least O
12 O
hours O
and O
receive O
a O
" O
rule O
out O
acute B
coronary I
syndrome I
" O
protocol O
, O
often O
with O
noninvasive O
testing O
prior O
to O
discharge O
. O

It O
is O
unclear O
whether O
a O
coronary O
CTA O
strategy O
would O
be O
efficacious O
in O
cocaine O
- O
associated O
chest B
pain I
, O
as O
coronary B
vasospasm I
may O
account O
for O
some O
of O
the O
ischemia B
. O

Six O
patients O
had O
coronary B
stenosis I
> O
or O
= O
50 O
% O
. O

CONCLUSIONS O
: O
Although O
cocaine O
- O
associated O
myocardial B
ischemia I
can O
result O
from O
coronary O
vasoconstriction O
, O
patients O
with O
cocaine O
associated O
chest B
pain I
, O
a O
non O
- O
ischemic B
ECG O
, O
and O
a O
TIMI O
risk O
score O
< O
2 O
may O
be O
safely O
discharged O
from O
the O
ED O
after O
a O
negative O
coronary O
CTA O
with O
a O
low O
risk O
of O
30 O
- O
day O
adverse O
events O
. O

Bilateral O
haemorrhagic B
infarction I
of I
the I
globus I
pallidus I
after O
cocaine O
and O
alcohol O
intoxication O
. O

Cocaine O
is O
a O
risk O
factor O
for O
both O
ischemic B
and I
haemorrhagic I
stroke I
. O

We O
present O
the O
case O
of O
a O
31 O
- O
year O
- O
old O
man O
with O
bilateral O
ischemia B
of I
the I
globus I
pallidus I
after O
excessive O
alcohol O
and O
intranasal O
cocaine O
use O
. O

Bilateral O
basal B
ganglia I
infarcts I
after O
the O
use O
of O
cocaine O
, O
without O
concurrent O
heroin O
use O
, O
have O
never O
been O
reported O
. O

In O
our O
patient O
, O
transient O
cardiac B
arrhythmia I
or O
respiratory B
dysfunction I
related O
to O
cocaine O
and O
/ O
or O
ethanol O
use O
were O
the O
most O
likely O
causes O
of O
cerebral B
hypoperfusion I
. O

Late O
fulminant O
posterior B
reversible I
encephalopathy I
syndrome I
after O
liver O
transplant O
. O

CASE O
: O
We O
report O
the O
case O
of O
a O
46 O
- O
year O
- O
old O
woman O
who O
received O
a O
liver O
transplant O
in O
our O
center O
as O
treatment O
for O
alcoholic B
cirrhosis I
and O
in O
whom O
either O
a O
fulminant O
course O
of O
posterior B
leukoencephalopathy I
or O
posterior B
reversible I
encephalopathy I
syndrome I
developed O
110 O
days O
after O
transplant O
. O

CONCLUSIONS O
: O
Posterior B
reversible I
encephalopathy I
syndrome I
after O
liver O
transplant O
is O
rare O
. O

Prolonged O
hypothermia B
as O
a O
bridge O
to O
recovery O
for O
cerebral B
edema I
and O
intracranial B
hypertension I
associated O
with O
fulminant B
hepatic I
failure I
. O

BACKGROUND O
: O
To O
review O
evidence O
- O
based O
treatment O
options O
in O
patients O
with O
cerebral B
edema I
complicating O
fulminant B
hepatic I
failure I
( O
FHF B
) O
and O
discuss O
the O
potential O
applications O
of O
hypothermia B
. O

METHOD O
: O
Case O
- O
based O
observations O
from O
a O
medical O
intensive O
care O
unit O
( O
MICU O
) O
in O
a O
tertiary O
care O
facility O
in O
a O
27 O
- O
year O
- O
old O
female O
with O
FHF B
from O
acetaminophen O
and O
resultant O
cerebral B
edema I
. O

Initial O
evaluation O
confirmed O
FHF B
from O
acetaminophen O
and O
cerebral B
edema I
. O

At O
re O
- O
warming O
, O
patient O
had O
resolution O
of O
her O
cerebral B
edema I
and O
intracranial B
hypertension I
. O

CONCLUSION O
: O
In O
patients O
with O
FHF B
and O
cerebral B
edema I
from O
acetaminophen O
overdose B
, O
prolonged O
therapeutic O
hypothermia B
could O
potentially O
be O
used O
as O
a O
life O
saving O
therapy O
and O
a O
bridge O
to O
hepatic O
and O
neurological O
recovery O
. O

Binasal B
visual I
field I
defects I
are O
not O
specific O
to O
vigabatrin O
. O

This O
study O
investigated O
the O
visual B
defects I
associated O
with O
the O
antiepileptic O
drug O
vigabatrin O
( O
VGB O
) O
. O

Groups O
were O
matched O
with O
respect O
to O
age O
, O
gender O
, O
and O
seizure B
frequency O
. O

Bilateral B
visual I
field I
abnormalities I
are O
common O
in O
the O
treated O
epilepsy B
population O
, O
irrespective O
of O
drug O
history O
. O

Assessment O
by O
conventional O
static O
perimetry O
may O
neither O
be O
sufficiently O
sensitive O
nor O
specific O
to O
reliably O
identify O
retinal B
toxicity I
associated O
with O
VGB O
. O

Smoking O
of O
crack O
cocaine O
as O
a O
risk O
factor O
for O
HIV B
infection I
among O
people O
who O
use O
injection O
drugs O
. O

BACKGROUND O
: O
Little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack O
cocaine O
has O
on O
the O
incidence O
of O
HIV B
infection I
. O

Given O
the O
increasing O
use O
of O
crack O
cocaine O
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
HIV B
infection I
. O

To O
determine O
whether O
the O
risk O
of O
HIV B
seroconversion I
among O
daily O
smokers O
of O
crack O
cocaine O
changed O
over O
time O
, O
we O
used O
Cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
May O
1 O
, O
1996 O
- O
Nov O
. O

Of O
these O
, O
137 O
acquired O
HIV B
infection I
during O
follow O
- O
up O
. O

After O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
HIV B
seroconversion I
among O
participants O
who O
were O
daily O
smokers O
of O
crack O
cocaine O
increased O
over O
time O
( O
period O
1 O
: O
hazard O
ratio O
[ O
HR O
] O
1 O
. O
03 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0 O
. O
57 O
- O
1 O
. O
85 O
; O
period O
2 O
: O
HR O
1 O
. O
68 O
, O
95 O
% O
CI O
1 O
. O
01 O
- O
2 O
. O
80 O
; O
and O
period O
3 O
: O
HR O
2 O
. O
74 O
, O
95 O
% O
CI O
1 O
. O
06 O
- O
7 O
. O
11 O
) O
. O

INTERPRETATION O
: O
Smoking O
of O
crack O
cocaine O
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
HIV B
seroconversion I
among O
people O
who O
were O
injection O
drug O
users O
. O

Cancer B
patients O
who O
have O
been O
treated O
with O
systemic O
adjuvant O
chemotherapy O
have O
described O
experiencing O
deteriorations O
in O
cognition O
. O

Liver O
- O
specific O
ablation O
of O
integrin O
- O
linked O
kinase O
in O
mice O
results O
in O
enhanced O
and O
prolonged O
cell O
proliferation O
and O
hepatomegaly B
after O
phenobarbital O
administration O
. O

Decreased O
Expression O
of O
Na O
/ O
K O
- O
ATPase O
, O
NHE3 O
, O
NBC1 O
, O
AQP1 O
and O
OAT O
in O
Gentamicin O
- O
induced O
Nephropathy B
. O

The O
present O
study O
was O
aimed O
to O
determine O
whether O
there O
is O
an O
altered O
regulation O
of O
tubular O
transporters O
in O
gentamicin O
- O
induced O
nephropathy B
. O

Gentamicin O
- O
induced O
nephropathy B
may O
at O
least O
in O
part O
be O
causally O
related O
with O
a O
decreased O
expression O
of O
Na O
( O
+ O
) O
/ O
K O
( O
+ O
) O
- O
ATPase O
, O
NHE3 O
, O
NBC1 O
, O
AQP1 O
and O
OAT O
. O

Acute B
renal I
failure I
after O
high O
- O
dose O
methotrexate O
therapy O
in O
a O
patient O
with O
ileostomy O
. O

High O
- O
dose O
methotrexate O
( O
HD O
- O
MTX O
) O
is O
an O
important O
treatment O
for O
Burkitt B
lymphoma I
, O
but O
can O
cause O
hepatic B
and I
renal I
toxicity I
when O
its O
clearance O
is O
delayed O
. O

We O
report O
a O
case O
of O
acute B
renal I
failure I
after O
HD O
- O
MTX O
therapy O
in O
a O
patient O
with O
ileostomy O
, O
The O
patient O
was O
a O
3 O
- O
year O
- O
old O
boy O
who O
had O
received O
a O
living O
- O
related O
liver O
transplantation O
for O
congenital O
biliary B
atresia I
. O

At O
day O
833 O
after O
the O
transplantation O
, O
he O
was O
diagnosed O
with O
PTLD B
( O
post B
- I
transplantation I
lymphoproliferative I
disorder I
, O
Burkitt B
- I
type I
malignant I
lymphoma I
) O
. O

Subsequent O
HD O
- O
MTX O
therapy O
caused O
acute B
renal I
failure I
that O
required O
continuous O
hemodialysis O
. O

We O
supposed O
that O
intravascular O
hypovolemia B
due O
to O
substantial O
drainage O
from O
the O
ileostoma O
caused O
acute B
prerenal I
failure I
. O

Longitudinal O
association O
of O
alcohol O
use O
with O
HIV B
disease I
progression O
and O
psychological O
health O
of O
women O
with O
HIV O
. O

We O
evaluated O
the O
association O
of O
alcohol O
consumption O
and O
depression B
, O
and O
their O
effects O
on O
HIV B
disease I
progression O
among O
women O
with O
HIV O
. O

Moreover O
, O
depression B
is O
associated O
with O
HIV B
disease I
progression O
. O

The O
present O
study O
aimed O
to O
explore O
the O
effect O
of O
MT O
induction O
on O
carmustine O
( O
BCNU O
) O
- O
induced O
hippocampal O
cognitive B
dysfunction I
in O
rats O
. O

The O
obtained O
data O
revealed O
that O
BCNU O
administration O
resulted O
in O
deterioration B
of I
learning I
and I
short I
- I
term I
memory I
( O
STM O
) O
, O
as O
measured O
by O
using O
radial O
arm O
water O
maze O
, O
accompanied O
with O
decreased O
hippocampal O
glutathione O
reductase O
( O
GR O
) O
activity O
and O
reduced O
glutathione O
( O
GSH O
) O
content O
. O

Also O
, O
BCNU O
administration O
increased O
serum O
tumor B
necrosis B
factor O
- O
alpha O
( O
TNFalpha O
) O
, O
hippocampal O
MT O
and O
malondialdehyde O
( O
MDA O
) O
contents O
as O
well O
as O
caspase O
- O
3 O
activity O
in O
addition O
to O
histological O
alterations O
. O

Fatal O
carbamazepine O
induced O
fulminant B
eosinophilic I
( O
hypersensitivity B
) O
myocarditis B
: O
emphasis O
on O
anatomical O
and O
histological O
characteristics O
, O
mechanisms O
and O
genetics O
of O
drug B
hypersensitivity I
and O
differential O
diagnosis O
. O

A O
frequently O
fatal O
, O
although O
exceptionally O
rare O
side O
effect O
of O
carbamazepine O
is O
necrotizing O
eosinophilic O
( O
hypersensitivity B
) O
myocarditis B
. O

We O
report O
a O
case O
of O
hypersensitivity B
myocarditis B
secondary O
to O
administration O
of O
carbamazepine O
. O

Acute O
hypersensitivity B
myocarditis B
was O
not O
suspected O
clinically O
, O
and O
the O
diagnosis O
was O
made O
post O
- O
mortem O
. O

Neuropsychiatric O
behaviors O
in O
the O
MPTP O
marmoset O
model O
of O
Parkinson B
' I
s I
disease I
. O

OBJECTIVES O
: O
Neuropsychiatric O
symptoms O
are O
increasingly O
recognised O
as O
a O
significant O
problem O
in O
patients O
with O
Parkinson B
' I
s I
disease I
( O
PD B
) O
. O

The O
levodopa O
- O
treated O
MPTP O
- O
lesioned O
marmoset O
was O
used O
as O
a O
model O
of O
neuropsychiatric B
symptoms I
in O
PD B
patients O
. O

Here O
we O
compare O
the O
time O
course O
of O
levodopa O
- O
induced O
motor O
fluctuations O
and O
neuropsychiatric B
- I
like I
behaviors I
to O
determine O
the O
relationship O
between O
duration O
of O
treatment O
and O
onset O
of O
symptoms O
. O

Animals O
were O
evaluated O
for O
parkinsonian B
disability I
, O
dyskinesia B
and O
on O
- O
time O
( O
motor O
fluctuations O
) O
and O
neuropsychiatric B
- I
like I
behaviors I
on O
Day O
0 O
( O
prior O
to O
levodopa O
) O
and O
on O
Days O
1 O
, O
7 O
, O
13 O
, O
27 O
and O
30 O
of O
treatment O
using O
post O
hoc O
DVD O
analysis O
by O
a O
trained O
rater O
, O
blind O
to O
the O
treatment O
day O
. O

RESULTS O
: O
The O
neuropsychiatric B
- I
like I
behavior I
rating O
scale O
demonstrated O
high O
interrater O
reliability O
between O
three O
trained O
raters O
of O
differing O
professional O
backgrounds O
. O

In O
contrast O
, O
levodopa O
- O
induced O
neuropsychiatric B
- I
like I
behaviors I
were O
present O
on O
Day O
1 O
of O
levodopa O
treatment O
and O
their O
severity O
did O
not O
correlate O
with O
duration O
of O
treatment O
. O

CONCLUSIONS O
: O
The O
data O
suggest O
that O
neuropsychiatric B
disorders I
in O
PD B
are O
more O
likely O
an O
interaction O
between O
levodopa O
and O
the O
disease O
state O
than O
a O
consequence O
of O
sensitisation O
to O
repeated O
dopaminergic O
therapy O
. O

BACKGROUND O
: O
Renal B
dysfunction I
induced O
by O
iodinated O
contrast O
medium O
( O
CM O
) O
administration O
can O
minimize O
the O
benefit O
of O
the O
interventional O
procedure O
in O
patients O
undergoing O
renal O
angioplasty O
( O
PTRA O
) O
. O

CONCLUSION O
: O
In O
this O
preliminary O
study O
patients O
submitted O
to O
PTRA O
showed O
a O
lower O
susceptibility O
to O
renal B
damage I
induced O
by O
CM O
administration O
than O
PCI O
patients O
. O

Medical O
and O
psychiatric O
outcomes O
for O
patients O
transplanted O
for O
acetaminophen O
- O
induced O
acute B
liver I
failure I
: O
a O
case O
- O
control O
study O
. O

BACKGROUND O
: O
Acetaminophen O
- O
induced O
hepatotoxicity B
is O
the O
most O
common O
cause O
of O
acute B
liver I
failure I
( O
ALF B
) O
in O
the O
UK O
. O

AIMS O
AND O
METHODS O
: O
We O
compared O
the O
severity O
of O
pretransplant O
illness O
, O
psychiatric O
co O
- O
morbidity O
, O
medical O
and O
psychosocial O
outcomes O
of O
all O
patients O
who O
had O
undergone O
liver O
transplantation O
( O
LT O
) O
emergently O
between O
1999 O
- O
2004 O
for O
acetaminophen O
- O
induced O
ALF B
( O
n O
= O
36 O
) O
with O
age O
- O
and O
sex O
- O
matched O
patients O
undergoing O
emergent O
LT O
for O
non O
- O
acetaminophen O
- O
induced O
ALF B
( O
n O
= O
35 O
) O
and O
elective O
LT O
for O
chronic B
liver I
disease I
( O
CLD B
, O
n O
= O
34 O
) O
. O

Antithrombotic O
drug O
use O
, O
cerebral B
microbleeds I
, O
and O
intracerebral B
hemorrhage I
: O
a O
systematic O
review O
of O
published O
and O
unpublished O
studies O
. O

Insights O
could O
be O
gained O
by O
pooling O
data O
on O
MB B
frequency O
stratified O
by O
antithrombotic O
use O
in O
cohorts O
with O
ICH B
and O
ischemic B
stroke I
( O
IS B
) O
/ O
transient B
ischemic I
attack I
( O
TIA B
) O
. O

METHODS O
: O
We O
performed O
a O
systematic O
review O
of O
published O
and O
unpublished O
data O
from O
cohorts O
with O
stroke B
or O
TIA B
to O
compare O
the O
presence O
of O
MB B
in O
: O
( O
1 O
) O
antithrombotic O
users O
vs O
nonantithrombotic O
users O
with O
ICH B
; O
( O
2 O
) O
antithrombotic O
users O
vs O
nonusers O
with O
IS B
/ O
TIA B
; O
and O
( O
3 O
) O
ICH B
vs O
ischemic B
events O
stratified O
by O
antithrombotic O
use O
. O

DESIGN O
: O
Dose O
response O
curves O
for O
nonsedating O
doses O
of O
morphine O
and O
CNSB002 O
given O
intraperitoneally O
alone O
and O
together O
in O
combinations O
were O
constructed O
for O
antihyperalgesic O
effect O
using O
paw O
withdrawal O
from O
noxious O
heat O
in O
two O
rat O
pain B
models O
: O
carrageenan O
- O
induced O
paw O
inflammation B
and O
streptozotocin O
( O
STZ O
) O
- O
induced O
diabetic B
neuropathy I
. O

Heparin O
- O
induced O
thrombocytopenia B
: O
a O
practical O
review O
. O

Heparin O
- O
induced O
thrombocytopenia B
( O
HIT B
) O
remains O
under O
- O
recognized O
despite O
its O
potentially O
devastating O
outcomes O
. O

Thrombosis B
and O
thrombocytopenia B
that O
follow O
comprise O
the O
2 O
hallmark O
traits O
of O
HIT B
, O
with O
the O
former O
largely O
responsible O
for O
significant O
vascular O
complications O
. O

HIT B
must O
be O
acknowledged O
for O
its O
intense O
predilection O
for O
thrombosis B
and O
suspected O
whenever O
thrombosis B
occurs O
after O
heparin O
exposure O
. O

Mitochondrial B
impairment I
contributes O
to O
cocaine O
- O
induced O
cardiac B
dysfunction I
: O
Prevention O
by O
the O
targeted O
antioxidant O
MitoQ O
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
mitochondrial O
function O
and O
ROS O
production O
in O
an O
experimental O
model O
of O
cocaine O
- O
induced O
cardiac B
dysfunction I
. O

We O
hypothesized O
that O
cocaine B
abuse I
may O
lead O
to O
altered O
mitochondrial O
function O
that O
in O
turn O
may O
cause O
left B
ventricular I
dysfunction I
. O

This O
uncoupling O
effect O
on O
oxidative O
phosphorylation O
was O
not O
detectable O
after O
short O
- O
term O
exposure O
to O
cocaine O
, O
suggesting O
that O
these O
mitochondrial B
abnormalities I
were O
a O
late O
rather O
than O
a O
primary O
event O
in O
the O
pathological O
response O
to O
cocaine O
. O

MitoQ O
, O
a O
mitochondrial O
- O
targeted O
antioxidant O
, O
was O
shown O
to O
completely O
prevent O
these O
mitochondrial B
abnormalities I
as O
well O
as O
cardiac B
dysfunction I
characterized O
here O
by O
a O
diastolic B
dysfunction I
studied O
with O
a O
conductance O
catheter O
to O
obtain O
pressure O
- O
volume O
data O
. O

Taken O
together O
, O
these O
results O
extend O
previous O
studies O
and O
demonstrate O
that O
cocaine O
- O
induced O
cardiac B
dysfunction I
may O
be O
due O
to O
a O
mitochondrial B
defect I
. O

Trimethoprim O
- O
induced O
immune O
hemolytic B
anemia I
in O
a O
pediatric O
oncology O
patient O
presenting O
as O
an O
acute O
hemolytic O
transfusion O
reaction O
. O

A O
10 O
- O
year O
- O
old O
male O
with O
acute B
leukemia I
presented O
with O
post O
- O
chemotherapy O
anemia B
. O

Drug O
- O
induced O
immune O
hemolytic B
anemia I
was O
suspected O
because O
of O
positive O
direct O
antiglobulin O
test O
, O
negative O
eluate O
, O
and O
microspherocytes O
on O
smear O
pre O
- O
and O
post O
- O
transfusion O
. O

Other O
causes O
of O
anemia B
should O
be O
considered O
in O
patients O
with O
worse O
- O
than O
- O
expected O
anemia B
after O
chemotherapy O
. O

Furthermore O
, O
hemolysis B
during O
transfusion O
is O
not O
always O
a O
transfusion O
reaction O
. O

OBJECTIVE O
: O
A O
multicenter O
, O
controlled O
trial O
showed O
that O
early O
blockade O
of O
the O
renin O
- O
angiotensin O
system O
in O
patients O
with O
type B
1 I
diabetes I
and O
normoalbuminuria O
did O
not O
retard O
the O
progression O
of O
nephropathy B
, O
suggesting O
that O
other O
mechanism O
( O
s O
) O
are O
involved O
in O
the O
pathogenesis O
of O
early O
diabetic B
nephropathy I
( O
diabetic B
nephropathy I
) O
. O

We O
have O
previously O
demonstrated O
that O
endothelial O
- O
mesenchymal O
- O
transition O
( O
EndoMT O
) O
contributes O
to O
the O
early O
development O
of O
renal O
interstitial O
fibrosis B
independently O
of O
microalbuminuria O
in O
mice O
with O
streptozotocin O
( O
STZ O
) O
- O
induced O
diabetes B
. O

Confocal O
microscopy O
and O
real O
- O
time O
PCR O
further O
demonstrated O
that O
SIS3 O
abrogated O
EndoMT O
, O
reduced O
renal O
fibrosis B
, O
and O
retarded O
progression O
of O
nephropathy B
. O

Blockade O
of O
EndoMT O
by O
SIS3 O
may O
provide O
a O
new O
strategy O
to O
retard O
the O
progression O
of O
diabetic B
nephropathy I
and O
other O
diabetes B
complications I
. O

Cytostatic O
and O
anti O
- O
angiogenic O
effects O
of O
temsirolimus O
in O
refractory O
mantle B
cell I
lymphoma I
. O

Mantle B
cell I
lymphoma I
( O
MCL B
) O
is O
a O
rare O
and O
aggressive O
type O
of O
B B
- I
cell I
non I
- I
Hodgkin I
' I
s I
lymphoma I
. O

However O
, O
a O
38 O
% O
remission O
rate O
has O
been O
recently O
reported O
in O
refractory O
MCL B
treated O
with O
temsirolimus O
, O
a O
mTOR O
inhibitor O
. O
Here O
we O
had O
the O
opportunity O
to O
study O
a O
case O
of O
refractory O
MCL B
who O
had O
tumor B
regression O
two O
months O
after O
temsirolimus O
treatment O
, O
and O
a O
progression O
- O
free O
survival O
of O
10 O
months O
. O

Comparison O
of O
the O
two O
biopsies O
showed O
that O
temsirolimus O
inhibited O
tumor B
cell O
proliferation O
through O
cell O
cycle O
arrest O
, O
but O
did O
not O
induce O
any O
change O
in O
the O
number O
of O
apoptotic O
tumor B
cells O
. O

Apart O
from O
this O
cytostatic O
effect O
, O
temsirolimus O
had O
an O
antiangiogenic O
effect O
with O
decrease O
of O
tumor B
microvessel O
density O
and O
of O
VEGF O
expression O
. O

Thus O
, O
temsirolimus O
reduced O
tumor B
burden O
through O
associated O
cytostatic O
and O
anti O
- O
angiogenic O
effects O
. O
This O
dual O
effect O
of O
temsirolimus O
on O
tumor B
tissue O
could O
contribute O
to O
its O
recently O
reported O
efficiency O
in O
refractory O
MCL B
resistant O
to O
conventional O
chemotherapy O
. O

Acute B
renal I
failure I
due O
to O
rifampicin O
. O

Rifampicin O
was O
administered O
thrice O
as O
one O
of O
the O
3 O
- O
4 O
drug O
regimen O
and O
each O
time O
he O
developed O
untoward O
side O
effects O
like O
nausea B
, O
vomiting B
and O
fever B
with O
chills O
and O
rigors O
. O

A O
76 O
year O
- O
old O
woman O
with O
a O
history O
of O
coronary O
artery O
bypass O
grafting O
and O
prior O
myocardial B
infarction I
was O
transferred O
to O
the O
emergency O
room O
with O
loss B
of I
consciousness I
due O
to O
marked O
bradycardia B
caused O
by O
hyperkalemia B
. O

Clinicians O
should O
be O
alert O
to O
the O
possibility O
of O
hyperkalemia B
, O
especially O
in O
elderly O
patients O
using O
ACE O
/ O
ARB O
in O
combination O
with O
potassium O
sparing O
agents O
and O
who O
have O
mild O
renal B
disturbance I
. O

Cerebrospinal O
fluid O
penetration O
of O
high O
- O
dose O
daptomycin O
in O
suspected O
Staphylococcus O
aureus O
meningitis B
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
methicillin O
- O
sensitive O
Staphylococcus O
aureus O
( O
MSSA O
) O
bacteremia B
with O
suspected O
MSSA O
meningitis B
treated O
with O
high O
- O
dose O
daptomycin O
assessed O
with O
concurrent O
serum O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
. O

CASE O
SUMMARY O
: O
A O
54 O
- O
year O
- O
old O
male O
presented O
to O
the O
emergency O
department O
with O
generalized O
weakness B
and O
presumed O
health O
- O
care O
- O
associated O
pneumonia B
shown O
on O
chest O
radiograph O
. O

On O
day O
8 O
, O
the O
patient O
developed O
acute B
renal I
failure I
( O
serum O
creatinine O
1 O
. O
9 O
mg O
/ O
dL O
, O
increased O
from O
1 O
. O
2 O
mg O
/ O
dL O
the O
previous O
day O
and O
0 O
. O
8 O
mg O
/ O
dL O
on O
admission O
) O
. O

The O
patient O
' O
s O
Glasgow O
Coma O
Score O
was O
3 O
, O
with O
normal O
findings O
shown O
on O
computed O
tomography O
scan O
of O
the O
head O
72 O
hours O
following O
an O
episode O
of O
cardiac B
arrest I
on O
day O
10 O
. O

Nafcillin O
was O
discontinued O
and O
daptomycin O
9 O
mg O
/ O
kg O
daily O
was O
initiated O
for O
suspected O
meningitis B
and O
was O
continued O
until O
the O
patient O
' O
s O
death O
on O
day O
16 O
. O

Further O
clinical O
evaluation O
in O
patients O
with O
confirmed O
meningitis B
is O
warranted O
. O

On O
the O
contrary O
, O
pretreatment O
with O
L O
- O
NAME O
( O
500 O
, O
700 O
and O
900 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
decreased O
convulsion B
incidence O
and O
severity O
and O
prolonged O
latency O
time O
to O
convulsion B
following O
injection O
with O
a O
convulsive B
dose O
of O
lindane O
( O
8 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

Two O
cases O
of O
severe O
delayed O
neurologic B
toxicity I
related O
to O
the O
administration O
of O
intrathecal O
( O
IT O
) O
combination O
chemotherapy O
including O
thiotepa O
( O
TSPA O
) O
are O
presented O
. O

Both O
cases O
developed O
axonal B
neuropathy I
with O
motor O
predominance O
in O
the O
lower O
extremities O
1 O
and O
6 O
months O
after O
IT O
chemotherapy O
was O
administered O
. O

To O
our O
knowledge O
, O
however O
, O
axonal B
neuropathy I
following O
administration O
of O
these O
three O
agents O
has O
not O
been O
previously O
described O
. O

Mefenamic O
acid O
- O
induced O
neutropenia B
and O
renal B
failure I
in O
elderly O
females O
with O
hypothyroidism B
. O

We O
report O
mefenamic O
acid O
- O
induced O
non O
- O
oliguric O
renal B
failure I
and O
severe O
neutropenia B
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

In O
order O
to O
identify O
risk O
factors O
associated O
with O
the O
development O
of O
hypercalcemia B
, O
indirect O
parameters O
of O
intestinal O
calcium O
reabsorption O
and O
bone O
turnover O
rate O
in O
these O
14 O
patients O
were O
compared O
with O
results O
in O
14 O
eucalcemic O
patients O
matched O
for O
age O
, O
sex O
, O
length O
of O
time O
on O
dialysis O
, O
and O
etiology O
of O
renal B
disease I
. O

Late O
- O
onset O
scleroderma B
renal I
crisis I
induced O
by O
tacrolimus O
and O
prednisolone O
: O
a O
case O
report O
. O

Scleroderma B
renal I
crisis I
( O
SRC B
) O
is O
a O
rare O
complication O
of O
systemic B
sclerosis I
( O
SSc B
) O
but O
can O
be O
severe O
enough O
to O
require O
temporary O
or O
permanent O
renal O
replacement O
therapy O
. O

Methyldopa O
- O
induced O
hemolytic B
anemia I
in O
a O
15 O
year O
old O
presenting O
as O
near O
- O
syncope B
. O

Methyldopa O
causes O
an O
autoimmune B
hemolytic I
anemia I
in O
a O
small O
percentage O
of O
patients O
who O
take O
the O
drug O
. O

We O
report O
a O
case O
of O
methyldopa O
- O
induced O
hemolytic B
anemia I
in O
a O
15 O
- O
year O
- O
old O
boy O
who O
presented O
to O
the O
emergency B
department I
with O
near O
- O
syncope B
. O

The O
boy O
had O
been O
treated O
with O
intravenous O
methyldopa O
during O
a O
trauma B
admission O
seven O
weeks O
prior O
to O
presentation O
. O

A O
brief O
review O
of O
autoimmune O
and O
drug O
- O
induced O
hemolytic B
anemias I
is O
provided O
. O

Patients O
with O
the O
diagnosis O
of O
methamphetamine O
based O
on O
DSM O
- O
IV O
were O
interviewed O
using O
the O
Mini O
International O
Neuropsychiatric O
Interview O
( O
M O
. O
I O
. O
N O
. O
I O
. O
) O
for O
methamphetamine O
- O
induced O
psychosis B
and O
other O
Axis O
I O
psychiatric B
disorders I
. O

RESULTS O
: O
Of O
292 O
subjects O
, O
47 O
. O
9 O
% O
of O
the O
subjects O
had O
a O
past O
history O
of O
psychotic B
symptoms I
and O
13 O
. O
0 O
% O
of O
the O
patients O
were O
having O
current O
psychotic B
symptoms I
. O

Co O
- O
morbid O
major O
depressive B
disorder I
( O
OR O
= O
7 O
. O
18 O
, O
95 O
CI O
= O
2 O
. O
612 O
- O
19 O
. O
708 O
) O
, O
bipolar B
disorder I
( O
OR O
= O
13 O
. O
807 O
, O
95 O
CI O
= O
5 O
. O
194 O
- O
36 O
. O
706 O
) O
, O
antisocial B
personality I
disorder I
( O
OR O
= O
12 O
. O
619 O
, O
95 O
CI O
= O
6 O
. O
702 O
- O
23 O
. O
759 O
) O
and O
heavy O
methamphetamine O
uses O
were O
significantly O
associated O
with O
lifetime O
methamphetamine O
- O
induced O
psychosis B
after O
adjusted O
for O
other O
factors O
. O

Major B
depressive I
disorder I
( O
OR O
= O
2 O
. O
870 O
, O
CI O
= O
1 O
. O
154 O
- O
7 O
. O
142 O
) O
and O
antisocial B
personality I
disorder I
( O
OR O
= O
3 O
. O
299 O
, O
95 O
CI O
= O
1 O
. O
375 O
- O
7 O
. O
914 O
) O
were O
the O
only O
factors O
associated O
with O
current O
psychosis B
. O

It O
was O
associated O
with O
co O
- O
morbid O
affective B
disorder I
, O
antisocial B
personality I
, O
and O
heavy O
methamphetamine O
use O
. O

It O
is O
recommended O
that O
all O
cases O
of O
methamphetamine O
dependence O
should O
be O
screened O
for O
psychotic B
symptoms I
. O

Cerebellar O
sensory O
processing O
alterations O
impact O
motor O
cortical O
plasticity O
in O
Parkinson B
' I
s I
disease I
: O
clues O
from O
dyskinetic B
patients O
. O

The O
plasticity O
of O
primary O
motor O
cortex O
( O
M1 O
) O
in O
patients O
with O
Parkinson B
' I
s I
disease I
( O
PD B
) O
and O
levodopa O
- O
induced O
dyskinesias B
( O
LIDs B
) O
is O
severely O
impaired O
. O

These O
results O
suggest O
that O
alterations O
in O
cerebellar O
sensory O
processing O
function O
, O
occurring O
secondary O
to O
abnormal O
basal O
ganglia O
signals O
reaching O
it O
, O
may O
be O
an O
important O
element O
contributing O
to O
the O
maladaptive O
sensorimotor O
plasticity O
of O
M1 O
and O
the O
emergence O
of O
abnormal B
involuntary I
movements I
. O

The O
long O
- O
term O
safety O
of O
danazol O
in O
women O
with O
hereditary B
angioedema I
. O

We O
therefore O
investigated O
the O
long O
- O
term O
safety O
of O
danazol O
by O
performing O
a O
retrospective O
chart O
review O
of O
60 O
female O
patients O
with O
hereditary B
angioedema I
treated O
with O
danazol O
for O
a O
continuous O
period O
of O
6 O
months O
or O
longer O
. O

Menstrual B
abnormalities I
( O
79 O
% O
) O
, O
weight B
gain I
( O
60 O
% O
) O
, O
muscle B
cramps I
/ O
myalgias B
( O
40 O
% O
) O
, O
and O
transaminase O
elevations O
( O
40 O
% O
) O
were O
the O
most O
common O
adverse O
reactions O
. O

In O
conclusion O
, O
we O
believe O
that O
physicians O
should O
carefully O
consider O
the O
risk O
of O
drug O
- O
induced O
hepatic B
injury I
when O
clopidogrel O
is O
prescribed O
. O

Bortezomib O
and O
dexamethasone O
as O
salvage O
therapy O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B
myeloma I
: O
analysis O
of O
long O
- O
term O
clinical O
outcomes O
. O

Bortezomib O
( O
bort O
) O
- O
dexamethasone O
( O
dex O
) O
is O
an O
effective O
therapy O
for O
relapsed O
/ O
refractory O
( O
R O
/ O
R O
) O
multiple B
myeloma I
( O
MM B
) O
. O

The O
most O
relevant O
adverse O
event O
was O
peripheral B
neuropathy I
, O
which O
occurred O
in O
78 O
% O
of O
the O
patients O
( O
grade O
II O
, O
38 O
% O
; O
grade O
III O
, O
21 O
% O
) O
and O
led O
to O
treatment O
discontinuation O
in O
6 O
% O
. O

Pubertal O
exposure O
to O
Bisphenol O
A O
increases O
anxiety B
- O
like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

Acetylcholinesterase O
( O
AChE O
) O
is O
a O
regulatory O
enzyme O
which O
is O
involved O
in O
anxiety B
- O
like O
behavior O
. O

Results O
from O
our O
behavioral O
phenotyping O
indicated O
that O
anxiety B
- O
like O
behavior O
was O
increased O
in O
mice O
exposed O
to O
BPA O
. O

Our O
findings O
showed O
that O
pubertal O
BPA O
exposure O
increased O
anxiety B
- O
like O
behavior O
, O
which O
may O
be O
associated O
with O
decreased O
AChE O
activity O
of O
the O
hippocampus O
in O
adult O
male O
mice O
. O

Further O
studies O
are O
necessary O
to O
investigate O
the O
cholinergic O
signaling O
of O
the O
hippocampus O
in O
PBE O
induced O
anxiety B
- O
like O
behaviors O
. O

Cardiovascular B
diseases I
( O
CVDs B
) O
are O
the O
major O
health O
problem O
of O
advanced O
as O
well O
as O
developing O
countries O
of O
the O
world O
. O

" O
Real O
- O
world O
" O
data O
on O
the O
efficacy O
and O
safety O
of O
lenalidomide O
and O
dexamethasone O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B
myeloma I
who O
were O
treated O
according O
to O
the O
standard O
clinical O
practice O
: O
a O
study O
of O
the O
Greek O
Myeloma B
Study O
Group O
. O

Lenalidomide O
and O
dexamethasone O
( O
RD O
) O
is O
a O
standard O
of O
care O
for O
relapsed O
/ O
refractory O
multiple B
myeloma I
( O
RRMM B
) O
, O
but O
there O
is O
limited O
published O
data O
on O
its O
efficacy O
and O
safety O
in O
the O
" O
real O
world O
" O
( O
RW O
) O
, O
according O
to O
the O
International O
Society O
of O
Pharmacoeconomics O
and O
Outcomes O
Research O
definition O
. O

Peripheral B
neuropathy I
was O
observed O
only O
in O
2 O
. O
5 O
% O
of O
patients O
and O
deep B
vein I
thrombosis I
in O
5 O
. O
7 O
% O
. O

Risk O
factors O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B
among O
multiethnic O
Malaysians O
with O
Parkinson B
' I
s I
disease I
. O

Chronic O
pulsatile O
levodopa O
therapy O
for O
Parkinson B
' I
s I
disease I
( O
PD B
) O
leads O
to O
the O
development O
of O
motor O
fluctuations O
and O
dyskinesia B
. O

We O
report O
here O
a O
retrospective O
study O
of O
123 O
children O
( O
median O
age O
, O
6 O
. O
5 O
years O
) O
receiving O
high O
- O
dose O
busulfan O
in O
combined O
chemotherapy O
before O
bone O
marrow O
transplantation O
for O
malignant O
solid O
tumors B
, O
brain B
tumors I
excluded O
. O

Twenty O
- O
seven O
patients O
were O
given O
a O
600 O
- O
mg O
/ O
m2 O
busulfan O
total O
dose O
with O
continuous O
i O
. O
v O
. O
infusion O
of O
clonazepam O
; O
none O
had O
any O
neurological B
symptoms I
. O

Busulfan O
levels O
were O
measured O
by O
a O
gas O
chromatographic O
- O
mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central B
nervous I
system I
disease I
under O
600 O
mg O
/ O
m2 O
busulfan O
with O
clonazepam O
: O
busulfan O
cerebrospinal O
fluid O
: O
plasma O
ratio O
was O
1 O
. O
39 O
. O

An O
unexpected O
diagnosis O
in O
a O
renal O
- O
transplant O
patient O
with O
proteinuria B
treated O
with O
everolimus O
: O
AL B
amyloidosis B
. O

However O
, O
clinical O
suspicion O
should O
always O
be O
supported O
by O
histological O
evidence O
in O
order O
to O
investigate O
potential O
alternate O
diagnoses O
such O
as O
acute O
or O
chronic O
rejection O
, O
interstitial O
fibrosis B
and O
tubular O
atrophy B
, O
or O
recurrent O
or O
de O
novo O
glomerulopathy B
. O

In O
this O
case O
we O
report O
the O
unexpected O
diagnosis O
of O
amyloidosis B
in O
a O
renal O
- O
transplant O
patient O
with O
pre O
- O
transplant O
monoclonal O
gammapathy O
of O
undetermined O
significance O
who O
developed O
proteinuria B
after O
conversion O
from O
tacrolimus O
to O
everolimus O
. O

Long O
- O
term O
oral O
galactose O
treatment O
prevents O
cognitive B
deficits I
in O
male O
Wistar O
rats O
treated O
intracerebroventricularly O
with O
streptozotocin O
. O

Basic O
and O
clinical O
research O
has O
demonstrated O
that O
dementia B
of O
sporadic O
Alzheimer B
' I
s I
disease I
( O
sAD O
) O
type O
is O
associated O
with O
dysfunction O
of O
the O
insulin O
- O
receptor O
( O
IR O
) O
system O
followed O
by O
decreased O
glucose O
transport O
via O
glucose O
transporter O
GLUT4 O
and O
decreased O
glucose O
metabolism O
in O
brain O
cells O
. O

Exclusively O
parenteral O
daily O
injections O
of O
galactose O
induce O
memory B
deterioration I
in O
rodents O
and O
are O
used O
to O
generate O
animal O
aging O
model O
, O
but O
the O
effects O
of O
oral O
galactose O
treatment O
on O
cognitive O
functions O
have O
never O
been O
tested O
. O

We O
have O
investigated O
the O
effects O
of O
continuous O
daily O
oral O
galactose O
( O
200 O
mg O
/ O
kg O
/ O
day O
) O
treatment O
on O
cognitive B
deficits I
in O
streptozotocin O
- O
induced O
( O
STZ O
- O
icv O
) O
rat O
model O
of O
sAD O
, O
tested O
by O
Morris O
Water O
Maze O
and O
Passive O
Avoidance O
test O
, O
respectively O
. O

One O
month O
of O
oral O
galactose O
treatment O
initiated O
immediately O
after O
the O
STZ O
- O
icv O
administration O
, O
successfully O
prevented O
development O
of O
the O
STZ O
- O
icv O
- O
induced O
cognitive B
deficits I
. O

Oral O
galactose O
exposure O
might O
have O
beneficial O
effects O
on O
learning O
and O
memory O
ability O
and O
could O
be O
worth O
investigating O
for O
improvement O
of O
cognitive B
deficits I
associated O
with O
glucose B
hypometabolism I
in O
AD B
. O

An O
investigation O
of O
the O
pattern O
of O
kidney B
injury I
in O
HIV O
- O
positive O
persons O
exposed O
to O
tenofovir O
disoproxil O
fumarate O
: O
an O
examination O
of O
a O
large O
population O
database O
( O
MHRA O
database O
) O
. O

Reports O
that O
satisfy O
defined O
criteria O
were O
classified O
as O
acute B
kidney I
injury I
, O
kidney B
tubular I
dysfunction I
and O
Fanconi B
syndrome I
. O

Of O
the O
407 O
Yellow O
Card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
TDF O
- O
related O
kidney B
disease I
, O
of O
which O
53 O
( O
50 O
% O
) O
had O
features O
of O
kidney B
tubular I
dysfunction I
, O
35 O
( O
33 O
% O
) O
were O
found O
to O
have O
features O
of O
glomerular B
dysfunction I
and O
18 O
( O
17 O
% O
) O
had O
Fanconi B
syndrome I
. O

The O
incidence O
of O
hospitalisation O
for O
TDF O
kidney O
adverse O
effects O
was O
high O
, O
particularly O
amongst O
patients O
with O
features O
of O
Fanconi B
syndrome I
. O

Exclusion O
criteria O
were O
any O
preexisting O
predisposing O
factor O
for O
delirium B
or O
other O
potentially O
confounding O
neurological B
dysfunctions I
. O

Methamphetamine O
( O
METH O
) O
triggers O
a O
disruption O
of O
the O
monoaminergic O
system O
and O
METH O
abuse O
leads O
to O
negative O
emotional O
states O
including O
depressive B
symptoms I
during O
drug O
withdrawal O
. O

Linezolid O
- O
induced O
optic B
neuropathy I
. O

We O
describe O
a O
case O
of O
progressive O
loss B
of I
vision I
associated O
with O
linezolid O
therapy O
. O

A O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid O
and O
ethambutol O
for O
extensively B
drug I
- I
resistant I
tuberculosis I
( O
XDR B
- I
TB I
) O
presented O
to O
us O
with O
painless O
progressive O
loss B
of I
vision I
in O
both O
eyes O
. O

Color O
vision O
was O
defective O
and O
fundus O
examination O
revealed O
optic B
disc I
edema I
in O
both O
eyes O
. O

Ethambutol O
- O
induced O
toxic B
optic I
neuropathy I
was O
suspected O
and O
tablet O
ethambutol O
was O
withdrawn O
. O

Deterioration B
of I
vision I
occurred O
despite O
withdrawal O
of O
ethambutol O
. O

Resuscitation O
with O
lipid O
, O
epinephrine O
, O
or O
both O
in O
levobupivacaine O
- O
induced O
cardiac B
toxicity I
in O
newborn O
piglets O
. O

METHODS O
: O
Newborn O
piglets O
received O
levobupivacaine O
until O
cardiovascular B
collapse I
occurred O
. O

Incidence O
of O
heparin O
- O
induced O
thrombocytopenia B
type I
II I
and O
postoperative O
recovery O
of O
platelet O
count O
in O
liver O
graft O
recipients O
: O
a O
retrospective O
cohort O
analysis O
. O

BACKGROUND O
: O
Thrombocytopenia B
in O
patients O
with O
end B
- I
stage I
liver I
disease I
is O
a O
common O
disorder O
caused O
mainly O
by O
portal B
hypertension I
, O
low O
levels O
of O
thrombopoetin O
, O
and O
endotoxemia B
. O

The O
impact O
of O
immune O
- O
mediated O
heparin O
- O
induced O
thrombocytopenia B
type I
II I
( O
HIT B
type I
II I
) O
as O
a O
cause O
of O
thrombocytopenia B
after O
liver O
transplantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

The O
aim O
of O
our O
study O
was O
to O
demonstrate O
the O
perioperative O
course O
of O
thrombocytopenia B
after O
liver O
transplantation O
and O
determine O
the O
occurrence O
of O
clinical O
HIT B
type I
II I
. O

METHOD O
: O
We O
retrospectively O
evaluated O
the O
medical O
records O
of O
205 O
consecutive O
adult O
patients O
who O
underwent O
full O
- O
size O
liver O
transplantation O
between O
January O
2006 O
and O
December O
2010 O
due O
to O
end B
- I
stage I
or I
malignant I
liver I
disease I
. O

Preoperative O
platelet O
count O
, O
postoperative O
course O
of O
platelets O
, O
and O
clinical O
signs O
of O
HIT B
type I
II I
were O
analyzed O
. O

RESULTS O
: O
A O
total O
of O
155 O
( O
75 O
. O
6 O
% O
) O
of O
205 O
patients O
had O
thrombocytopenia B
before O
transplantation O
, O
significantly O
influenced O
by O
Model O
of O
End B
- I
Stage I
Liver I
Disease I
score O
and O
liver B
cirrhosis I
. O

Regarding O
HIT B
II I
, O
there O
were O
four O
( O
1 O
. O
95 O
% O
) O
patients O
with O
a O
background O
of O
HIT B
type I
II I
. O

CONCLUSIONS O
: O
The O
incidence O
of O
HIT B
in O
patients O
with O
end B
- I
stage I
hepatic I
failure I
is O
, O
with O
about O
1 O
. O
95 O
% O
, O
rare O
. O

For O
further O
reduction O
of O
HIT B
type I
II I
, O
the O
use O
of O
intravenous O
heparin O
should O
be O
avoided O
and O
the O
prophylactic O
anticoagulation O
should O
be O
performed O
with O
low O
- O
molecular O
- O
weight O
heparin O
after O
normalization O
of O
platelet O
count O
. O

Takotsubo B
syndrome I
( O
or O
apical B
ballooning I
syndrome I
) O
secondary O
to O
Zolmitriptan O
. O

Takotsubo B
syndrome I
( O
TS B
) O
, O
also O
known O
as O
broken B
heart I
syndrome I
, O
is O
characterized O
by O
left O
ventricle O
apical O
ballooning O
with O
elevated O
cardiac O
biomarkers O
and O
electrocardiographic O
changes O
suggestive O
of O
an O
acute B
coronary I
syndrome I
( O
ie O
, O
ST O
- O
segment O
elevation O
, O
T O
wave O
inversions O
, O
and O
pathologic O
Q O
waves O
) O
. O

Emergent O
coronary O
angiogram O
revealed O
normal O
coronary O
arteries O
with O
moderately O
reduced O
left O
ventricular O
ejection O
fraction O
with O
wall O
motion O
abnormalities O
consistent O
with O
TS B
. O

But O
before O
this O
event O
, O
she O
was O
taking O
zolmitriptan O
2 O
- O
3 O
times O
daily O
for O
several O
days O
because O
of O
a O
persistent O
migraine B
headache I
. O

Extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary B
artery I
vasospasm I
secondary O
to O
zolmitriptan O
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
TS B
. O

CONCLUSIONS O
: O
Given O
this O
record O
of O
impaired B
memory I
and O
clinically O
significant O
levels O
of O
depression B
, O
impulsiveness B
, O
and O
sleep B
disturbance I
, O
the O
prognosis O
for O
the O
current O
generation O
of O
ecstasy O
users O
is O
a O
major O
cause O
for O
concern O
. O

Association O
of O
common O
genetic O
variants O
of O
HOMER1 O
gene O
with O
levodopa O
adverse O
effects O
in O
Parkinson B
' I
s I
disease I
patients O
. O

Levodopa O
is O
the O
most O
effective O
symptomatic O
therapy O
for O
Parkinson B
' I
s I
disease I
, O
but O
its O
chronic O
use O
could O
lead O
to O
chronic O
adverse O
outcomes O
, O
such O
as O
motor O
fluctuations O
, O
dyskinesia B
and O
visual B
hallucinations I
. O

A O
total O
of O
205 O
patients O
with O
idiopathic B
Parkinson I
' I
s I
disease I
were O
investigated O
. O

The O
rs4704559 O
G O
allele O
was O
associated O
with O
a O
lower O
prevalence O
of O
dyskinesia B
( O
prevalence O
ratio O
( O
PR O
) O
= O
0 O
. O
615 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
0 O
. O
426 O
- O
0 O
. O
887 O
, O
P O
= O
0 O
. O
009 O
) O
and O
visual B
hallucinations I
( O
PR O
= O
0 O
. O
515 O
, O
95 O
% O
CI O
0 O
. O
295 O
- O
0 O
. O
899 O
, O
P O
= O
0 O
. O
020 O
) O
. O

GEM O
- O
P O
chemotherapy O
is O
active O
in O
the O
treatment O
of O
relapsed O
Hodgkin B
lymphoma I
. O

Hodgkin B
lymphoma I
( O
HL B
) O
is O
a O
relatively O
chemosensitive O
malignancy B
. O

The O
most O
common O
grade O
3 O
/ O
4 O
toxicities B
were O
haematological O
: O
neutropenia B
54 O
% O
and O
thrombocytopenia B
51 O
% O
. O

RATIONALE O
: O
Ecstasy O
( O
MDMA O
) O
is O
a O
psychostimulant O
drug O
which O
is O
increasingly O
associated O
with O
psychobiological B
dysfunction I
. O

RESULTS O
: O
Both O
user O
groups O
exhibited O
significantly O
greater O
levels O
of O
anxiety B
and O
depression B
than O
nonusers O
. O

CONCLUSIONS O
: O
The O
increases O
in O
anxiety B
and O
depression B
are O
in O
line O
with O
previous O
observations O
in O
recreational O
ecstasy O
- O
polydrug O
users O
. O

BACKGROUND O
: O
Ifosfamide O
is O
an O
alkylating O
agent O
useful O
in O
the O
treatment O
of O
a O
wide O
range O
of O
cancers B
including O
sarcomas B
, O
lymphoma B
, O
gynecologic B
and I
testicular I
cancers I
. O

METHODS O
: O
Retrospective O
chart O
review O
including O
clinical O
data O
and O
EEG O
recordings O
was O
done O
on O
five O
patients O
, O
admitted O
to O
MD O
Anderson O
Cancer B
Center O
between O
years O
2009 O
and O
2012 O
, O
who O
developed O
ifosfamide O
related O
acute O
encephalopathy B
. O

Two O
patients O
developed O
generalized O
convulsions B
while O
one O
patient O
developed O
continuous O
non B
- I
convulsive I
status I
epilepticus I
( O
NCSE B
) O
that O
required O
ICU O
admission O
and O
intubation O
. O

Incidence O
of O
contrast O
- O
induced O
nephropathy B
in O
hospitalised O
patients O
with O
cancer B
. O

OBJECTIVES O
: O
To O
determine O
the O
frequency O
of O
and O
possible O
factors O
related O
to O
contrast O
- O
induced O
nephropathy B
( O
CIN O
) O
in O
hospitalised O
patients O
with O
cancer B
. O

Patients O
with O
risk O
factors O
for O
acute B
renal I
failure I
were O
excluded O
. O

CIN O
developed O
4 O
. O
5 O
- O
times O
more O
frequently O
in O
patients O
with O
cancer B
who O
had O
undergone O
recent O
chemotherapy O
. O

Contrast O
- O
induced O
nephropathy B
( O
CIN O
) O
is O
a O
concern O
for O
oncological O
patients O
undergoing O
CT O
. O

Syndrome B
of I
inappropriate I
antidiuretic I
hormone I
secretion O
associated O
with O
desvenlafaxine O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
syndrome B
of I
inappropriate I
anti I
- I
diuretic I
hormone I
( O
SIADH B
) O
secretion O
associated O
with O
desvenlafaxine O
. O

Her O
medications O
included O
desvenlafaxine O
, O
and O
symptoms O
included O
nausea B
, O
anxiety B
and O
confusion B
. O

Single O
dose O
of O
DOX O
was O
associated O
with O
increased O
cardiac B
disarrangement I
, O
necrosis B
, O
and O
DNA O
damage O
( O
strand O
breaks O
( O
SBs O
) O
and O
oxidized O
pyrimidines O
) O
and O
decreased O
TAP O
. O

Tacrolimus O
- O
related O
seizure B
after O
pediatric O
liver O
transplantation O
- O
- O
a O
single O
- O
center O
experience O
. O

All O
exhibited O
generalized O
tonic B
- I
clonic I
seizures I
within O
the O
first O
two O
wk O
after O
LT O
. O

Univariate O
analysis O
showed O
that O
the O
risk O
factors O
associated O
with O
seizures B
after O
pediatric O
LT O
included O
gender O
, O
pediatric O
end B
- I
stage I
liver I
disease I
score O
before O
surgery O
, O
Child O
- O
Pugh O
score O
before O
surgery O
, O
serum O
total O
bilirubin O
after O
surgery O
, O
and O
trough O
TAC O
level O
. O

All O
children O
who O
experienced O
seizures B
survived O
with O
good O
graft O
function O
and O
remained O
seizure B
- O
free O
without O
anti O
- O
epileptic B
drugs O
over O
a O
mean O
follow O
- O
up O
period O
of O
33 O
. O
7 O
+ O
14 O
. O
6 O
months O
. O

In O
the O
saline O
treated O
group O
, O
the O
first O
significant O
decline O
in O
passive O
avoidance O
response O
was O
observed O
at O
four O
weeks O
, O
and O
complete O
memory B
loss I
was O
found O
five O
weeks O
after O
the O
acquisition O
of O
the O
passive O
avoidance O
task O
. O

The O
present O
results O
demonstrate O
that O
CCK O
- O
8 O
attenuates O
the O
effect O
of O
morphine O
on O
hippocampal O
LTP O
through O
CCK2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
CCK O
- O
8 O
on O
morphine O
- O
induced O
memory B
impairment I
. O

Glial O
activation O
and O
post O
- O
synaptic O
neurotoxicity B
: O
the O
key O
events O
in O
Streptozotocin O
( O
ICV O
) O
induced O
memory B
impairment I
in O
rats O
. O

Present O
study O
clearly O
suggests O
that O
glial O
activation O
and O
post O
synaptic O
neurotoxicity B
are O
the O
key O
factors O
in O
STZ O
induced O
memory B
impairment I
and O
neuronal O
cell O
death O
. O

Comparison O
of O
effects O
of O
isotonic O
sodium O
chloride O
with O
diltiazem O
in O
prevention O
of O
contrast O
- O
induced O
nephropathy B
. O

INTRODUCTION O
AND O
OBJECTIVE O
: O
Contrast O
- O
induced O
nephropathy B
( O
CIN O
) O
significantly O
increases O
the O
morbidity O
and O
mortality O
of O
patients O
. O

Among O
a O
total O
of O
60 O
patients O
included O
in O
the O
study O
, O
16 O
patients O
developed O
acute B
renal I
failure I
( O
ARF B
) O
on O
the O
second O
day O
after O
contrast O
material O
was O
injected O
( O
26 O
. O
6 O
% O
) O
. O

Neurocognitive O
and O
neuroradiologic O
central O
nervous O
system O
late O
effects O
in O
children O
treated O
on O
Pediatric O
Oncology O
Group O
( O
POG O
) O
P9605 O
( O
standard O
risk O
) O
and O
P9201 O
( O
lesser O
risk O
) O
acute B
lymphoblastic I
leukemia I
protocols O
( O
ACCL0131 O
) O
: O
a O
methotrexate O
consequence O
? O

Concerns O
about O
long O
- O
term O
methotrexate O
( O
MTX O
) O
neurotoxicity B
in O
the O
1990s O
led O
to O
modifications O
in O
intrathecal O
( O
IT O
) O
therapy O
, O
leucovorin O
rescue O
, O
and O
frequency O
of O
systemic O
MTX O
administration O
in O
children O
with O
acute B
lymphoblastic I
leukemia I
. O

In O
this O
study O
, O
neurocognitive O
outcomes O
and O
neuroradiologic O
evidence O
of O
leukoencephalopathy B
were O
compared O
in O
children O
treated O
with O
intense O
central O
nervous O
system O
( O
CNS O
) O
- O
directed O
therapy O
( O
P9605 O
) O
versus O
those O
receiving O
fewer O
CNS O
- O
directed O
treatment O
days O
during O
intensive O
consolidation O
( O
P9201 O
) O
. O

A O
total O
of O
66 O
children O
from O
16 O
Pediatric O
Oncology O
Group O
institutions O
with O
" O
standard O
- O
risk O
" O
acute B
lymphoblastic I
leukemia I
, O
1 O
. O
00 O
to O
9 O
. O
99 O
years O
at O
diagnosis O
, O
without O
evidence O
of O
CNS O
leukemia B
at O
diagnosis O
were O
enrolled O
on O
ACCL0131 O
: O
28 O
from O
P9201 O
and O
38 O
from O
P9605 O
. O

Significantly O
more O
P9605 O
patients O
developed O
leukoencephalopathy B
compared O
with O
P9201 O
patients O
( O
68 O
% O
, O
95 O
% O
confidence O
interval O
49 O
% O
- O
83 O
% O
vs O
. O
22 O
% O
, O
95 O
% O
confidence O
interval O
5 O
% O
- O
44 O
% O
; O
P O
= O
0 O
. O
001 O
) O
identified O
as O
late O
as O
7 O
. O
7 O
years O
after O
the O
end O
of O
treatment O
. O

Tranexamic O
acid O
overdosage O
- O
induced O
generalized O
seizure B
in O
renal B
failure I
. O

We O
report O
a O
45 O
- O
year O
- O
old O
lady O
with O
chronic B
kidney I
disease I
stage O
4 O
due O
to O
chronic O
tubulointerstial B
disease I
. O

She O
was O
admitted O
to O
our O
center O
for O
severe O
anemia B
due O
to O
menorrhagia B
and O
deterioration B
of I
renal I
function I
. O

Two O
hours O
after O
the O
sixth O
dose O
of O
TNA O
, O
she O
had O
an O
episode O
of O
generalized O
tonic B
clonic I
convulsions I
. O

Investigations O
of O
the O
patient O
revealed O
no O
biochemical O
or O
structural O
central O
nervous B
system I
abnormalities I
that O
could O
have O
provoked O
the O
convulsions B
. O

Pre O
- O
treatment O
of O
bupivacaine O
- O
induced O
cardiovascular B
depression I
using O
different O
lipid O
formulations O
of O
propofol O
. O

Drug B
- I
Induced I
Acute I
Liver I
Injury I
Within O
12 O
Hours O
After O
Fluvastatin O
Therapy O
. O

Although O
statins O
are O
generally O
well O
- O
tolerated O
drugs O
, O
recent O
cases O
of O
drug B
- I
induced I
liver I
injury I
associated O
with O
their O
use O
have O
been O
reported O
. O

A O
52 O
- O
year O
- O
old O
Chinese O
man O
reported O
with O
liver B
damage I
, O
which O
appeared O
12 O
hours O
after O
beginning O
treatment O
with O
fluvastatin O
. O

Therefore O
, O
when O
prescribing O
statins O
, O
the O
possibility O
of O
hepatic B
damage I
should O
be O
taken O
into O
account O
. O

Fluconazole O
associated O
agranulocytosis B
and O
thrombocytopenia B
. O

CASE O
: O
We O
describe O
a O
second O
case O
of O
fluconazole O
associated O
agranulocytosis B
with O
thrombocytopenia B
and O
recovery O
upon O
discontinuation O
of O
therapy O
. O

CONCLUSION O
: O
According O
to O
Naranjo O
' O
s O
algorithm O
the O
likelihood O
that O
our O
patient O
' O
s O
agranulocytosis B
and O
thrombocytopenia B
occurred O
as O
a O
result O
of O
therapy O
with O
fluconazole O
is O
probable O
, O
with O
a O
total O
of O
six O
points O
. O

In O
particular O
the O
temporal O
relationship O
of O
bone B
marrow I
suppression I
to O
the O
initiation O
of O
fluconazole O
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

AIMS O
: O
To O
investigate O
whether O
alterations O
of O
myocardial B
strain I
and O
high O
- O
sensitive O
cardiac O
troponin O
T O
( O
cTnT O
) O
could O
predict O
future O
cardiac B
dysfunction I
in O
patients O
after O
epirubicin O
exposure O
. O

METHODS O
: O
Seventy O
- O
five O
patients O
with O
non B
- I
Hodgkin I
lymphoma I
treated O
with O
epirubicin O
were O
studied O
. O

Cardiotoxicity B
was O
defined O
as O
a O
reduction O
of O
the O
LVEF O
of O
> O
5 O
% O
to O
< O
55 O
% O
with O
symptoms O
of O
heart B
failure I
or O
an O
asymptomatic O
reduction O
of O
the O
LVEF O
of O
> O
10 O
% O
to O
< O
55 O
% O
. O

CONCLUSIONS O
: O
GLS O
combined O
with O
cTnT O
may O
provide O
a O
reliable O
and O
non O
- O
invasive O
method O
to O
predict O
cardiac B
dysfunction I
in O
patients O
receiving O
anthracycline O
- O
based O
chemotherapy O
. O

Poisoning B
with O
yellow O
phosphorus O
classically O
manifests O
with O
acute B
hepatitis I
leading O
to O
acute B
liver I
failure I
which O
may O
need O
liver O
transplantation O
. O

Paradoxical O
severe O
agitation B
induced O
by O
add O
- O
on O
high O
- O
doses O
quetiapine O
in O
schizo B
- I
affective I
disorder I
. O

We O
report O
the O
case O
of O
a O
35 O
- O
year O
- O
old O
patient O
suffering O
from O
schizo B
- I
affective I
disorder I
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first O
- O
generation O
antipsychotics O
, O
zuclopenthixol O
( O
100 O
mg O
/ O
day O
) O
and O
lithium O
( O
1200 O
mg O
/ O
day O
) O
( O
serum O
lithium O
= O
0 O
. O
85 O
mEq O
/ O
l O
) O
. O

This O
patient O
had O
no O
associated O
personality B
disorder I
( O
particularly O
no O
antisocial B
disorder I
) O
and O
no O
substance B
abuse I
disorder I
. O

Within O
the O
48 O
h O
following O
the O
gradual O
introduction O
of O
quetiapine O
( O
up O
to O
600 O
mg O
/ O
day O
) O
, O
the O
patient O
presented O
severe O
agitation B
without O
an O
environmental O
explanation O
, O
contrasting O
with O
the O
absence O
of O
a O
history O
of O
aggressiveness B
or O
personality B
disorder I
. O

LF O
prevented O
body O
weight B
loss I
and O
significantly O
reduced O
the O
elevated O
plasma O
H2O2 O
and O
increased O
FRAP O
values O
. O

The O
association O
between O
tranexamic O
acid O
and O
convulsive B
seizures B
after O
cardiac O
surgery O
: O
a O
multivariate O
analysis O
in O
11 O
529 O
patients O
. O

A O
convulsive B
seizure B
was O
defined O
as O
a O
transient O
episode O
of O
disturbed O
brain O
function O
characterised O
by O
abnormal B
involuntary I
motor I
movements I
. O

A O
total O
of O
100 O
( O
0 O
. O
9 O
% O
) O
patients O
developed O
postoperative O
convulsive B
seizures B
. O

Generalised B
and I
focal I
seizures I
were O
identified O
in O
68 O
and O
32 O
patients O
, O
respectively O
. O

The O
median O
( O
IQR O
[ O
range O
] O
) O
time O
after O
surgery O
when O
the O
seizure B
occurred O
was O
7 O
( O
6 O
- O
12 O
[ O
1 O
- O
216 O
] O
) O
h O
and O
8 O
( O
6 O
- O
11 O
[ O
4 O
- O
18 O
] O
) O
h O
, O
respectively O
. O

Independent O
predictors O
of O
postoperative O
seizures B
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive B
heart I
failure I
, O
deep O
hypothermic B
circulatory O
arrest O
, O
duration O
of O
aortic O
cross O
- O
clamp O
and O
tranexamic O
acid O
. O

Patients O
with O
convulsive B
seizures B
had O
2 O
. O
5 O
times O
higher O
in O
- O
hospital O
mortality O
rates O
and O
twice O
the O
length O
of O
hospital O
stay O
compared O
with O
patients O
without O
convulsive B
seizures B
. O

Mean O
( O
IQR O
[ O
range O
] O
) O
length O
of O
stay O
in O
the O
intensive O
care O
unit O
was O
115 O
( O
49 O
- O
228 O
[ O
32 O
- O
481 O
] O
) O
h O
in O
patients O
with O
convulsive B
seizures B
compared O
with O
26 O
( O
22 O
- O
69 O
[ O
14 O
- O
1080 O
] O
) O
h O
in O
patients O
without O
seizures B
( O
p O
< O
0 O
. O
001 O
) O
. O

Previous O
studies O
indicate O
that O
ecstasy O
users O
have O
marked O
and O
persistent O
neurocognitive O
and O
sleep B
- I
related I
impairments I
. O

Ecstasy O
users O
demonstrated O
impaired B
overnight I
memory I
consolidation O
, O
a O
finding O
that O
was O
more O
pronounced O
following O
associative O
interference O
. O

In O
the O
preceding O
months O
, O
the O
patient O
had O
a O
number O
of O
admissions O
with O
transient O
unilateral O
hemiparesis B
with O
facial O
droop O
, O
and O
had O
been O
started O
on O
valproate O
for O
presumed O
hemiplegic B
migraine I
. O

Cerebellar B
and I
oculomotor I
dysfunction I
induced O
by O
rapid O
infusion O
of O
pethidine O
. O

In O
patients O
with O
impaired B
renal I
and I
liver I
function I
, O
and O
those O
who O
need O
long O
- O
term O
pain B
control O
, O
pethidine O
may O
cause O
excitatory O
central O
nervous O
system O
( O
CNS O
) O
effects O
through O
its O
neurotoxic B
metabolite O
, O
norpethidine O
, O
resulting O
in O
irritability B
and O
seizure B
attack O
. O

Baboon B
syndrome I
induced O
by O
ketoconazole O
. O

The O
patient O
was O
diagnosed O
with O
drug O
- O
induced O
baboon B
syndrome I
based O
on O
his O
history O
, O
which O
included O
prior O
sensitivity O
to O
topical O
ketoconazole O
, O
a O
physical O
examination O
, O
and O
histopathological O
findings O
. O

Baboon B
syndrome I
is O
a O
drug O
- O
or O
contact O
allergen O
- O
related O
maculopapular B
eruption I
that O
typically O
involves O
the O
flexural O
and O
gluteal O
areas O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
ketoconazole O
- O
induced O
baboon B
syndrome I
in O
the O
English O
literature O
. O

An O
84 O
- O
year O
- O
old O
male O
received O
oral O
pilsicainide O
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial B
fibrillation I
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden B
cardiac I
death I
two O
days O
later O
. O

Although O
the O
oral O
administration O
of O
class O
IC O
drugs O
, O
including O
pilsicainide O
, O
is O
effective O
to O
terminate O
atrial B
fibrillation I
, O
careful O
consideration O
must O
be O
taken O
before O
giving O
these O
drugs O
to O
octogenarians O
. O

All O
- O
trans O
retinoic O
acid O
- O
induced O
inflammatory O
myositis B
in O
a O
patient O
with O
acute B
promyelocytic I
leukemia I
. O

All O
- O
trans O
retinoic O
acid O
( O
ATRA O
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute B
promyelocytic I
leukemia I
( O
APL B
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

Tolerability O
of O
lomustine O
in O
combination O
with O
cyclophosphamide O
in O
dogs O
with O
lymphoma B
. O

This O
retrospective O
study O
describes O
toxicity B
associated O
with O
a O
protocol O
of O
lomustine O
( O
CCNU O
) O
and O
cyclophosphamide O
( O
CTX O
) O
in O
dogs O
with O
lymphoma B
. O

No O
dogs O
had O
evidence O
of O
either O
renal B
toxicity I
or O
hemorrhagic B
cystitis I
. O

On O
the O
basis O
of O
the O
findings O
reported O
herein O
, O
a O
dose O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
CCNU O
combined O
with O
250 O
mg O
/ O
m O
( O
2 O
) O
of O
CTX O
( O
divided O
over O
5 O
days O
) O
q O
4 O
wk O
is O
tolerable O
in O
tumor B
- O
bearing O
dogs O
. O

A O
37 O
- O
year O
- O
old O
Caucasian O
woman O
with O
a O
history O
of O
T B
- I
cell I
lymphoblastic I
lymphoma I
was O
admitted O
for O
relapsed O
disease O
. O

She O
developed O
relapsed O
disease O
10 O
months O
later O
with O
leukemic B
involvement O
. O

At O
the O
time O
of O
treatment O
, O
she O
was O
on O
continuous O
renal O
replacement O
therapy O
due O
to O
sequelae O
of O
tumor B
lysis I
syndrome I
( O
TLS B
) O
. O

Predominantly O
sensory O
, O
though O
also O
motor O
and O
autonomic O
, O
peripheral B
neuropathy I
started O
in O
her O
feet O
, O
ascended O
proximally O
to O
the O
mid O
- O
thoracic O
region O
, O
and O
eventually O
included O
her O
distal O
upper O
extremities O
. O

Here O
, O
we O
describe O
the O
case O
of O
a O
15 O
- O
year O
- O
old O
girl O
who O
was O
on O
a O
long O
- O
term O
therapy O
with O
valproate O
due O
to O
epilepsy B
and O
revealed O
impaired B
consciousness I
with O
hyperammonemia B
12 O
days O
after O
renal O
transplantation O
. O

Bortezomib O
and O
high O
- O
dose O
dexamethasone O
- O
containing O
regimens O
are O
considered O
to O
be O
generally O
tolerable O
with O
few O
severe O
bacterial B
infections I
in O
patients O
with O
B O
- O
cell O
malignancies B
. O

Physicians O
should O
recognise O
the O
possibility O
of O
fatal O
bacterial B
infections I
related O
to O
bortezomib O
plus O
high O
- O
dose O
dexamethasone O
in O
elderly O
patients O
, O
and O
we O
believe O
this O
case O
warrants O
further O
investigation O
. O

Many O
efficacious O
cancer B
treatments O
cause O
significant O
cardiac O
morbidity O
, O
yet O
biomarkers O
or O
functional O
indices O
of O
early O
damage O
, O
which O
would O
allow O
monitoring O
and O
intervention O
, O
are O
lacking O
. O

In O
this O
study O
, O
we O
have O
utilized O
a O
rat O
model O
of O
progressive O
doxorubicin O
( O
DOX O
) O
- O
induced O
cardiomyopathy B
, O
applying O
multiple O
approaches O
, O
including O
cardiac O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
to O
provide O
the O
most O
comprehensive O
characterization O
to O
date O
of O
the O
timecourse O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
underlying O
this O
toxicity B
. O

Electron O
microscopy O
of O
the O
myocardium O
revealed O
subcellular B
degeneration I
and O
marked O
mitochondrial O
changes O
after O
a O
single O
dose O
. O

Histopathological O
analysis O
revealed O
progressive O
cardiomyocyte B
degeneration I
, O
hypertrophy B
/ O
cytomegaly O
, O
and O
extensive O
vacuolation O
after O
two O
doses O
. O

Functional O
indices O
assessed O
by O
cardiac O
MRI O
( O
including O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
, O
cardiac O
output O
, O
and O
E O
/ O
A O
ratio O
) O
declined O
progressively O
, O
reaching O
statistical O
significance O
after O
two O
doses O
and O
culminating O
in O
" O
clinical O
" O
LV B
dysfunction I
by O
12 O
weeks O
. O

Troponin O
I O
levels O
positively O
correlated O
with O
delayed O
and O
peak O
gadolinium O
contrast O
enhancement O
, O
histopathological O
grading O
, O
and O
diastolic B
dysfunction I
. O

In O
summary O
, O
subcellular O
cardiomyocyte B
degeneration I
was O
the O
earliest O
marker O
, O
followed O
by O
progressive O
functional O
decline O
and O
histopathological O
manifestations O
. O

However O
, O
all O
indices O
predated O
" O
clinical O
" O
LV B
dysfunction I
and O
thus O
warrant O
further O
evaluation O
as O
predictive O
biomarkers O
. O

Intradermal O
injections O
of O
glutamate O
and O
capsaicin O
are O
attractive O
to O
use O
in O
human O
experimental O
pain B
models O
because O
hyperalgesia B
and O
allodynia B
mimic O
isolated O
aspects O
of O
clinical O
pain B
disorders I
. O

Ocular O
- O
specific O
ER O
stress O
reduction O
rescues O
glaucoma B
in O
murine O
glucocorticoid O
- O
induced O
glaucoma B
. O

Administration O
of O
glucocorticoids O
induces O
ocular B
hypertension I
in O
some O
patients O
. O

If O
untreated O
, O
these O
patients O
can O
develop O
a O
secondary O
glaucoma B
that O
resembles O
primary B
open I
- I
angle I
glaucoma I
( O
POAG B
) O
. O

The O
underlying O
pathology O
of O
glucocorticoid O
- O
induced O
glaucoma B
is O
not O
fully O
understood O
, O
due O
in O
part O
to O
lack O
of O
an O
appropriate O
animal O
model O
. O

Here O
, O
we O
developed O
a O
murine O
model O
of O
glucocorticoid O
- O
induced O
glaucoma B
that O
exhibits O
glaucoma B
features O
that O
are O
observed O
in O
patients O
. O

Treatment O
of O
WT O
mice O
with O
topical O
ocular O
0 O
. O
1 O
% O
dexamethasone O
led O
to O
elevation O
of O
intraocular O
pressure O
( O
IOP O
) O
, O
functional O
and O
structural O
loss O
of O
retinal B
ganglion I
cells O
, O
and O
axonal B
degeneration I
, O
resembling O
glucocorticoid O
- O
induced O
glaucoma B
in O
human O
patients O
. O

Furthermore O
, O
dexamethasone O
- O
induced O
ocular B
hypertension I
was O
associated O
with O
chronic O
ER O
stress O
of O
the O
trabecular O
meshwork O
( O
TM O
) O
. O

Dexamethasone O
induced O
the O
transcriptional O
factor O
CHOP O
, O
a O
marker O
for O
chronic O
ER O
stress O
, O
in O
the O
anterior O
segment O
tissues O
, O
and O
Chop O
deletion O
reduced O
ER O
stress O
in O
these O
tissues O
and O
prevented O
dexamethasone O
- O
induced O
ocular B
hypertension I
. O

Furthermore O
, O
reduction O
of O
ER O
stress O
in O
the O
TM O
with O
sodium O
4 O
- O
phenylbutyrate O
prevented O
dexamethasone O
- O
induced O
ocular B
hypertension I
in O
WT O
mice O
. O

Our O
data O
indicate O
that O
ER O
stress O
contributes O
to O
glucocorticoid O
- O
induced O
ocular B
hypertension I
and O
suggest O
that O
reducing O
ER O
stress O
has O
potential O
as O
a O
therapeutic O
strategy O
for O
treating O
glucocorticoid O
- O
induced O
glaucoma B
. O

Hydroxytyrosol O
ameliorates O
oxidative O
stress O
and O
mitochondrial B
dysfunction I
in O
doxorubicin O
- O
induced O
cardiotoxicity B
in O
rats O
with O
breast B
cancer I
. O

Oxidative O
stress O
is O
involved O
in O
several O
processes O
including O
cancer B
, O
aging O
and O
cardiovascular B
disease I
, O
and O
has O
been O
shown O
to O
potentiate O
the O
therapeutic O
effect O
of O
drugs O
such O
as O
doxorubicin O
. O

Doxorubicin O
causes O
significant O
cardiotoxicity B
characterized O
by O
marked O
increases O
in O
oxidative O
stress O
and O
mitochondrial B
dysfunction I
. O

Herein O
, O
we O
investigate O
whether O
doxorubicin O
- O
associated O
chronic O
cardiac B
toxicity I
can O
be O
ameliorated O
with O
the O
antioxidant O
hydroxytyrosol O
in O
rats O
with O
breast B
cancer I
. O

Thirty O
- O
six O
rats O
bearing O
breast B
tumors I
induced O
chemically O
were O
divided O
into O
4 O
groups O
: O
control O
, O
hydroxytyrosol O
( O
0 O
. O
5mg O
/ O
kg O
, O
5days O
/ O
week O
) O
, O
doxorubicin O
( O
1mg O
/ O
kg O
/ O
week O
) O
, O
and O
doxorubicin O
plus O
hydroxytyrosol O
. O

Hydroxytyrosol O
improved O
the O
cardiac B
disturbances I
enhanced O
by O
doxorubicin O
by O
significantly O
reducing O
the O
percentage O
of O
altered O
mitochondria O
and O
oxidative O
damage O
. O

This O
study O
demonstrates O
that O
hydroxytyrosol O
protect O
rat O
heart B
damage I
provoked O
by O
doxorubicin O
decreasing O
oxidative O
damage O
and O
mitochondrial O
alterations O
. O

A O
62 O
- O
year O
- O
old O
man O
was O
found O
to O
have O
bradycardia B
, O
hypothermia B
and O
respiratory B
failure I
3 O
weeks O
after O
initiation O
of O
amiodarone O
therapy O
for O
atrial B
fibrillation I
. O

This O
case O
represents O
the O
most O
thoroughly O
investigated O
case O
of O
amiodarone O
- O
induced O
myxoedema B
coma I
with O
a O
history O
significant O
for O
subclinical O
thyroid B
disease I
. O

Use O
of O
argatroban O
and O
catheter O
- O
directed O
thrombolysis B
with O
alteplase O
in O
an O
oncology O
patient O
with O
heparin O
- O
induced O
thrombocytopenia B
with O
thrombosis B
. O

PURPOSE O
: O
The O
case O
of O
an O
oncology O
patient O
who O
developed O
heparin O
- O
induced O
thrombocytopenia B
with O
thrombosis B
( O
HITT B
) O
and O
was O
treated O
with O
argatroban O
plus O
catheter O
- O
directed O
thrombolysis B
( O
CDT O
) O
with O
alteplase O
is O
presented O
. O

SUMMARY O
: O
A O
63 O
- O
year O
- O
old O
Caucasian O
man O
with O
renal O
amyloidosis B
undergoing O
peripheral O
blood O
stem O
cell O
collection O
for O
an O
autologous O
stem O
cell O
transplant O
developed O
extensive O
bilateral O
upper B
- I
extremity I
deep I
venous I
thrombosis I
( O
DVT B
) O
and O
pulmonary B
embolism I
secondary O
to O
heparin O
- O
induced O
thrombocytopenia B
. O

After O
one O
week O
of O
therapy O
, O
he O
was O
transferred O
to O
the O
intensive O
care O
unit O
with O
cardiopulmonary O
compromise O
related O
to O
superior B
vena I
cava I
( I
SVC I
) I
syndrome I
. O

Although O
the O
patient O
recovered O
, O
he O
experienced O
permanent O
vision B
and I
hearing I
loss I
, O
as O
well O
as O
end B
- I
stage I
renal I
disease I
. O

CONCLUSION O
: O
A O
63 O
- O
year O
- O
old O
man O
with O
renal O
amyloidosis B
and O
SVC B
syndrome I
secondary O
to O
HITT B
was O
successfully O
treated O
with O
argatroban O
and O
CDT O
with O
alteplase O
. O

BACKGROUND O
: O
S O
- O
53482 O
and O
S O
- O
23121 O
are O
N O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality B
, O
teratogenicity B
( O
mainly O
ventricular B
septal I
defects I
and O
wavy O
ribs O
) O
, O
and O
growth B
retardation I
in O
rats O
in O
conventional O
oral O
developmental O
toxicity B
studies O
. O

Toxicity B
included O
embryolethality B
, O
teratogenicity B
, O
and O
growth B
retardation I
. O

Dermal O
administration O
of O
S O
- O
23121 O
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic B
death I
and O
ventricular B
septal I
defect I
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
S O
- O
23121 O
. O

Rates O
of O
Renal B
Toxicity I
in O
Cancer B
Patients O
Receiving O
Cisplatin O
With O
and O
Without O
Mannitol O
. O

OBJECTIVE O
: O
We O
aimed O
to O
evaluate O
the O
rates O
of O
cisplatin O
- O
induced O
nephrotoxicity B
in O
cancer B
patients O
receiving O
single O
- O
agent O
cisplatin O
with O
and O
without O
mannitol O
. O

Data O
were O
collected O
on O
adult O
cancer B
patients O
receiving O
single O
- O
agent O
cisplatin O
as O
an O
outpatient O
from O
January O
2011 O
to O
September O
2012 O
. O

The O
primary O
outcome O
was O
acute B
kidney I
injury I
( O
AKI B
) O
. O

RESULTS O
: O
We O
evaluated O
143 O
patients O
who O
received O
single O
- O
agent O
cisplatin O
; O
97 O
. O
2 O
% O
of O
patients O
had O
head B
and I
neck I
cancer I
as O
their O
primary O
malignancy B
. O

Metformin O
protects O
against O
seizures B
, O
learning B
and I
memory I
impairments I
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole O
- O
induced O
kindling O
in O
mice O
. O

Cognitive B
impairment I
, O
the O
most O
common O
and O
severe O
comorbidity O
of O
epilepsy B
, O
greatly O
diminishes O
the O
quality O
of O
life O
. O

Oxidative O
stress O
is O
considered O
to O
play O
an O
important O
role O
in O
epileptogenesis O
and O
cognitive B
deficits I
, O
and O
antioxidants O
have O
a O
putative O
antiepileptic O
potential O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
ameliorative O
effects O
of O
metformin O
on O
seizures B
, O
cognitive B
impairment I
and O
brain O
oxidative O
stress O
markers O
observed O
in O
pentylenetetrazole O
- O
induced O
kindling O
animals O
. O

We O
found O
that O
metformin O
suppressed O
the O
progression O
of O
kindling O
, O
ameliorated O
the O
cognitive B
impairment I
and O
decreased O
brain O
oxidative O
stress O
. O

Thus O
the O
present O
study O
concluded O
that O
metformin O
may O
be O
a O
potential O
agent O
for O
the O
treatment O
of O
epilepsy B
as O
well O
as O
a O
protective O
medicine O
against O
cognitive B
impairment I
induced O
by O
seizures B
. O

AIMS O
: O
Doxorubicin O
( O
DOX O
) O
is O
an O
effective O
anti O
- O
cancer B
therapeutic O
, O
but O
is O
associated O
with O
both O
acute O
and O
late O
- O
stage O
cardiotoxicity B
. O

Children O
are O
particularly O
sensitive O
to O
DOX O
- O
induced O
heart B
failure I
. O

To O
investigate O
effects O
of O
aconitine O
on O
myocardial B
injury I
, O
we O
performed O
cytotoxicity B
assay O
in O
neonatal O
rat O
ventricular O
myocytes O
( O
NRVMs O
) O
, O
as O
well O
as O
measured O
lactate O
dehydrogenase O
level O
in O
the O
culture O
medium O
of O
NRVMs O
and O
activities O
of O
serum O
cardiac O
enzymes O
in O
rats O
. O

The O
results O
showed O
that O
aconitine O
resulted O
in O
myocardial B
injury I
and O
reduced O
NRVMs O
viability O
dose O
- O
dependently O
. O

Chronic O
treatment O
with O
metformin O
suppresses O
toll O
- O
like O
receptor O
4 O
signaling O
and O
attenuates O
left B
ventricular I
dysfunction I
following O
myocardial B
infarction I
. O

In O
the O
present O
study O
, O
the O
effect O
of O
chronic O
pre O
- O
treatment O
with O
metformin O
on O
cardiac B
dysfunction I
and O
toll O
- O
like O
receptor O
4 O
( O
TLR4 O
) O
activities O
following O
myocardial B
infarction I
and O
their O
relation O
with O
AMPK O
were O
assessed O
. O

Isoproterenol O
( O
100mg O
/ O
kg O
) O
was O
injected O
subcutaneously O
on O
the O
13th O
and O
14th O
days O
to O
induce O
acute B
myocardial I
infarction I
. O

The O
left B
ventricular I
dysfunction I
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg O
/ O
kg O
of O
metformin O
. O

Metfromin O
markedly O
lowered O
isoproterenol O
- O
induced O
elevation O
in O
the O
levels O
of O
TLR4 O
mRNA O
, O
myeloid O
differentiation O
protein O
88 O
( O
MyD88 O
) O
, O
tumor B
necrosis B
factor O
- O
alpha O
( O
TNF O
- O
a O
) O
, O
and O
interleukin O
6 O
( O
IL O
- O
6 O
) O
in O
the O
heart O
tissues O
. O

Two O
cases O
of O
propylthiouracil O
- O
associated O
acute O
hepatitis B
, O
one O
case O
of O
fatal O
methimazole O
- O
associated O
hepatocellular B
necrosis I
and O
one O
case O
of O
propylthiouracil O
- O
associated O
lupus B
- I
like I
syndrome I
are O
described O
. O

Neuroleptic B
malignant I
syndrome I
induced O
by O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
in O
a O
Japanese O
patient O
with O
Huntington B
' I
s I
disease I
at O
the O
terminal O
stage O
of O
recurrent O
breast B
cancer I
. O

We O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
Japanese O
woman O
with O
neuroleptic B
malignant I
syndrome I
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride O
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine O
( O
12 O
. O
5 O
mg O
/ O
day O
) O
for O
Huntington B
' I
s I
disease I
. O

She O
also O
had O
advanced O
breast B
cancer I
when O
the O
combination O
therapy O
was O
initiated O
. O

To O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic B
malignant I
syndrome I
due O
to O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
has O
not O
been O
previously O
reported O
. O

A O
63 O
year O
- O
old O
Caucasian O
man O
on O
metoprolol O
200 O
mg O
/ O
day O
for O
stable O
coronary B
artery I
disease I
was O
prescribed O
a O
90 O
- O
day O
course O
of O
oral O
terbinafine O
250 O
mg O
/ O
day O
for O
onychomycosis B
. O

Optochiasmatic O
and O
peripheral B
neuropathy I
due O
to O
ethambutol O
overtreatment O
. O

Ethambutol O
is O
known O
to O
cause O
optic B
neuropathy I
and O
, O
more O
rarely O
, O
axonal O
polyneuropathy B
. O

We O
characterize O
the O
clinical O
, O
neurophysiological O
, O
and O
neuroimaging O
findings O
in O
a O
72 O
- O
year O
- O
old O
man O
who O
developed O
visual B
loss I
and O
paresthesias B
after O
11 O
weeks O
of O
exposure O
to O
a O
supratherapeutic O
dose O
of O
ethambutol O
. O

Testosterone O
ameliorates O
streptozotocin O
- O
induced O
memory B
impairment I
in O
male O
rats O
. O

AIM O
: O
To O
study O
the O
effects O
of O
testosterone O
on O
streptozotocin O
( O
STZ O
) O
- O
induced O
memory B
impairment I
in O
male O
rats O
. O

Administration O
of O
flutamide O
, O
letrozole O
or O
tamoxifen O
significantly O
impaired B
the I
memory I
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone O
replacement O
in O
improving O
STZ O
- O
and O
castration O
- O
induced O
memory B
impairment I
. O

CONCLUSION O
: O
Testosterone O
administration O
ameliorates O
STZ O
- O
and O
castration O
- O
induced O
memory B
impairment I
in O
male O
Wistar O
rats O
. O

It O
is O
widely O
used O
in O
folk O
medicine O
to O
treat O
skin B
diseases I
in O
both O
humans O
and O
animals O
as O
well O
as O
the O
seed O
decoction O
has O
been O
used O
to O
treat O
diarrheas B
and O
inflammatory B
diseases I
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
GFC O
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure B
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino O
acid O
( O
r O
- O
aminobutyric O
acid O
( O
GABA O
) O
, O
glutamine O
, O
aspartate O
and O
glutathione O
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
AChE O
) O
activity O
in O
mice O
hippocampus O
after O
seizures B
. O

GFC O
produced O
an O
increased O
latency O
to O
first O
seizure B
, O
at O
doses O
25mg O
/ O
kg O
( O
20 O
. O
12 O
+ O
2 O
. O
20 O
min O
) O
, O
50mg O
/ O
kg O
( O
20 O
. O
95 O
+ O
2 O
. O
21 O
min O
) O
or O
75 O
mg O
/ O
kg O
( O
23 O
. O
43 O
+ O
1 O
. O
99 O
min O
) O
when O
compared O
with O
seized O
mice O
. O

The O
results O
indicate O
that O
GFC O
can O
exert O
anticonvulsant O
activity O
and O
reduce O
the O
frequency O
of O
installation O
of O
pilocarpine O
- O
induced O
status B
epilepticus I
, O
as O
demonstrated O
by O
increase O
in O
latency O
to O
first O
seizure B
and O
decrease O
in O
mortality O
rate O
of O
animals O
. O

Standard O
operating O
procedures O
for O
antibiotic O
therapy O
and O
the O
occurrence O
of O
acute B
kidney I
injury I
: O
a O
prospective O
, O
clinical O
, O
non O
- O
interventional O
, O
observational O
study O
. O

INTRODUCTION O
: O
Acute B
kidney I
injury I
( O
AKI B
) O
occurs O
in O
7 O
% O
of O
hospitalized O
and O
66 O
% O
of O
Intensive O
Care O
Unit O
( O
ICU O
) O
patients O
. O

Rhabdomyolysis B
in O
a O
hepatitis B
C I
virus I
infected I
patient O
treated O
with O
telaprevir O
and O
simvastatin O
. O

A O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis B
C I
virus I
infection I
received O
triple O
therapy O
with O
ribavirin O
, O
pegylated O
interferon O
and O
telaprevir O
. O

Simvastatin O
plasma O
concentration O
increased O
30 O
times O
in O
this O
patient O
and O
statin O
induced O
muscle B
toxicity I
is O
related O
to O
the O
concentration O
of O
the O
statin O
in O
blood O
. O

Combination O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
VTD O
) O
as O
a O
consolidation O
therapy O
after O
autologous O
stem O
cell O
transplantation O
for O
symptomatic O
multiple B
myeloma I
in O
Japanese O
patients O
. O

Consolidation O
therapy O
for O
patients O
with O
multiple B
myeloma I
( O
MM B
) O
has O
been O
widely O
adopted O
to O
improve O
treatment O
response O
following O
autologous O
stem O
cell O
transplantation O
. O

Grade O
3 O
- O
4 O
neutropenia B
and O
thrombocytopenia B
were O
documented O
in O
four O
and O
three O
patients O
( O
17 O
and O
13 O
% O
) O
, O
respectively O
, O
but O
drug O
dose O
reduction O
due O
to O
cytopenia B
was O
not O
required O
in O
any O
case O
. O

Peripheral B
neuropathy I
was O
common O
( O
63 O
% O
) O
, O
but O
severe O
grade O
3 O
- O
4 O
peripheral B
neuropathy I
was O
not O
observed O
. O

Conversion O
to O
sirolimus O
ameliorates O
cyclosporine O
- O
induced O
nephropathy B
in O
the O
rat O
: O
focus O
on O
serum O
, O
urine O
, O
gene O
, O
and O
protein O
renal O
expression O
biomarkers O
. O

Protocols O
of O
conversion O
from O
cyclosporin O
A O
( O
CsA O
) O
to O
sirolimus O
( O
SRL O
) O
have O
been O
widely O
used O
in O
immunotherapy O
after O
transplantation O
to O
prevent O
CsA O
- O
induced O
nephropathy B
, O
but O
the O
molecular O
mechanisms O
underlying O
these O
protocols O
remain O
nuclear O
. O

Renal B
lesions I
were O
analyzed O
in O
hematoxylin O
and O
eosin O
, O
periodic O
acid O
- O
Schiff O
, O
and O
Masson O
' O
s O
trichrome O
stains O
. O

SRL O
- O
treated O
rats O
presented O
proteinuria B
and O
NGAL O
( O
serum O
and O
urinary O
) O
as O
the O
best O
markers O
of O
renal B
impairment I
. O

Short O
CsA O
treatment O
presented O
slight O
or O
even O
absent O
kidney B
lesions I
and O
TGF O
- O
b O
, O
NF O
- O
kb O
, O
mTOR O
, O
PCNA O
, O
TP53 O
, O
KIM O
- O
1 O
, O
and O
CTGF O
as O
relevant O
gene O
and O
protein O
changes O
. O

Prolonged O
CsA O
exposure O
aggravated O
renal B
damage I
, O
without O
clear O
changes O
on O
the O
traditional O
markers O
, O
but O
with O
changes O
in O
serums O
TGF O
- O
b O
and O
IL O
- O
7 O
, O
TBARs O
clearance O
, O
and O
kidney O
TGF O
- O
b O
and O
mTOR O
. O

Conversion O
to O
SRL O
prevented O
CsA O
- O
induced O
renal B
damage I
evolution O
( O
absent O
/ O
mild O
grade O
lesions O
) O
, O
while O
NGAL O
( O
serum O
versus O
urine O
) O
seems O
to O
be O
a O
feasible O
biomarker O
of O
CsA O
replacement O
to O
SRL O
. O

Kinin O
B2 O
receptor O
deletion O
and O
blockage O
ameliorates O
cisplatin O
- O
induced O
acute B
renal I
injury I
. O

Cisplatin O
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute B
kidney I
injury I
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine O
and O
urea O
, O
increase O
the O
acute B
tubular I
necrosis I
score O
and O
up O
- O
regulate O
cytokines O
( O
e O
. O
g O
. O
, O
IL O
- O
1b O
and O
TNF O
- O
a O
) O
. O

To O
examine O
the O
role O
of O
the O
kinin O
B2 O
receptor O
in O
cisplatin O
- O
induced O
acute B
kidney I
injury I
, O
kinin O
B2 O
receptor O
knockout O
mice O
were O
challenged O
with O
cisplatin O
. O

B2 O
receptor O
- O
deficient O
mice O
were O
less O
sensitive O
to O
this O
drug O
than O
the O
WT O
mice O
, O
as O
shown O
by O
reduced O
weight B
loss I
, O
better O
preservation O
of O
kidney O
function O
, O
down O
regulation O
of O
inflammatory O
cytokines O
and O
less O
acute B
tubular I
necrosis I
. O

Thus O
, O
our O
data O
suggest O
that O
the O
kinin O
B2 O
receptor O
is O
involved O
in O
cisplatin O
- O
induced O
acute B
kidney I
injury I
by O
mediating O
the O
necrotic B
process O
and O
the O
expression O
of O
inflammatory O
cytokines O
, O
thus O
resulting O
in O
declined O
renal O
function O
. O

Disease O
activity O
markers O
, O
including O
signs O
of O
ocular O
inflammation B
, O
evidence O
of O
retinal B
vasculitis I
, O
Swedish O
interactive O
threshold O
algorithm O
- O
short O
wavelength O
automated O
perimetry O
Humphrey O
visual O
field O
analysis O
, O
electroretinographic O
parameters O
, O
and O
optical O
coherence O
tomography O
were O
recorded O
. O

Data O
on O
occurrence O
of O
cataract B
and O
raised B
intraocular I
pressure I
were O
collected O
in O
all O
eyes O
. O

Active O
vasculitis B
was O
noted O
in O
36 O
. O
3 O
% O
patients O
at O
baseline O
and O
0 O
% O
at O
3 O
years O
of O
follow O
- O
up O
. O

More O
than O
20 O
% O
( O
47 O
. O
61 O
- O
67 O
. O
2 O
% O
) O
reduction O
in O
central O
retinal O
thickness O
was O
noted O
in O
all O
patients O
with O
cystoid B
macular I
edema I
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimplant O
. O

Adverse O
events O
included O
increased B
intraocular I
pressure I
( O
54 O
. O
5 O
% O
) O
and O
cataract B
formation O
( O
100 O
% O
) O
. O

It O
is O
associated O
with O
significant O
side O
effects O
of O
cataract B
and O
ocular B
hypertension I
requiring O
treatment O
. O

Optimal O
precurarizing O
dose O
of O
rocuronium O
to O
decrease O
fasciculation B
and O
myalgia B
following O
succinylcholine O
administration O
. O

BACKGROUND O
: O
Succinylcholine O
commonly O
produces O
frequent O
adverse O
effects O
, O
including O
muscle B
fasciculation I
and O
myalgia B
. O

The O
current O
study O
identified O
the O
optimal O
dose O
of O
rocuronium O
to O
prevent O
succinylcholine O
- O
induced O
fasciculation B
and O
myalgia B
and O
evaluated O
the O
influence O
of O
rocuronium O
on O
the O
speed O
of O
onset O
produced O
by O
succinylcholine O
. O

All O
patients O
received O
succinylcholine O
1 O
. O
5 O
mg O
/ O
kg O
at O
2 O
minutes O
after O
the O
precurarization O
, O
and O
were O
assessed O
the O
incidence O
and O
severity O
of O
fasciculations B
, O
while O
myalgia B
was O
assessed O
at O
24 O
hours O
after O
surgery O
. O

RESULTS O
: O
The O
incidence O
and O
severity O
of O
visible O
muscle B
fasciculation I
was O
significantly O
less O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
( O
P O
< O
0 O
. O
001 O
) O
. O

Those O
of O
myalgia B
tend O
to O
decrease O
according O
to O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
, O
but O
there O
was O
no O
significance O
( O
P O
= O
0 O
. O
072 O
) O
. O

CONCLUSIONS O
: O
Precurarization O
with O
0 O
. O
04 O
mg O
/ O
kg O
rocuronium O
was O
the O
optimal O
dose O
considering O
the O
reduction O
in O
the O
incidence O
and O
severity O
of O
fasciculation B
and O
myalgia B
with O
acceptable O
onset O
time O
, O
and O
the O
safe O
and O
effective O
precurarization O
. O

Absence O
of O
PKC O
- O
alpha O
attenuates O
lithium O
- O
induced O
nephrogenic B
diabetes I
insipidus I
. O

Lithium O
, O
an O
effective O
antipsychotic O
, O
induces O
nephrogenic B
diabetes I
insipidus I
( O
NDI B
) O
in O
40 O
% O
of O
patients O
. O

We O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension B
on O
drug O
treatment O
with O
amlodipine O
developed O
loss B
of I
taste I
sensation I
. O

Clinicians O
need O
to O
be O
aware O
of O
prescribing O
concomitant O
medications O
that O
increase O
the O
risk O
of O
myopathy B
or O
inhibit O
the O
CYP3A4 O
enzyme O
. O

Butyrylcholinesterase B
deficiency I
is O
characterized O
by O
prolonged O
apnea B
after O
the O
use O
of O
muscle O
relaxants O
( O
suxamethonium O
or O
mivacurium O
) O
in O
patients O
who O
have O
mutations O
in O
the O
BCHE O
gene O
. O

Delayed O
anemia B
after O
treatment O
with O
injectable O
artesunate O
in O
the O
Democratic O
Republic O
of O
the O
Congo O
: O
a O
manageable O
issue O
. O

Cases O
of O
delayed O
hemolytic B
anemia I
have O
been O
described O
after O
treatment O
with O
injectable O
artesunate O
, O
the O
current O
World O
Health O
Organization O
( O
WHO O
) O
- O
recommended O
first O
- O
line O
drug O
for O
the O
treatment O
of O
severe O
malaria B
. O

A O
total O
of O
350 O
patients O
( O
215 O
[ O
61 O
. O
4 O
% O
] O
< O
5 O
years O
of O
age O
and O
135 O
[ O
38 O
. O
6 O
% O
] O
> O
5 O
years O
of O
age O
) O
were O
followed O
- O
up O
after O
treatment O
with O
injectable O
artesunate O
for O
severe O
malaria B
in O
hospitals O
and O
health O
centers O
of O
the O
Democratic O
Republic O
of O
the O
Congo O
. O

All O
cases O
of O
delayed O
anemia B
were O
clinically O
manageable O
and O
resolved O
within O
one O
month O
. O

Regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
and O
apoptotic O
pathways O
by O
betaine O
attenuates O
isoproterenol O
- O
induced O
acute O
myocardial B
injury I
in O
rats O
. O

Acute O
myocardial B
ischemic I
injury I
was O
induced O
in O
rats O
by O
subcutaneous O
injection O
of O
isoproterenol O
( O
85 O
mg O
/ O
kg O
) O
, O
for O
two O
consecutive O
days O
. O

The O
protective O
role O
of O
betaine O
on O
myocardial B
damage I
was O
further O
confirmed O
by O
histopathological O
examination O
. O

Quetiapine O
- O
induced O
neutropenia B
in O
a O
bipolar B
patient O
with O
hepatocellular B
carcinoma I
. O

A O
case O
of O
a O
patient O
with O
hepatocellular B
carcinoma I
that O
developed O
neutropenia B
after O
treatment O
with O
quetiapine O
is O
described O
here O
. O

CASE O
REPORT O
: O
A O
62 O
- O
year O
- O
old O
Taiwanese O
widow O
with O
bipolar B
disorder I
was O
diagnosed O
with O
hepatocellular B
carcinoma I
at O
age O
60 O
. O

Hepatic B
dysfunction I
may O
be O
one O
of O
the O
possible O
risk O
factors O
, O
and O
concomitant O
fever B
may O
be O
a O
diagnostic O
marker O
for O
adverse O
reaction O
to O
quetiapine O
. O

The O
potential O
protective O
effect O
of O
the O
dietary O
antioxidant O
curcumin O
( O
120 O
mg O
/ O
Kg O
/ O
day O
for O
6 O
days O
) O
against O
the O
renal B
injury I
induced O
by O
maleate O
was O
evaluated O
. O

Tubular O
proteinuria B
and O
oxidative O
stress O
were O
induced O
by O
a O
single O
injection O
of O
maleate O
( O
400 O
mg O
/ O
kg O
) O
in O
rats O
. O

Maleate O
- O
induced O
renal B
injury I
included O
increase O
in O
renal O
vascular O
resistance O
and O
in O
the O
urinary O
excretion O
of O
total O
protein O
, O
glucose O
, O
sodium O
, O
neutrophil O
gelatinase O
- O
associated O
lipocalin O
( O
NGAL O
) O
and O
N O
- O
acetyl O
b O
- O
D O
- O
glucosaminidase O
( O
NAG O
) O
, O
upregulation O
of O
kidney B
injury I
molecule O
( O
KIM O
) O
- O
1 O
, O
decrease O
in O
renal O
blood O
flow O
and O
claudin O
- O
2 O
expression O
besides O
of O
necrosis B
and O
apoptosis O
of O
tubular O
cells O
on O
24 O
h O
. O

It O
is O
concluded O
that O
curcumin O
is O
able O
to O
attenuate O
in O
vivo O
maleate O
- O
induced O
nephropathy B
and O
in O
vitro O
cell O
damage O
. O

MK O
- O
801 O
, O
a O
noncompetitive O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
receptor O
antagonist O
, O
was O
tested O
for O
anticonvulsant O
effects O
in O
rats O
using O
two O
seizure B
models O
, O
coadministration O
of O
lithium O
and O
pilocarpine O
and O
administration O
of O
a O
high O
dose O
of O
pilocarpine O
alone O
. O

Second O
, O
the O
anticonvulsant O
effect O
of O
MK O
- O
801 O
in O
the O
lithium O
- O
pilocarpine O
model O
only O
occurred O
after O
initial O
periods O
of O
seizure B
activity O
. O

Administration O
of O
MK O
- O
801 O
30 O
or O
60 O
min O
after O
pilocarpine O
, O
i O
. O
e O
. O
, O
during O
status B
epilepticus I
, O
gradually O
reduced O
electrical O
and O
behavioral O
seizure B
activity O
and O
greatly O
enhanced O
the O
survival O
rate O
. O

These O
results O
suggest O
that O
activation O
of O
NMDA O
receptors O
plays O
an O
important O
role O
in O
status B
epilepticus I
and O
brain B
damage I
in O
the O
lithium O
- O
pilocarpine O
model O
. O

Continuous O
infusion O
tobramycin O
combined O
with O
carbenicillin O
for O
infections B
in O
cancer B
patients O
. O

The O
cure O
rate O
of O
infections B
in O
cancer B
patients O
is O
adversely O
affected O
by O
neutropenia B
( O
less O
than O
1 O
, O
000 O
/ O
mm3 O
) O
. O

There O
were O
125 O
infectious O
episodes O
in O
116 O
cancer B
patients O
receiving O
myelosuppressive O
chemotherapy O
. O

The O
most O
common O
pathogen O
was O
Klebsiella O
pneumoniae B
and O
this O
, O
together O
with O
Escherichia O
coli O
and O
Pseudomonas O
aeruginosa O
, O
accounted O
for O
74 O
% O
of O
all O
gram B
- I
negative I
bacillary I
infections I
. O

This O
antibiotic O
regimen O
showed O
both O
therapeutic O
efficacy O
and O
acceptable O
renal B
toxicity I
for O
these O
patients O
. O

Incidence O
of O
solid O
tumours B
among O
pesticide O
applicators O
exposed O
to O
the O
organophosphate O
insecticide O
diazinon O
in O
the O
Agricultural O
Health O
Study O
: O
an O
updated O
analysis O
. O

OBJECTIVE O
: O
Diazinon O
, O
a O
common O
organophosphate O
insecticide O
with O
genotoxic O
properties O
, O
was O
previously O
associated O
with O
lung B
cancer I
in O
the O
Agricultural O
Health O
Study O
( O
AHS O
) O
cohort O
, O
but O
few O
other O
epidemiological O
studies O
have O
examined O
diazinon O
- O
associated O
cancer B
risk O
. O

We O
used O
updated O
diazinon O
exposure O
and O
cancer B
incidence O
information O
to O
evaluate O
solid O
tumour B
risk O
in O
the O
AHS O
. O

METHODS O
: O
Male O
pesticide O
applicators O
in O
Iowa O
and O
North O
Carolina O
reported O
lifetime O
diazinon O
use O
at O
enrolment O
( O
1993 O
- O
1997 O
) O
and O
follow O
- O
up O
( O
1998 O
- O
2005 O
) O
; O
cancer B
incidence O
was O
assessed O
through O
2010 O
( O
North O
Carolina O
) O
/ O
2011 O
( O
Iowa O
) O
. O

Among O
applicators O
with O
usage O
information O
sufficient O
to O
evaluate O
exposure O
- O
response O
patterns O
, O
we O
used O
Poisson O
regression O
to O
estimate O
adjusted O
rate O
ratios O
( O
RRs O
) O
and O
95 O
% O
CI O
for O
cancer B
sites O
with O
> O
10 O
exposed O
cases O
for O
both O
lifetime O
( O
LT O
) O
exposure O
days O
and O
intensity O
- O
weighted O
( O
IW O
) O
lifetime O
exposure O
days O
( O
accounting O
for O
factors O
impacting O
exposure O
) O
. O

RESULTS O
: O
We O
observed O
elevated O
lung B
cancer I
risks O
( O
N O
= O
283 O
) O
among O
applicators O
with O
the O
greatest O
number O
of O
LT O
( O
RR O
= O
1 O
. O
60 O
; O
95 O
% O
CI O
1 O
. O
11 O
to O
2 O
. O
31 O
; O
Ptrend O
= O
0 O
. O
02 O
) O
and O
IW O
days O
of O
diazinon O
use O
( O
RR O
= O
1 O
. O
41 O
; O
95 O
% O
CI O
0 O
. O
98 O
to O
2 O
. O
04 O
; O
Ptrend O
= O
0 O
. O
08 O
) O
. O

Kidney B
cancer I
( O
N O
= O
94 O
) O
risks O
were O
non O
- O
significantly O
elevated O
( O
RRLT O
days O
= O
1 O
. O
77 O
; O
95 O
% O
CI O
0 O
. O
90 O
to O
3 O
. O
51 O
; O
Ptrend O
= O
0 O
. O
09 O
; O
RRIW O
days O
1 O
. O
37 O
; O
95 O
% O
CI O
0 O
. O
64 O
to O
2 O
. O
92 O
; O
Ptrend O
= O
0 O
. O
50 O
) O
, O
as O
were O
risks O
for O
aggressive O
prostate B
cancer I
( O
N O
= O
656 O
) O
. O

CONCLUSIONS O
: O
Our O
updated O
evaluation O
of O
diazinon O
provides O
additional O
evidence O
of O
an O
association O
with O
lung B
cancer I
risk O
. O

Newly O
identified O
links O
to O
kidney B
cancer I
and O
associations O
with O
aggressive O
prostate B
cancer I
require O
further O
evaluation O
. O

Associations O
of O
Ozone O
and O
PM2 O
. O
5 O
Concentrations O
With O
Parkinson B
' I
s I
Disease I
Among O
Participants O
in O
the O
Agricultural O
Health O
Study O
. O

OBJECTIVE O
: O
This O
study O
describes O
associations O
of O
ozone O
and O
fine O
particulate O
matter O
with O
Parkinson B
' I
s I
disease I
observed O
among O
farmers O
in O
North O
Carolina O
and O
Iowa O
. O

METHODS O
: O
We O
used O
logistic O
regression O
to O
determine O
the O
associations O
of O
these O
pollutants O
with O
self O
- O
reported O
, O
doctor O
- O
diagnosed O
Parkinson B
' I
s I
disease I
. O

RESULTS O
: O
We O
observed O
positive O
associations O
of O
Parkinson B
' I
s I
disease I
with O
ozone O
( O
odds O
ratio O
= O
1 O
. O
39 O
; O
95 O
% O
CI O
: O
0 O
. O
98 O
to O
1 O
. O
98 O
) O
and O
fine O
particulate O
matter O
( O
odds O
ratio O
= O
1 O
. O
34 O
; O
95 O
% O
CI O
: O
0 O
. O
93 O
to O
1 O
. O
93 O
) O
in O
North O
Carolina O
but O
not O
in O
Iowa O
. O

CONCLUSIONS O
: O
The O
plausibility O
of O
an O
effect O
of O
ambient O
concentrations O
of O
these O
pollutants O
on O
Parkinson B
' I
s I
disease I
risk O
is O
supported O
by O
experimental O
data O
demonstrating O
damage O
to O
dopaminergic O
neurons O
at O
relevant O
concentrations O
. O

Low O
functional O
programming O
of O
renal O
AT2R O
mediates O
the O
developmental O
origin O
of O
glomerulosclerosis B
in O
adult O
offspring O
induced O
by O
prenatal O
caffeine O
exposure O
. O

UNASSIGNED O
: O
Our O
previous O
study O
has O
indicated O
that O
prenatal O
caffeine O
exposure O
( O
PCE O
) O
could O
induce O
intrauterine B
growth I
retardation I
( O
IUGR B
) O
of O
offspring O
. O

Recent O
research O
suggested O
that O
IUGR B
is O
a O
risk O
factor O
for O
glomerulosclerosis B
. O

However O
, O
whether O
PCE O
could O
induce O
glomerulosclerosis B
and O
its O
underlying O
mechanisms O
remain O
unknown O
. O

This O
study O
aimed O
to O
demonstrate O
the O
induction O
to O
glomerulosclerosis B
in O
adult O
offspring O
by O
PCE O
and O
its O
intrauterine O
programming O
mechanisms O
. O

The O
results O
revealed O
that O
the O
adult O
offspring O
kidneys O
in O
the O
PCE O
group O
exhibited O
glomerulosclerosis B
as O
well O
as O
interstitial B
fibrosis I
, O
accompanied O
by O
elevated O
levels O
of O
serum O
creatinine O
and O
urine O
protein O
. O

These O
results O
demonstrated O
that O
PCE O
could O
induce O
dysplasia B
of I
fetal I
kidneys I
as O
well O
as O
glomerulosclerosis B
of O
adult O
offspring O
, O
and O
the O
low O
functional O
programming O
of O
renal O
AT2R O
might O
mediate O
the O
developmental O
origin O
of O
adult O
glomerulosclerosis B
. O

UNASSIGNED O
: O
Epidemiological O
studies O
of O
1 O
, O
3 O
- O
butadiene O
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic B
myeloid I
leukemia I
( O
CML B
) O
. O

Ionizing O
radiation O
is O
capable O
of O
inducing O
the O
requisite O
CML B
- O
associated O
t O
( O
9 O
: O
22 O
) O
translocation O
( O
Philadelphia B
chromosome I
) O
in O
appropriate O
cells O
in O
vitro O
but O
, O
thus O
far O
, O
chemicals O
have O
not O
shown O
this O
capacity O
. O

Cancer B
incidence O
and O
metolachlor O
use O
in O
the O
Agricultural O
Health O
Study O
: O
An O
update O
. O

Environmental O
Protection O
Agency O
based O
on O
increased O
liver B
neoplasms I
in O
female O
rats O
. O

We O
evaluated O
cancer B
incidence O
through O
2010 O
/ O
2011 O
( O
NC O
/ O
IA O
) O
for O
49 O
, O
616 O
applicators O
, O
53 O
% O
of O
whom O
reported O
ever O
using O
metolachlor O
. O

We O
used O
Poisson O
regression O
to O
evaluate O
relations O
between O
two O
metrics O
of O
metolachlor O
use O
( O
lifetime O
days O
, O
intensity O
- O
weighted O
lifetime O
days O
) O
and O
cancer B
incidence O
. O

We O
saw O
no O
association O
between O
metolachlor O
use O
and O
incidence O
of O
all O
cancers B
combined O
( O
n O
= O
5 O
, O
701 O
with O
a O
5 O
- O
year O
lag O
) O
or O
most O
site O
- O
specific O
cancers B
. O

For O
liver B
cancer I
, O
in O
analyses O
restricted O
to O
exposed O
workers O
, O
elevations O
observed O
at O
higher O
categories O
of O
use O
were O
not O
statistically O
significant O
. O

A O
similar O
pattern O
was O
observed O
for O
follicular B
cell I
lymphoma I
, O
but O
no O
other O
lymphoma B
subtypes O
. O

An O
earlier O
suggestion O
of O
increased O
lung B
cancer I
risk O
at O
high O
levels O
of O
metolachlor O
use O
in O
this O
cohort O
was O
not O
confirmed O
in O
this O
update O
. O

This O
suggestion O
of O
an O
association O
between O
metolachlor O
and O
liver B
cancer I
among O
pesticide O
applicators O
is O
a O
novel O
finding O
and O
echoes O
observation O
of O
increased O
liver B
neoplasms I
in O
some O
animal O
studies O
. O

However O
, O
our O
findings O
for O
both O
liver B
cancer I
and O
follicular O
cell O
lymphoma B
warrant O
follow O
- O
up O
to O
better O
differentiate O
effects O
of O
metolachlor O
use O
from O
other O
factors O
. O

There O
is O
considerable O
interest O
in O
identifying O
the O
molecular O
mechanisms O
that O
relate O
early O
- O
life O
iAs O
exposure O
to O
the O
development O
of O
these O
latent O
diseases O
, O
particularly O
in O
relationship O
to O
cancer B
. O

OBJECTIVES O
: O
This O
work O
summarizes O
research O
on O
the O
molecular O
mechanisms O
that O
underlie O
the O
increased O
risk O
of O
cancer B
development O
in O
adulthood O
that O
is O
associated O
with O
early O
- O
life O
iAs O
exposure O
. O

DISCUSSION O
: O
Epigenetic O
reprogramming O
that O
imparts O
functional O
changes O
in O
gene O
expression O
, O
the O
development O
of O
cancer B
stem O
cells O
, O
and O
immunomodulation O
are O
plausible O
underlying O
mechanisms O
by O
which O
early O
- O
life O
iAs O
exposure O
elicits O
latent O
carcinogenic O
effects O
. O

CONCLUSIONS O
: O
Evidence O
is O
mounting O
that O
relates O
early O
- O
life O
iAs O
exposure O
and O
cancer B
development O
later O
in O
life O
. O

Nifedipine O
induced O
bradycardia B
in O
a O
patient O
with O
autonomic B
neuropathy I
. O

An O
80 O
year O
old O
diabetic B
male O
with O
evidence O
of O
peripheral B
and I
autonomic I
neuropathy I
was O
admitted O
with O
chest B
pain I
. O

Autoradiographic O
evidence O
of O
estrogen O
binding O
sites O
in O
nuclei O
of O
diethylstilbesterol O
induced O
hamster O
renal B
carcinomas I
. O

Estrogen O
binding O
sites O
were O
demonstrated O
by O
autoradiography O
in O
one O
transplantable O
and O
five O
primary O
diethylstilbesterol O
induced O
renal B
carcinomas I
in O
three O
hamsters O
. O

Radiolabelling O
, O
following O
the O
in O
vivo O
injection O
of O
3H O
- O
17 O
beta O
estradiol O
, O
was O
increased O
only O
over O
the O
nuclei O
of O
tumor B
cells O
; O
stereologic O
analysis O
revealed O
a O
4 O
. O
5 O
- O
to O
6 O
. O
7 O
- O
times O
higher O
concentration O
of O
reduced O
silver O
grains O
over O
nuclei O
than O
cytoplasm O
of O
these O
cells O
. O

This O
is O
the O
first O
published O
report O
documenting O
the O
preferential O
in O
vivo O
binding O
of O
estrogen O
to O
nuclei O
of O
cells O
in O
estrogen O
induced O
hamster O
renal B
carcinomas I
. O

During O
hypotension B
, O
the O
heart O
rate O
was O
stable O
without O
tachy B
- I
or I
bradycardia I
. O

Tonic B
- I
clonic I
seizures I
followed O
intravenous O
fluorescein O
injection O
for O
fundus O
angiography O
in O
a O
47 O
- O
year O
- O
old O
male O
. O

Phenytoin O
induced O
fatal O
hepatic B
injury I
. O

A O
61 O
year O
old O
female O
developed O
fatal O
hepatic B
failure I
after O
phenytoin O
administration O
. O

A O
typical O
multisystem O
clinical O
pattern O
precedes O
the O
manifestations O
of O
hepatic B
injury I
. O

The O
hematologic O
, O
biochemical O
and O
pathologic O
features O
indicate O
a O
mixed O
hepatocellular B
damage I
due O
to O
drug B
hypersensitivity I
. O

Effect O
of O
alkylxanthines O
on O
gentamicin O
- O
induced O
acute B
renal I
failure I
in O
the O
rat O
. O

Adenosine O
antagonists O
have O
been O
previously O
shown O
to O
be O
of O
benefit O
in O
some O
ischaemic B
and O
nephrotoxic B
models O
of O
acute B
renal I
failure I
( O
ARF B
) O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines O
with O
different O
potencies O
as O
adenosine O
antagonists O
8 O
- O
phenyltheophylline O
, O
theophylline O
and O
enprofylline O
, O
were O
examined O
in O
rats O
developing O
acute B
renal I
failure I
after O
4 O
daily O
injections O
of O
gentamicin O
( O
200 O
mg O
kg O
- O
1 O
) O
. O

Blepharoconjunctivitis B
, O
subjective O
complaints O
of O
dry B
eyes I
, O
blurred B
vision I
, O
contact O
lens O
intolerance O
, O
and O
photodermatitis B
are O
reversible O
side O
effects O
. O

More O
serious O
ocular O
adverse O
reactions O
include O
papilledema B
, O
pseudotumor B
cerebri I
, O
and O
white O
or O
gray O
subepithelial O
corneal B
opacities I
; O
all O
of O
these O
are O
reversible O
if O
the O
drug O
is O
discontinued O
. O

Isotretinoin O
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital B
abnormalities I
after O
maternal O
use O
( O
including O
microphthalmos B
, O
orbital O
hypertelorism B
, O
and O
optic B
nerve I
hypoplasia I
) O
. O

Procaterol O
and O
terbutaline O
in O
bronchial B
asthma I
. O

Procaterol O
, O
a O
new O
beta O
- O
2 O
adrenoceptor O
stimulant O
, O
was O
studied O
in O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
trial O
in O
patients O
with O
bronchial B
asthma I
. O

Subacute O
effects O
of O
propranolol O
and O
B O
24 O
/ O
76 O
on O
isoproterenol O
- O
induced O
rat O
heart B
hypertrophy I
in O
correlation O
with O
blood O
pressure O
. O

The O
studies O
were O
performed O
using O
an O
experimental O
model O
of O
isoproterenol O
- O
induced O
heart B
hypertrophy I
in O
rats O
. O

A O
correlation O
of O
the O
blood O
pressure O
was O
neither O
found O
in O
the O
development O
nor O
in O
the O
attempt O
to O
suppress O
the O
development O
of O
heart B
hypertrophy I
with O
the O
two O
beta O
- O
receptor O
blockers O
. O

Thus O
, O
the O
investigations O
did O
not O
provide O
any O
evidence O
that O
the O
beta O
- O
receptor O
blockers O
propranolol O
and O
B O
24 O
/ O
76 O
have O
the O
potency O
to O
prevent O
isoproterenol O
from O
producing O
heart B
hypertrophy I
. O

Increased O
anxiogenic O
effects O
of O
caffeine O
in O
panic B
disorders I
. O

The O
effects O
of O
oral O
administration O
of O
caffeine O
( O
10 O
mg O
/ O
kg O
) O
on O
behavioral O
ratings O
, O
somatic O
symptoms O
, O
blood O
pressure O
and O
plasma O
levels O
of O
3 O
- O
methoxy O
- O
4 O
- O
hydroxyphenethyleneglycol O
( O
MHPG O
) O
and O
cortisol O
were O
determined O
in O
17 O
healthy O
subjects O
and O
21 O
patients O
meeting O
DSM O
- O
III O
criteria O
for O
agoraphobia B
with O
panic B
attacks I
or O
panic B
disorder I
. O

Caffeine O
produced O
significantly O
greater O
increases O
in O
subject O
- O
rated O
anxiety B
, O
nervousness O
, O
fear O
, O
nausea B
, O
palpitations B
, O
restlessness B
, O
and O
tremors B
in O
the O
patients O
compared O
with O
healthy O
subjects O
. O

Seventy O
- O
one O
percent O
of O
the O
patients O
reported O
that O
the O
behavioral O
effects O
of O
caffeine O
were O
similar O
to O
those O
experienced O
during O
panic B
attacks I
. O

Because O
caffeine O
is O
an O
adenosine O
receptor O
antagonist O
, O
these O
results O
suggest O
that O
some O
panic B
disorder I
patients O
may O
have O
abnormalities B
in I
neuronal I
systems I
involving O
adenosine O
. O

Patients O
with O
anxiety B
disorders I
may O
benefit O
by O
avoiding O
caffeine O
- O
containing O
foods O
and O
beverages O
. O

Electron O
microscopic O
investigations O
of O
the O
cyclophosphamide O
- O
induced O
lesions B
of I
the I
urinary I
bladder I
of O
the O
rat O
and O
their O
prevention O
by O
mesna O
. O

Increase O
in O
intragastric O
pressure O
during O
suxamethonium O
- O
induced O
muscle B
fasciculations I
in O
children O
: O
inhibition O
by O
alfentanil O
. O

The O
incidence O
and O
intensity O
of O
muscle B
fasciculations I
caused O
by O
suxamethonium O
were O
significantly O
greater O
in O
the O
control O
than O
in O
the O
alfentanil O
group O
. O

The O
intragastric O
pressure O
during O
muscle B
fasciculations I
was O
significantly O
higher O
in O
the O
control O
group O
( O
16 O
+ O
/ O
- O
0 O
. O
7 O
( O
SEM O
) O
cm O
H2O O
) O
than O
in O
the O
alfentanil O
group O
( O
7 O
. O
7 O
+ O
/ O
- O
1 O
. O
5 O
( O
SEM O
) O
cm O
H2O O
) O
. O

The O
increase O
in O
intragastric O
pressure O
was O
directly O
related O
to O
the O
intensity O
of O
muscle B
fasciculations I
( O
regression O
line O
: O
y O
= O
0 O
. O
5 O
+ O
4 O
. O
78x O
with O
r O
of O
0 O
. O
78 O
) O
. O

It O
is O
concluded O
that O
intragastric O
pressure O
increases O
significantly O
during O
muscle B
fasciculations I
caused O
by O
suxamethonium O
in O
healthy O
children O
. O

Alfentanil O
50 O
micrograms O
kg O
- O
1 O
effectively O
inhibits O
the O
incidence O
and O
intensity O
of O
suxamethonium O
- O
induced O
muscle B
fasciculations I
; O
moreover O
, O
intragastric O
pressure O
remains O
at O
its O
control O
value O
. O

The O
acute O
effect O
of O
insulin O
treatment O
on O
the O
earlier O
reported O
protective O
effect O
of O
streptozotocin O
diabetes B
against O
the O
cardiotoxic B
effect O
of O
high O
doses O
of O
isoproterenol O
( O
ISO O
) O
was O
investigated O
in O
rats O
. O

Mefenamic O
acid O
, O
26 O
( O
22 O
- O
30 O
) O
mg O
/ O
kg O
, O
prevented O
seizures B
and O
protected O
rats O
from O
seizure B
- O
related O
brain B
damage I
induced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

Acute B
neurologic I
dysfunction I
after O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B
glioma I
. O

Etoposide O
( O
VP O
- O
16 O
- O
213 O
) O
has O
been O
used O
in O
the O
treatment O
of O
many O
solid O
tumors B
and O
hematologic B
malignancies I
. O

When O
used O
in O
high O
doses O
and O
in O
conjunction O
with O
autologous O
bone O
marrow O
transplantation O
, O
this O
agent O
has O
activity O
against O
several O
treatment O
- O
resistant O
cancers B
including O
malignant B
glioma I
. O

In O
six O
of O
eight O
patients O
( O
75 O
% O
) O
who O
we O
treated O
for O
recurrent O
or O
resistant O
glioma B
, O
sudden O
severe O
neurologic B
deterioration I
occurred O
. O

Significant O
clinical O
manifestations O
have O
included O
confusion B
, O
papilledema B
, O
somnolence B
, O
exacerbation O
of O
motor B
deficits I
, O
and O
sharp O
increase O
in O
seizure B
activity O
. O

In O
all O
patients O
, O
computerized O
tomographic O
( O
CT O
) O
brain O
scans O
demonstrated O
stability O
in O
tumor B
size O
and O
peritumor O
edema B
when O
compared O
with O
pretransplant O
scans O
. O

This O
complication O
appears O
to O
represent O
a O
significant O
new O
toxicity B
of O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B
glioma I
. O

Progressive O
bile B
duct I
injury I
after O
thiabendazole O
administration O
. O

A O
27 O
- O
yr O
- O
old O
man O
developed O
jaundice B
2 O
wk O
after O
exposure O
to O
thiabendazole O
. O

This O
case O
represents O
an O
example O
of O
" O
idiosyncratic O
" O
drug B
- I
induced I
liver I
damage I
in O
which O
the O
primary O
target O
of O
injury O
is O
the O
bile O
duct O
. O

Increasing O
recognition O
of O
the O
importance O
of O
calcium O
in O
the O
pathogenesis O
of O
cardiovascular B
disease I
has O
stimulated O
research O
into O
the O
use O
of O
calcium O
channel O
blocking O
agents O
for O
treatment O
of O
a O
variety O
of O
cardiovascular B
diseases I
. O

Selectivity O
for O
the O
cerebrovascular O
bed O
makes O
nimodipine O
potentially O
useful O
in O
the O
treatment O
of O
subarachnoid B
hemorrhage I
, O
migraine B
headache I
, O
dementia B
, O
and O
stroke B
. O

An O
experimental O
model O
of O
focal B
segmental I
glomerular I
sclerosis I
( O
FSGS B
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin O
- O
aminonucleoside O
( O
AMNS O
) O
and O
protamine O
sulfate O
( O
PS O
) O
. O

They O
developed O
nephrotic B
syndrome I
and O
finally O
renal B
failure I
. O

Therefore O
, O
it O
is O
suggested O
that O
the O
administration O
of O
PS O
enhances O
the O
toxicity B
of O
AMNS O
on O
the O
glomerulus O
and O
readily O
produces O
progressive O
FSGS B
in O
rats O
resulting O
in O
the O
end B
- I
stage I
renal I
disease I
. O

We O
have O
described O
a O
patient O
with O
severe O
rheumatoid B
arthritis I
and O
a O
history O
of O
mefenamic O
acid O
nephropathy B
in O
whom O
hyperkalemia B
and O
inappropriate O
hypoaldosteronism B
were O
caused O
by O
both O
indomethacin O
and O
naproxen O
, O
without O
major O
decline O
in O
renal O
function O
. O

It O
is O
likely O
that O
preexisting O
renal B
disease I
predisposed O
this O
patient O
to O
type B
IV I
renal I
tubular I
acidosis I
with O
prostaglandin O
synthetase O
inhibitors O
. O

Cardiac O
symptoms O
, O
including O
hypotension B
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal B
carcinoma I
while O
being O
treated O
with O
cisplatin O
( O
CDDP O
) O
and O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
. O

In O
two O
patients O
, O
hypotension B
was O
associated O
with O
severe O
left B
ventricular I
dysfunction I
. O

Fatal O
aplastic B
anemia I
in O
a O
patient O
treated O
with O
carbamazepine O
. O

A O
case O
of O
fatal O
aplastic B
anemia I
due O
to O
carbamazepine O
treatment O
in O
an O
epileptic B
woman O
is O
reported O
. O

Despite O
concerns O
of O
fatal O
bone B
marrow I
toxicity I
due O
to O
carbamazepine O
, O
this O
is O
only O
the O
fourth O
documented O
and O
published O
report O
. O

Hypertension B
in O
neuroblastoma B
induced O
by O
imipramine O
. O

Hypertension B
is O
a O
well O
- O
known O
finding O
in O
some O
patients O
with O
neuroblastoma B
. O

We O
report O
the O
occurrence O
of O
severe O
hypertension B
( O
blood O
pressure O
190 O
/ O
160 O
) O
in O
a O
4 O
- O
year O
- O
old O
girl O
with O
neuroblastoma B
who O
was O
given O
Imipramine O
to O
control O
a O
behavior B
disorder I
. O

It O
was O
determined O
later O
that O
this O
patient O
' O
s O
tumor B
was O
recurring O
at O
the O
time O
of O
her O
hypertensive B
episode O
. O

From O
this O
experience O
, O
we O
urge O
extreme O
caution O
in O
the O
use O
of O
tricyclic O
antidepressants O
in O
children O
with O
active O
neuroblastoma B
. O

Rechallenge O
of O
patients O
who O
developed O
oral B
candidiasis I
or O
hoarseness B
with O
beclomethasone O
dipropionate O
. O

Eighty O
patients O
who O
were O
to O
receive O
CYA O
50 O
mg O
/ O
kg O
/ O
d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transplants O
for O
aplastic B
anemia I
, O
Wiskott B
- I
Aldrich I
syndrome I
, O
or O
severe B
combined I
immunodeficiency I
syndrome I
. O

Six O
of O
the O
14 O
patients O
died O
with O
congestive B
heart I
failure I
. O

Congestive B
heart I
failure I
caused O
or O
contributed O
to O
death O
in O
0 O
/ O
32 O
patients O
in O
Group O
1 O
v O
6 O
/ O
52 O
( O
12 O
% O
) O
of O
patients O
in O
Group O
2 O
( O
P O
less O
than O
0 O
. O
25 O
) O
. O

We O
conclude O
that O
the O
CYA O
cardiotoxicity B
correlates O
with O
CYA O
dosage O
as O
calculated O
by O
body O
surface O
area O
, O
and O
that O
patients O
with O
aplastic B
anemia I
and O
immunodeficiencies B
can O
be O
effectively O
prepared O
for O
bone O
marrow O
grafting O
at O
a O
CYA O
dose O
of O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
for O
four O
days O
with O
a O
lower O
incidence O
of O
cardiotoxicity B
than O
patients O
whose O
CYA O
dosage O
is O
calculated O
based O
on O
weight O
. O

Experimental O
studies O
in O
healthy O
human O
volunteers O
indicate O
aminoglycosides O
cause O
proximal O
tubular O
damage O
in O
most O
patients O
, O
but O
rarely O
, O
if O
ever O
, O
cause O
glomerular B
or I
tubular I
dysfunction I
. O

Clinical O
trials O
of O
aminoglycosides O
in O
seriously O
ill O
patients O
indicate O
that O
the O
relative O
risk O
for O
developing O
acute B
renal I
failure I
during O
therapy O
ranges O
from O
8 O
to O
10 O
and O
that O
the O
attributable O
risk O
is O
70 O
% O
to O
80 O
% O
. O

Further O
analysis O
of O
these O
data O
suggests O
that O
the O
duration O
of O
therapy O
, O
plasma O
aminoglycoside O
levels O
, O
liver B
disease I
, O
advanced O
age O
, O
high O
initial O
estimated O
creatinine O
clearance O
and O
, O
possibly O
, O
female O
gender O
all O
increase O
the O
risk O
for O
nephrotoxicity B
. O

Other O
causes O
of O
acute B
renal I
failure I
, O
such O
as O
shock B
, O
appear O
to O
have O
an O
additive O
effect O
. O

Flurothyl O
seizure B
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium O
glutamate O
( O
MSG O
) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl O
seizure B
testing O
. O

These O
studies O
were O
undertaken O
to O
determine O
if O
neonatal O
administration O
of O
MSG O
produced O
permanent O
alterations O
in O
seizure B
susceptibility O
, O
since O
previous O
investigations O
were O
inconclusive O
. O

A O
flurothyl O
ether O
seizure B
screening O
technique O
was O
used O
to O
evaluate O
seizure B
susceptibility O
in O
adult O
mice O
that O
received O
neonatal O
injections O
of O
MSG O
( O
4 O
mg O
/ O
g O
and O
1 O
mg O
/ O
g O
) O
. O

MSG O
treatment O
resulted O
in O
significant O
reductions O
in O
whole O
brain O
weight O
but O
did O
not O
alter O
seizure B
threshold O
. O

A O
naloxone O
( O
5 O
mg O
/ O
kg O
) O
challenge O
was O
also O
ineffective O
in O
altering O
the O
seizure B
thresholds O
of O
either O
control O
of O
MSG O
- O
treated O
mice O
. O

Flurothyl O
ether O
produced O
hypothermia B
which O
was O
correlated O
with O
the O
duration O
of O
flurothyl O
exposure O
; O
however O
, O
the O
relationship O
of O
hypothermia B
to O
seizure B
induction O
was O
unclear O
. O

Flurothyl O
seizure B
testing O
proved O
to O
be O
a O
rapid O
and O
reliable O
technique O
with O
which O
to O
evaluate O
seizure B
susceptibility O
. O

Pilocarpine O
, O
given O
intraperitoneally O
to O
rats O
, O
reproduces O
the O
neuropathological O
sequelae O
of O
temporal B
lobe I
epilepsy I
and O
provides O
a O
relevant O
animal O
model O
for O
studying O
mechanisms O
of O
buildup O
of O
convulsive B
activity O
and O
pathways O
operative O
in O
the O
generalization O
and O
propagation O
of O
seizures B
within O
the O
forebrain O
. O

Morphological O
analysis O
of O
frontal O
forebrain O
sections O
with O
light O
microscopy O
revealed O
seizure B
- O
related O
damage O
to O
the O
hippocampal O
formation O
, O
thalamus O
, O
amygdala O
, O
olfactory O
cortex O
, O
substantia O
nigra O
and O
neocortex O
, O
which O
is O
typically O
observed O
with O
pilocarpine O
in O
doses O
exceeding O
350 O
mg O
/ O
kg O
. O

This O
treatment O
was O
also O
sufficient O
to O
protect O
animals O
from O
the O
occurrence O
of O
brain B
damage I
. O

Human O
and O
canine O
ventricular O
vasoactive O
intestinal O
polypeptide O
: O
decrease O
with O
heart B
failure I
. O

Myocardial O
levels O
of O
VIP O
were O
assayed O
before O
and O
after O
the O
development O
of O
heart B
failure I
in O
two O
canine O
models O
. O

In O
the O
first O
, O
cobalt O
cardiomyopathy B
was O
induced O
in O
eight O
dogs O
; O
VIP O
( O
by O
radioimmunoassay O
) O
decreased O
from O
35 O
+ O
/ O
- O
11 O
pg O
/ O
mg O
protein O
( O
mean O
+ O
/ O
- O
SD O
) O
to O
5 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
six O
dogs O
with O
doxorubicin O
- O
induced O
heart B
failure I
, O
VIP O
decreased O
from O
31 O
+ O
/ O
- O
7 O
to O
11 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
addition O
, O
VIP O
content O
of O
left O
ventricular O
muscle O
of O
resected O
failing O
hearts O
in O
10 O
patients O
receiving O
a O
heart O
transplant O
was O
compared O
with O
the O
papillary O
muscles O
in O
14 O
patients O
( O
five O
with O
rheumatic B
disease I
, O
nine O
with O
myxomatous B
degeneration I
) O
receiving O
mitral O
valve O
prostheses O
. O

The O
lowest O
myocardial O
VIP O
concentration O
was O
found O
in O
the O
hearts O
of O
patients O
with O
coronary B
disease I
( O
one O
patient O
receiving O
a O
transplant O
and O
three O
receiving O
mitral O
prostheses O
) O
( O
6 O
. O
3 O
+ O
/ O
- O
1 O
. O
9 O
pg O
/ O
mg O
protein O
) O
. O

The O
hearts O
without O
coronary B
artery I
disease I
( O
average O
ejection O
fraction O
of O
this O
group O
62 O
% O
+ O
/ O
- O
10 O
% O
) O
had O
a O
VIP O
concentration O
of O
14 O
. O
1 O
+ O
/ O
- O
7 O
. O
9 O
pg O
/ O
mg O
protein O
, O
and O
this O
was O
greater O
than O
in O
hearts O
of O
the O
patients O
with O
coronary B
disease I
and O
the O
hearts O
of O
patients O
receiving O
a O
transplant O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

Non O
- O
invasive O
detection O
of O
coronary B
artery I
disease I
by O
body O
surface O
electrocardiographic O
mapping O
after O
dipyridamole O
infusion O
. O

Electrocardiographic O
changes O
after O
dipyridamole O
infusion O
( O
0 O
. O
568 O
mg O
/ O
kg O
/ O
4 O
min O
) O
were O
studied O
in O
41 O
patients O
with O
coronary B
artery I
disease I
and O
compared O
with O
those O
after O
submaximal O
treadmill O
exercise O
by O
use O
of O
the O
body O
surface O
mapping O
technique O
. O

Patients O
were O
divided O
into O
three O
groups O
; O
19 O
patients O
without O
myocardial B
infarction I
( O
non O
- O
MI B
group O
) O
, O
14 O
with O
anterior B
infarction I
( O
ANT B
- I
MI I
) O
and O
eight O
with O
inferior B
infarction I
( O
INF B
- I
MI I
) O
. O

After O
dipyridamole O
, O
ischemic B
ST O
- O
segment O
depression B
( O
0 O
. O
05 O
mV O
or O
more O
) O
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B
group O
, O
29 O
% O
of O
the O
ANT B
- I
MI I
group O
, O
63 O
% O
of O
the O
INF B
- I
MI I
group O
and O
61 O
% O
of O
the O
total O
population O
. O

Exercise O
- O
induced O
ST O
depression B
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B
group O
, O
43 O
% O
of O
the O
ANT B
- I
MI I
group O
, O
38 O
% O
of O
the O
INF B
- I
MI I
group O
and O
61 O
% O
of O
the O
total O
. O

We O
conclude O
that O
the O
dipyridamole O
ECG O
test O
is O
as O
useful O
as O
the O
exercise O
ECG O
test O
for O
the O
assessment O
of O
coronary B
artery I
disease I
. O

In O
5 O
consecutive O
patients O
with O
rheumatoid B
arthritis I
who O
received O
intravenous O
high O
- O
dose O
methylprednisolone O
( O
MP O
) O
therapy O
( O
1 O
g O
daily O
for O
2 O
or O
3 O
consecutive O
days O
) O
, O
a O
decline O
in O
pulse O
rate O
was O
observed O
, O
most O
pronounced O
on O
day O
4 O
. O

High O
- O
dose O
MP O
may O
be O
contraindicated O
in O
patients O
with O
known O
heart B
disease I
. O

Improvement O
by O
denopamine O
( O
TA O
- O
064 O
) O
of O
pentobarbital O
- O
induced O
cardiac B
failure I
in O
the O
dog O
heart O
- O
lung O
preparation O
. O

The O
efficacy O
of O
denopamine O
, O
an O
orally O
active O
beta O
1 O
- O
adrenoceptor O
agonist O
, O
in O
improving O
cardiac B
failure I
was O
assessed O
in O
dog O
heart O
- O
lung O
preparations O
. O

The O
results O
warrant O
clinical O
trials O
of O
denopamine O
in O
the O
treatment O
of O
cardiac B
failure I
. O

Sixty O
patients O
( O
age O
- O
range O
one O
month O
to O
14 O
years O
) O
with O
other O
types O
of O
epilepsy B
than O
infantile B
spasms I
were O
treated O
with O
clonazepam O
. O

The O
incidence O
of O
side O
effects O
such O
as O
drowsiness B
and O
ataxia B
was O
only O
5 O
% O
. O

Overall O
, O
1 O
, O
453 O
patients O
experienced O
a O
total O
of O
2 O
, O
658 O
adverse O
events O
, O
the O
most O
common O
being O
fatigue B
, O
dizziness B
, O
and O
weakness B
. O

Salicylate O
nephropathy B
in O
the O
Gunn O
rat O
: O
potential O
role O
of O
prostaglandins O
. O

We O
examined O
the O
potential O
role O
of O
prostaglandins O
in O
the O
development O
of O
analgesic O
nephropathy B
in O
the O
Gunn O
strain O
of O
rat O
. O

These O
rats O
are O
also O
highly O
susceptible O
to O
develop O
papillary B
necrosis I
with O
analgesic O
administration O
. O

The O
changes O
in O
renal O
prostaglandin O
synthesis O
were O
accompanied O
by O
evidence O
of O
renal B
damage I
in O
aspirin O
- O
treated O
jj O
but O
not O
jJ O
rats O
as O
evidenced O
by O
: O
increased O
incidence O
and O
severity O
of O
hematuria B
( O
p O
less O
than O
0 O
. O
01 O
) O
; O
increased O
serum O
creatinine O
( O
p O
less O
than O
0 O
. O
05 O
) O
; O
and O
increase O
in O
outer O
medullary O
histopathologic O
lesions O
( O
p O
less O
than O
0 O
. O
005 O
compared O
to O
either O
sham O
- O
treated O
jj O
or O
aspirin O
- O
treated O
jJ O
) O
. O

These O
results O
suggest O
that O
enhanced O
prostaglandin O
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin O
synthesis O
may O
lead O
to O
pathological B
renal I
medullary I
lesions I
and O
deterioration B
of I
renal I
function I
. O

During O
the O
1 O
hour O
after O
administration O
of O
the O
drug O
the O
incidence O
of O
ventricular B
fibrillation I
or O
sustained O
ventricular B
tachycardia I
among O
the O
204 O
patients O
with O
acute O
myocardial B
infarction I
was O
low O
, O
1 O
. O
5 O
% O
. O

Cardiovascular B
dysfunction I
and O
hypersensitivity B
to O
sodium O
pentobarbital O
induced O
by O
chronic O
barium O
chloride O
ingestion O
. O

Analysis O
of O
in O
vivo O
myocardial O
excitability O
, O
contractility O
, O
and O
metabolic O
characteristics O
at O
16 O
months O
revealed O
other O
significant O
barium O
- O
induced O
disturbances B
within I
the I
cardiovascular I
system I
. O

The O
most O
distinctive O
aspect O
of O
the O
barium O
effect O
was O
a O
demonstrated O
hypersensitivity B
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
. O

Overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic B
disturbances I
, O
and O
the O
hypersensitivity B
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic B
disorder I
induced O
by O
chronic O
barium O
exposure O
. O

Mesangial O
function O
and O
glomerular B
sclerosis I
in O
rats O
with O
aminonucleoside O
nephrosis B
. O

The O
possible O
relationship O
between O
mesangial B
dysfunction I
and O
development O
of O
glomerular B
sclerosis I
was O
studied O
in O
the O
puromycin O
aminonucleoside O
( O
PAN O
) O
model O
. O

At O
5 O
months O
glomerular B
sclerosis I
was O
found O
in O
7 O
. O
6 O
+ O
/ O
- O
3 O
. O
4 O
% O
of O
the O
glomeruli O
of O
PAN O
rats O
; O
glomeruli O
of O
the O
controls O
were O
normal O
. O

Similar O
to O
the O
remnant O
kidney O
model O
in O
PAN O
nephrosis B
the O
development O
of O
glomerular B
sclerosis I
may O
be O
related O
to O
" O
mesangial O
overloading O
. O
" O

Mice O
sensitive O
to O
the O
convulsant O
effects O
of O
nicotine O
had O
greater O
alpha O
- O
bungarotoxin O
binding O
in O
the O
hippocampus O
than O
seizure B
insensitive O
mice O
. O

The O
binding O
sites O
from O
seizure B
sensitive O
and O
resistant O
mice O
were O
equally O
affected O
by O
treatment O
with O
dithiothreitol O
, O
trypsin O
or O
heat O
. O

Thus O
it O
appears O
that O
the O
difference O
between O
seizure B
sensitive O
and O
insensitive O
animals O
may O
be O
due O
to O
a O
difference O
in O
hippocampal O
nicotinic O
receptor O
concentration O
as O
measured O
with O
alpha O
- O
bungarotoxin O
binding O
. O

It O
is O
concluded O
that O
PAP O
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
APAP O
- O
induced O
renal B
tubular I
necrosis I
. O

Recurrent O
subarachnoid B
hemorrhage I
associated O
with O
aminocaproic O
acid O
therapy O
and O
acute B
renal I
artery I
thrombosis I
. O

These O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial B
vascular I
thrombosis I
in O
patients O
with O
SAH B
, O
arteriolar O
and O
capillary O
fibrin O
thrombi B
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
EACA O
, O
or O
other O
thromboembolic B
phenomena I
. O

Since O
intravascular O
fibrin O
thrombi B
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
EACA O
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi B
in O
patients O
with O
disseminated B
intravascular I
coagulation I
or O
other O
" O
consumption B
coagulopathies I
. O
" O
This O
report O
describes O
subtotal O
infarction B
of O
the O
kidney O
due O
to O
thrombosis B
of I
a I
normal I
renal I
artery I
. O

Effect O
of O
vincristine O
sulfate O
on O
Pseudomonas B
infections I
in O
monkeys O
. O

We O
conclude O
that O
previously O
reported O
hypoglycemia B
, O
hyperbilirubinemia B
, O
polycythemia B
, O
neonatal B
apnea I
, O
and O
bradycardia B
are O
not O
invariable O
and O
cannot O
be O
statistically O
correlated O
with O
chronic O
propranolol O
therapy O
. O

Growth B
retardation I
, O
however O
, O
appears O
to O
be O
significant O
in O
both O
of O
our O
series O
. O

Comparing O
the O
relative O
sensitivity O
to O
central O
depression B
and O
excitation O
revealed O
that O
rats O
were O
least O
likely O
to O
have O
convulsions B
at O
doses O
that O
did O
not O
first O
cause O
loss B
of I
consciousness I
, O
while O
cats O
most O
clearly O
showed O
marked O
central O
excitatory O
actions O
. O

Signs O
of O
FZP O
toxocity B
in O
cats O
included O
excessive O
salivation B
, O
extreme O
apprehensive O
behavior O
, O
retching O
, O
muscle B
tremors I
and O
convulsions B
. O

Use O
of O
propranolol O
in O
the O
treatment O
of O
idiopathic B
orthostatic I
hypotension I
. O

Five O
patients O
with O
idiopathic B
orthostatic I
hypotension I
who O
had O
physiologic O
and O
biochemical O
evidence O
of O
severe O
autonomic O
dysfunction O
were O
included O
in O
the O
study O
. O

They O
all O
exhibited O
markedly O
reduced O
plasma O
catecholamines O
and O
plasma O
renin O
activity O
in O
both O
recumbent O
and O
upright O
positions O
and O
had O
marked O
hypersensitivity B
to O
the O
pressor O
effects O
of O
infused O
norepinephrine O
. O

The O
studies O
suggest O
that O
propranolol O
is O
a O
useful O
drug O
in O
selected O
patients O
with O
severe O
idiopathic B
orthostatic I
hypotension I
. O

Hormones O
and O
risk O
of O
breast B
cancer I
. O

Analysis O
of O
site O
of O
infection B
showed O
a O
preponderance O
of O
abdominal B
infections I
in O
liver O
patients O
, O
intrathoracic O
infections B
in O
heart O
patients O
, O
and O
urinary B
tract I
infections I
in O
renal O
patients O
. O

Aza O
patients O
had O
significantly O
more O
staphylococcal B
infections I
than O
all O
other O
transplant O
groups O
( O
P O
less O
than O
0 O
. O
005 O
) O
, O
and O
systemic O
fungal B
infections I
occurred O
only O
in O
the O
liver O
transplant O
group O
. O

Of O
the O
cyclosporine O
patients O
, O
15 O
% O
had O
symptoms O
related O
to O
CMV B
infection I
. O

Serological O
evidence O
for O
Epstein B
Barr I
Virus I
infection I
was O
found O
in O
20 O
% O
of O
65 O
cyclosporine O
patients O
studied O
. O

Three O
had O
associated O
symptoms O
, O
and O
one O
developed O
a O
lymphoma B
. O

Vasopressin O
plays O
a O
major O
role O
in O
the O
pathogenesis O
of O
DOCA O
- O
salt O
hypertension B
, O
since O
the O
elevation O
of O
blood O
pressure O
was O
not O
substantial O
in O
the O
rats O
with O
lithium O
- O
treated O
diabetes B
insipidus I
after O
DOCA O
- O
salt O
treatment O
. O

Toxic B
hepatitis I
induced O
by O
disulfiram O
in O
a O
non O
- O
alcoholic O
. O

A O
reversible O
toxic B
liver I
damage I
was O
observed O
in O
a O
non O
- O
alcoholic O
woman O
treated O
with O
disulfiram O
. O

Atrial B
thrombosis I
involving O
the O
heart O
of O
F O
- O
344 O
rats O
ingesting O
quinacrine O
hydrochloride O
. O

Rats O
treated O
with O
500 O
ppm O
quinacrine O
hydrochloride O
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial B
thrombosis I
. O

The O
lesion O
was O
associated O
with O
cardiac B
hypertrophy I
and O
dilatation O
and O
focal O
myocardial B
degeneration I
. O

Rats O
died O
from O
cardiac B
hypertrophy I
with O
severe O
acute O
and O
chronic O
congestion O
of O
the O
lungs O
, O
liver O
, O
and O
other O
organs O
. O

Seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine O
hydrochloride O
and O
1 O
, O
000 O
ppm O
sodium O
nitrite O
simultaneously O
in O
the O
diet O
had O
thrombosis B
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial B
thrombosis I
. O

Alternating B
sinus I
rhythm I
and O
intermittent O
sinoatrial B
block I
induced O
by O
propranolol O
. O

Alternating B
sinus I
rhythm I
and O
intermittent O
sinoatrial B
( I
S I
- I
A I
) I
block I
was O
observed O
in O
a O
57 O
- O
year O
- O
old O
woman O
, O
under O
treatment O
for O
angina B
with O
80 O
mg O
propranolol O
daily O
. O

In O
one O
recording O
a O
short O
period O
of O
regular O
sinus O
rhythm O
with O
intermittent O
2 O
/ O
1 O
S B
- I
A I
block I
was O
observed O
. O

The O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol O
and O
when O
the O
drug O
was O
restarted O
a O
2 O
/ O
1 O
S B
- I
A I
block I
was O
seen O
. O

This O
was O
accepted O
as O
evidence O
for O
propranolol O
being O
the O
cause O
of O
this O
conduction B
disorder I
. O

Animals O
with O
a O
tumor B
( O
diameter O
, O
15 O
. O
8 O
+ O
/ O
- O
3 O
. O
3 O
mm O
) O
were O
treated O
with O
iv O
injections O
of O
doxorubicin O
on O
5 O
consecutive O
days O
, O
followed O
by O
1 O
weekly O
injection O
for O
7 O
weeks O
( O
dose O
range O
, O
0 O
. O
015 O
- O
4 O
. O
0 O
mg O
/ O
kg O
body O
wt O
) O
. O

Complete O
disappearance O
of O
the O
tumor B
was O
induced O
with O
1 O
. O
0 O
mg O
doxorubicin O
/ O
kg O
. O

Light O
microscopic O
evidence O
of O
renal B
damage I
was O
seen O
above O
a O
dose O
of O
0 O
. O
5 O
mg O
doxorubicin O
/ O
kg O
, O
which O
resulted O
in O
albuminuria B
and O
very O
low O
serum O
albumin O
levels O
. O

The O
same O
experiments O
were O
performed O
with O
non O
- O
tumor B
- O
bearing O
rats O
, O
in O
which O
no O
major O
differences O
were O
observed O
. O

Albuminuria B
due O
to O
renal B
damage I
led O
to O
extremely O
low O
serum O
albumin O
levels O
, O
so O
ascites B
and O
hydrothorax B
were O
not O
necessarily O
a O
consequence O
of O
the O
observed O
cardiomyopathy B
. O

Anticholinesterases O
were O
administered O
in O
an O
attempt O
to O
antagonize O
prolonged O
neuromuscular B
blockade I
following O
the O
administration O
of O
succinylcholine O
in O
a O
patient O
later O
found O
to O
be O
homozygous O
for O
atypical O
plasma O
cholinesterase O
. O

In O
the O
same O
animals O
the O
occurrence O
of O
clonic B
seizures I
was O
scored O
as O
to O
time O
of O
onset O
and O
severity O
for O
20 O
min O
after O
drug O
administration O
. O

When O
these O
proceeded O
to O
tonic B
seizures I
, O
death O
occurred O
in O
less O
than O
20 O
min O
. O

Animals O
surviving O
for O
20 O
min O
were O
immediately O
stressed O
by O
a O
swim O
test O
in O
25 O
degrees O
C O
water O
, O
and O
death O
- O
producing O
tonic B
seizures I
were O
scored O
for O
2 O
min O
. O

Treatment O
of O
ovarian B
cancer I
with O
a O
combination O
of O
cis O
- O
platinum O
, O
adriamycin O
, O
cyclophosphamide O
and O
hexamethylmelamine O
. O

During O
the O
last O
2 O
1 O
/ O
2 O
years O
, O
38 O
patients O
with O
ovarian B
cancer I
were O
treated O
with O
a O
combination O
of O
cisplatinum O
( O
CPDD O
) O
, O
50 O
mg O
/ O
m2 O
, O
adriamycin O
, O
30 O
mg O
/ O
m2 O
, O
cyclophosphamide O
, O
300 O
mg O
/ O
m2 O
, O
on O
day O
1 O
; O
and O
hexamethylmelamine O
( O
HMM O
) O
, O
6 O
mg O
/ O
kg O
daily O
, O
for O
14 O
days O
. O

Hematologic B
toxicity I
was O
moderate O
and O
with O
reversible O
anemia B
developing O
in O
71 O
% O
of O
patients O
. O

HMM O
gastrointestinal B
toxicity I
necessitated O
discontinuation O
of O
the O
drug O
in O
5 O
patients O
. O

A O
case O
of O
nontraumatic O
dissecting B
aneurysm I
of O
the O
basilar O
artery O
in O
association O
with O
hypertension B
, O
smoke O
, O
and O
oral O
contraceptives O
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked B
- I
in I
syndrome I
. O

Propylthiouracil O
- O
induced O
hepatic B
damage I
. O

Two O
cases O
of O
propylthiouracil O
- O
induced O
liver B
damage I
have O
been O
observed O
. O

The O
first O
case O
is O
of O
an O
acute O
type O
of O
damage O
, O
proven O
by O
rechallenge O
; O
the O
second O
presents O
a O
clinical O
and O
histologic O
picture O
resembling O
chronic B
active I
hepatitis I
, O
with O
spontaneous O
remission O
. O

Bepridil O
, O
a O
novel O
active O
compound O
for O
prophylactic O
treatment O
of O
anginal B
attacks I
, O
induced O
persistent O
bradycardia B
and O
a O
non O
- O
specific O
anti O
- O
tachycardial B
effect O
, O
the O
mechanisms O
of O
which O
were O
investigated O
in O
vitro O
and O
in O
vivo O
. O

Hepatitis B
and O
renal B
tubular I
acidosis I
after O
anesthesia O
with O
methoxyflurane O
. O

A O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute B
cholecystitis I
under O
methoxyflurane O
anesthesia O
developed O
postoperatively O
a O
hepatic B
insufficiency I
syndrome I
and O
renal B
tubular I
acidosis I
. O

Antirifampicin O
antibodies O
in O
acute O
rifampicin O
- O
associated O
renal B
failure I
. O

5 O
patients O
with O
acute B
renal I
failure I
( O
3 O
with O
thrombopenia B
and O
hemolysis B
) O
induced O
by O
the O
reintroduction O
of O
rifampicin O
are O
described O
. O

Antibodies O
suggested O
to O
be O
of O
the O
IgM O
class O
were O
detected O
in O
all O
3 O
patients O
with O
hematological B
disorders I
. O

The O
pattern O
of O
non O
- O
specific O
acute B
tubular I
necrosis I
found O
in O
the O
2 O
biopsied O
patients O
, O
indistinguishable O
from O
that O
of O
ischemic O
origin O
, O
raised O
the O
possibility O
of O
a O
vascular O
- O
mediated O
damage O
. O

Invasive O
carcinoma B
of I
the I
renal I
pelvis I
following O
cyclophosphamide O
therapy O
for O
nonmalignant O
disease O
. O

A O
47 O
- O
year O
- O
old O
woman O
with O
right O
hydroureteronephrosis B
due O
to O
ureterovesical O
junction O
obstruction O
had O
gross O
hematuria B
after O
being O
treated O
for O
five O
years O
wtih O
cyclophosphamide O
for O
cerebral B
vasculitis I
. O

The O
pathology O
specimen O
contained O
clinically O
occult O
invasive O
carcinoma B
of I
the I
renal I
pelvis I
. O

Although O
the O
ability O
of O
cyclophosphamide O
to O
cause O
hemorrhagic B
cystitis I
and O
urine O
cytologic O
abnormalities O
indistinguishable O
from O
high O
grade O
carcinoma B
is O
well O
known O
, O
it O
is O
less O
widely O
appreciated O
that O
it O
is O
also O
associated O
with O
carcinoma B
of I
the I
urinary I
tract I
. O

Twenty O
carcinomas B
of I
the I
urinary I
bladder I
and O
one O
carcinoma B
of I
the I
prostate I
have O
been O
reported O
in O
association O
with O
its O
use O
. O

The O
present O
case O
is O
the O
first O
carcinoma B
of I
the I
renal I
pelvis I
reported O
in O
association O
with O
cyclophosphamide O
treatment O
. O

It O
is O
the O
third O
urinary B
tract I
cancer I
reported O
in O
association O
with O
cyclophosphamide O
treatment O
for O
nonmalignant O
disease O
. O

The O
association O
of O
the O
tumor B
with O
preexisting O
hydroureteronephrosis B
suggests O
that O
stasis O
prolonged O
and O
intensified O
exposure O
of O
upper O
urinary O
tract O
epithelium O
to O
cyclophosphamide O
. O

Bilateral O
retinal B
artery I
and I
choriocapillaris I
occlusion I
following O
the O
injection O
of O
long O
- O
acting O
corticosteroid O
suspensions O
in O
combination O
with O
other O
drugs O
: O
I O
. O

Two O
well O
- O
documented O
cases O
of O
bilateral O
retinal B
artery I
and I
choriocapillaris I
occlusions I
with O
blindness B
following O
head O
and O
neck O
soft O
- O
tissue O
injection O
with O
methylprednisolone O
acetate O
in O
combination O
with O
lidocaine O
, O
epinephrine O
, O
or O
penicillin O
are O
reported O
. O

The O
acute O
observations O
included O
hazy O
sensorium O
, O
superior O
gaze O
palsy B
, O
pupillary B
abnormalities I
, O
and O
conjunctival O
hemorrhages B
with O
edema B
. O

Follow O
- O
up O
changes O
showed O
marked O
visual B
loss I
, O
constricted O
visual O
fields O
, O
optic O
nerve O
pallor O
, O
vascular O
attenuation O
, O
and O
chorioretinal B
atrophy I
. O

Total O
blindness B
with O
a O
transient O
tonic B
pupillary I
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
developed O
in O
a O
54 O
- O
year O
- O
old O
man O
after O
the O
use O
of O
quinine O
sulfate O
for O
leg B
cramps I
. O

Suxamethonium O
- O
induced O
jaw B
stiffness I
and O
myalgia B
associated O
with O
atypical O
cholinesterase O
: O
case O
report O
. O

In O
response O
to O
this O
a O
marked O
jaw B
stiffness I
occurred O
which O
lasted O
for O
two O
minutes O
and O
the O
anaesthesia O
were O
terminated O
. O

Four O
hours O
of O
apnoea B
ensued O
and O
he O
suffered O
generalized O
severe O
myalgia B
lasting O
for O
one O
week O
. O

The O
case O
shows O
that O
prolonged B
jaw I
rigidity I
and O
myalgia B
may O
occur O
after O
suxamethonium O
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium O
. O

Indomethacin O
- O
induced O
hyperkalemia B
in O
three O
patients O
with O
gouty B
arthritis I
. O

We O
describe O
three O
patients O
in O
whom O
severe O
, O
life O
- O
threatening O
hyperkalemia B
and O
renal B
insufficiency I
developed O
after O
treatment O
of O
acute O
gouty B
arthritis I
with O
indomethacin O
. O

Careful O
attention O
to O
renal O
function O
and O
potassium O
balance O
in O
patients O
receiving O
indomethacin O
or O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
, O
particularly O
in O
those O
patients O
with O
diabetes B
mellitus I
or O
preexisting O
renal B
disease I
, O
will O
help O
prevent O
this O
potentially O
serious O
complication O
. O

Venous O
pain B
occurred O
in O
68 O
% O
of O
patients O
and O
50 O
% O
had O
redness O
, O
pain B
or O
swelling B
related O
to O
the O
injection O
site O
, O
in O
some O
cases O
lasting O
up O
to O
three O
weeks O
after O
anaesthesia O
. O

We O
evaluated O
the O
severity O
of O
motor B
disability I
and O
dyskinesias B
in O
seven O
levodopa O
- O
responsive O
patients O
with O
Parkinson B
' I
s I
disease I
after O
an O
acute O
challenge O
with O
the O
mixed O
dopamine O
agonist O
, O
apomorphine O
, O
before O
and O
after O
the O
administration O
of O
fluoxetine O
( O
20 O
mg O
twice O
per O
day O
) O
for O
11 O
+ O
/ O
- O
1 O
days O
. O

After O
fluoxetine O
treatment O
, O
there O
was O
a O
significant O
47 O
% O
improvement O
( O
p O
< O
0 O
. O
05 O
) O
of O
apomorphine O
- O
induced O
dyskinesias B
without O
modification O
of O
parkinsonian B
motor B
disability I
. O

The O
dyskinesias B
were O
reduced O
predominantly O
in O
the O
lower O
limbs O
during O
the O
onset O
and O
disappearance O
of O
dystonic B
dyskinesias I
( O
onset O
- O
and O
end O
- O
of O
- O
dose O
dyskinesias B
) O
and O
in O
the O
upper O
limbs O
during O
choreic B
mid I
- I
dose I
dyskinesias I
. O

The O
results O
suggest O
that O
increased O
brain O
serotoninergic O
transmission O
with O
fluoxetine O
may O
reduce O
levodopa O
- O
or O
dopamine O
agonist O
- O
induced O
dyskinesias B
without O
aggravating O
parkinsonian B
motor B
disability I
. O

A O
large O
population O
- O
based O
follow O
- O
up O
study O
of O
trimethoprim O
- O
sulfamethoxazole O
, O
trimethoprim O
, O
and O
cephalexin O
for O
uncommon O
serious O
drug B
toxicity I
. O

We O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim O
- O
sulfamethoxazole O
( O
TMP O
- O
SMZ O
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim O
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin O
, O
to O
estimate O
the O
risk O
of O
serious O
liver B
, I
blood I
, I
skin I
, I
and I
renal I
disorders I
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

The O
risk O
of O
clinically O
important O
idiopathic O
liver B
disease I
was O
similar O
for O
persons O
prescribed O
TMP O
- O
SMZ O
( O
5 O
. O
2 O
/ O
100 O
, O
000 O
) O
and O
those O
prescribed O
trimethoprim O
alone O
( O
3 O
. O
8 O
/ O
100 O
, O
000 O
) O
. O

Only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
TMP O
- O
SMZ O
; O
of O
seven O
with O
erythema B
multiforme I
and O
Stevens B
- I
Johnson I
syndrome I
, O
four O
were O
exposed O
to O
TMP O
- O
SMZ O
. O

Finally O
, O
only O
five O
cases O
of O
acute O
parenchymal O
renal B
disease I
occurred O
, O
none O
likely O
to O
be O
caused O
by O
a O
study O
drug O
. O

RESULTS O
: O
Of O
29 O
patients O
who O
received O
lidocaine O
in O
the O
setting O
of O
cocaine O
- O
associated O
MI B
, O
no O
patient O
died O
; O
exhibited O
bradydysrhythmias B
, O
ventricular B
tachycardia I
, O
or O
ventricular B
fibrillation I
; O
or O
experienced O
seizures B
after O
administration O
of O
lidocaine O
( O
95 O
% O
confidence O
interval O
, O
0 O
% O
to O
11 O
% O
) O
. O

CONCLUSION O
: O
Despite O
theoretical O
concerns O
that O
lidocaine O
may O
enhance O
cocaine O
toxicity B
, O
the O
use O
of O
lidocaine O
in O
patients O
with O
cocaine O
- O
associated O
MI B
was O
not O
associated O
with O
significant O
cardiovascular B
or I
central I
nervous I
system I
toxicity I
. O

Experimental O
progressive O
muscular B
dystrophy I
and O
its O
treatment O
with O
high O
doses O
anabolizing O
agents O
. O

We O
are O
still O
a O
long O
way O
from O
discovering O
an O
unequivocal O
pathogenetic O
interpretation O
of O
progressive O
muscular B
dystrophy I
in O
man O
. O

Myopathy B
due O
to O
lack O
of O
vitamin O
E O
and O
myopathy B
induced O
by O
certain O
viruses O
have O
much O
in O
common O
anatomically O
and O
pathologically O
with O
the O
human O
form O
. O

It O
is O
thus O
confirmed O
that O
the O
histological O
characteristics O
of O
myopathic B
rat O
muscle O
induced O
experimentally O
are O
extraordinarily O
similar O
to O
those O
of O
human O
myopathy B
as O
confirmed O
during O
biopsies O
performed O
at O
the O
Orthopaedic O
Traumatological O
Centre O
, O
Florence O
. O

The O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic B
patients O
by O
using O
anabolizing O
steroids O
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
( O
Dianabol O
, O
CIBA O
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic B
by O
a O
diet O
deficient O
in O
vitamin O
E O
. O

In O
this O
way O
they O
obtained O
appreciable O
changes O
in O
body O
weight O
( O
increased O
from O
50 O
to O
70 O
g O
after O
forty O
days O
at O
a O
dose O
of O
5 O
mg O
per O
day O
of O
anabolizing O
agent O
) O
, O
but O
most O
of O
all O
they O
found O
histological O
changes O
due O
to O
" O
regenerative O
" O
changes O
in O
the O
muscle O
tissue O
, O
which O
however O
maintained O
its O
myopathic B
characteristics O
in O
the O
control O
animals O
that O
were O
not O
treated O
with O
the O
anabolizing O
agent O
. O

The O
authors O
conclude O
by O
affirming O
the O
undoubted O
efficacy O
of O
the O
anabolizing O
steroids O
in O
experimental O
myopathic B
disease I
, O
but O
they O
have O
reservations O
as O
to O
the O
transfer O
of O
the O
results O
into O
the O
human O
field O
, O
where O
high O
dosage O
cannot O
be O
carried O
out O
continuously O
because O
of O
the O
effects O
of O
the O
drug O
on O
virility O
; O
because O
the O
tissue O
injury O
too O
often O
occurs O
at O
an O
irreversible O
stage O
vis O
- O
a O
- O
vis O
the O
" O
regeneration O
" O
of O
the O
muscle O
tissue O
; O
and O
finally O
because O
the O
dystrophic O
injurious O
agent O
is O
certainly O
not O
the O
lack O
of O
vitamin O
E O
but O
something O
as O
yet O
unknown O
. O

Paclitaxel O
( O
Taxol O
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
by O
3 O
- O
hour O
infusion O
was O
combined O
with O
carboplatin O
in O
a O
phase O
I O
/ O
II O
study O
directed O
to O
patients O
with O
non B
- I
small I
cell I
lung I
cancer I
. O

The O
225 O
mg O
/ O
m2 O
level O
was O
expanded O
for O
the O
phase O
II O
study O
since O
the O
highest O
level O
achieved O
( O
250 O
mg O
/ O
m2 O
) O
required O
modification O
because O
of O
nonhematologic O
toxicities B
( O
arthralgia B
and O
sensory B
neuropathy I
) O
. O

Carboplatin O
did O
not O
appear O
to O
add O
to O
the O
hematologic B
toxicities I
observed O
, O
and O
the O
paclitaxel O
/ O
carboplatin O
combination O
could O
be O
dosed O
every O
3 O
weeks O
. O

The O
dose O
- O
dependent O
effect O
of O
misoprostol O
on O
indomethacin O
- O
induced O
renal B
dysfunction I
in O
well O
compensated O
cirrhosis B
. O

Misoprostol O
( O
200 O
micrograms O
) O
has O
been O
shown O
to O
acutely O
counteract O
the O
indomethacin O
- O
induced O
renal B
dysfunction I
in O
well O
compensated O
cirrhotic B
patients O
. O

Parameters O
of O
renal O
hemodynamics O
and O
tubular O
sodium O
and O
water O
handling O
were O
assessed O
by O
clearance O
techniques O
in O
26 O
well O
compensated O
cirrhotic B
patients O
before O
and O
after O
an O
oral O
combination O
of O
50 O
mg O
of O
indomethacin O
and O
various O
doses O
of O
misoprostol O
. O

However O
, O
until O
this O
apparent O
ability O
of O
200 O
micrograms O
of O
misoprostol O
to O
prevent O
the O
adverse O
effects O
of O
indomethacin O
on O
renal O
function O
is O
confirmed O
with O
chronic O
frequent O
dosing O
, O
it O
would O
be O
prudent O
to O
avoid O
nonsteroidal O
anti O
- O
inflammatory O
therapy O
in O
patients O
with O
cirrhosis B
. O

Increased O
frequency O
and O
severity O
of O
angio B
- I
oedema I
related O
to O
long O
- O
term O
therapy O
with O
angiotensin O
- O
converting O
enzyme O
inhibitor O
in O
two O
patients O
. O

Adverse O
reactions O
to O
drugs O
are O
well O
recognized O
as O
a O
cause O
of O
acute O
or O
chronic O
urticaria B
, O
and O
angio B
- I
oedema I
. O

Angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
, O
used O
to O
treat O
hypertension B
and O
congestive B
heart I
failure I
, O
were O
introduced O
in O
Europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

Soon O
after O
the O
introduction O
of O
ACE O
inhibitors O
, O
acute O
bouts O
of O
angio B
- I
oedema I
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

We O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ACE O
inhibitors O
after O
long O
- O
term O
use O
and O
in O
patients O
with O
pre O
- O
existing O
angio B
- I
oedema I
. O

Transvenous O
right O
ventricular O
pacing O
during O
cardiopulmonary O
resuscitation O
of O
pediatric O
patients O
with O
acute O
cardiomyopathy B
. O

We O
describe O
the O
cardiopulmonary O
resuscitation O
efforts O
on O
five O
patients O
who O
presented O
in O
acute O
circulatory B
failure I
from O
myocardial B
dysfunction I
. O

These O
patients O
had O
a O
second O
event O
of O
cardiac B
arrest I
, O
resulting O
in O
death O
, O
within O
10 O
to O
60 O
minutes O
. O

We O
conclude O
that O
cardiac O
pacing O
during O
resuscitative O
efforts O
in O
pediatric O
patients O
suffering O
from O
acute O
myocardial B
dysfunction I
may O
not O
have O
long O
- O
term O
value O
in O
and O
of O
itself O
; O
however O
, O
if O
temporary O
hemodynamic O
stability O
is O
achieved O
by O
this O
procedure O
, O
it O
may O
provide O
additional O
time O
needed O
to O
institute O
other O
therapeutic O
modalities O
. O

OBJECTIVE O
: O
To O
report O
two O
cases O
of O
a O
possible O
adverse O
interaction O
between O
clonidine O
and O
verapamil O
resulting O
in O
atrioventricular B
( I
AV I
) I
block I
in O
both O
patients O
and O
severe O
hypotension B
in O
one O
patient O
. O

After O
the O
addition O
of O
a O
minimal O
dose O
of O
clonidine O
( O
0 O
. O
15 O
mg O
bid O
) O
, O
she O
developed O
complete O
AV B
block I
and O
severe O
hypotension B
, O
which O
resolved O
upon O
cessation O
of O
all O
medications O
. O

After O
the O
addition O
of O
clonidine O
0 O
. O
15 O
mg O
bid O
she O
developed O
complete O
AV B
block I
, O
which O
resolved O
after O
all O
therapy O
was O
stopped O
. O

S O
- O
312 O
, O
S O
- O
312 O
- O
d O
, O
but O
not O
S O
- O
312 O
- O
l O
, O
L O
- O
type O
calcium O
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic B
tonic I
convulsions I
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine O
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O

The O
patient O
had O
no O
history O
of O
underlying O
ischaemic B
heart I
disease I
or O
Prinzmetal B
' I
s I
angina I
. O

Mechanisms O
for O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
- O
mediated O
nephropathy B
in O
rats O
. O

Studies O
were O
performed O
to O
examine O
the O
mechanisms O
for O
the O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
( O
GM O
) O
- O
mediated O
nephropathy B
. O

Administration O
of O
GM O
at O
40 O
mg O
/ O
kg O
sc O
for O
13 O
days O
to O
rats O
induced O
a O
significant O
reduction O
in O
renal O
blood O
flow O
( O
RBF O
) O
and O
inulin O
clearance O
( O
CIn O
) O
as O
well O
as O
marked O
tubular B
damage I
. O

A O
significant O
reduction O
in O
urinary O
guanosine O
3 O
' O
, O
5 O
' O
- O
cyclic O
monophosphate O
( O
cGMP O
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin O
- O
1 O
contents O
were O
also O
observed O
in O
GM O
- O
mediated O
nephropathy B
. O

SOD O
did O
not O
attenuate O
the O
tubular B
damage I
. O

In O
contrast O
, O
DMTU O
significantly O
reduced O
the O
tubular B
damage I
and O
lipid O
peroxidation O
, O
but O
it O
did O
not O
affect O
renal O
hemodynamics O
and O
vasoactive O
substances O
. O

These O
results O
suggest O
that O
1 O
) O
both O
SOD O
and O
DMTU O
have O
protective O
effects O
on O
GM O
- O
mediated O
nephropathy B
, O
2 O
) O
the O
mechanisms O
for O
the O
protective O
effects O
differ O
for O
SOD O
and O
DMTU O
, O
and O
3 O
) O
superoxide O
anions O
play O
a O
critical O
role O
in O
GM O
- O
induced O
renal O
vasoconstriction O
. O

Cephalothin O
- O
induced O
immune O
hemolytic B
anemia I
. O

A O
patient O
with O
renal B
disease I
developed O
Coombs O
- O
positive O
hemolytic B
anemia I
while O
receiving O
cephalothin O
therapy O
. O

Careful O
investigation O
of O
drug O
- O
induced O
hemolytic B
anemias I
reveals O
the O
complexity O
of O
the O
immune O
mechanisms O
involved O
. O

The O
ability O
of O
cardiomyocytes O
to O
synthesize O
DNA O
in O
response O
to O
experimentally O
induced O
cardiac B
hypertrophy I
was O
assessed O
in O
adult O
mice O
. O

No O
DNA O
synthesis O
, O
as O
assessed O
by O
autoradiographic O
analysis O
of O
isolated O
cardiomyocytes O
, O
was O
observed O
in O
control O
or O
hypertrophic B
hearts I
. O

To O
determine O
whether O
the O
capacity O
for O
reactive O
DNA O
synthesis O
was O
also O
subject O
to O
genetic O
regulation O
, O
cardiac B
hypertrophy I
was O
induced O
in O
the O
strains O
of O
mice O
comprising O
the O
extremes O
of O
the O
nuclear O
number O
survey O
. O

These O
data O
indicate O
that O
adult O
mouse O
atrial O
and O
ventricular O
cardiomyocytes O
do O
not O
synthesize O
DNA O
in O
response O
to O
isoproterenol O
- O
induced O
cardiac B
hypertrophy I
. O

Indications O
for O
transplantation O
were O
idiopathic B
cardiomyopathy I
( O
52 O
% O
) O
, O
congenital B
heart I
disease I
( O
35 O
% O
) O
with O
and O
without O
prior O
repair O
( O
71 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
hypertrophic B
cardiomyopathy I
( O
5 O
% O
) O
, O
valvular B
heart I
disease I
( O
3 O
% O
) O
, O
and O
doxorubicin O
cardiomyopathy B
( O
5 O
% O
) O
. O

Cytomegalovirus B
infections I
were O
treated O
successfully O
with O
ganciclovir O
in O
11 O
patients O
. O

Twenty O
- O
one O
patients O
( O
60 O
% O
) O
have O
undergone O
annual O
catheterizations O
and O
no O
sign O
of O
graft O
atherosclerosis B
has O
been O
observed O
. O

No O
patient O
was O
disabled O
and O
no O
lymphoproliferative B
disorder I
was O
observed O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

In O
some O
cases O
, O
a O
high O
serum O
concentration O
of O
citalopram O
( O
> O
600 O
nmol O
/ O
L O
) O
in O
elderly O
patients O
has O
been O
associated O
with O
increased O
somnolence B
and O
movement B
difficulties I
. O

Widespread O
cognitive B
disorders I
, O
such O
as O
delirium B
, O
have O
not O
been O
previously O
linked O
with O
high O
blood O
levels O
of O
SSRIs O
. O

Pulmonary B
edema I
and O
shock B
after O
high O
- O
dose O
aracytine O
- O
C O
for O
lymphoma B
; O
possible O
role O
of O
TNF O
- O
alpha O
and O
PAF O
. O

It O
was O
characterized O
by O
the O
onset O
of O
fever B
, O
diarrhea B
, O
shock B
, O
pulmonary B
edema I
, O
acute B
renal I
failure I
, O
metabolic B
acidosis I
, O
weight B
gain I
and O
leukocytosis B
. O

As O
TNF O
and O
PAF O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock B
and O
adult B
respiratory I
distress I
syndrome I
, O
we O
hypothesize O
that O
high O
- O
dose O
Ara O
- O
C O
may O
be O
associated O
with O
cytokine O
release O
. O

Protective O
effect O
of O
clentiazem O
against O
epinephrine O
- O
induced O
cardiac B
injury I
in O
rats O
. O

We O
investigated O
the O
effects O
of O
clentiazem O
, O
a O
1 O
, O
5 O
- O
benzothiazepine O
calcium O
antagonist O
, O
on O
epinephrine O
- O
induced O
cardiomyopathy B
in O
rats O
. O

With O
2 O
- O
week O
chronic O
epinephrine O
infusion O
, O
16 O
of O
30 O
rats O
died O
within O
4 O
days O
, O
and O
severe O
ischemic B
lesions I
and O
fibrosis B
of O
the O
left O
ventricles O
were O
observed O
. O

Treatment O
with O
clentiazem O
prevented O
epinephrine O
- O
induced O
death O
( O
P O
< O
. O
05 O
) O
, O
and O
attenuated O
the O
ventricular O
ischemic B
lesions I
and O
fibrosis B
, O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
conclusion O
, O
clentiazem O
attenuated O
epinephrine O
- O
induced O
cardiac B
injury I
, O
possibly O
through O
its O
effect O
on O
the O
adrenergic O
pathway O
. O

The O
ischemia B
probably O
induced O
by O
coronary B
artery I
spasm I
was O
reversed O
by O
nitroglycerin O
and O
calcium O
blocking O
agents O
. O

After O
sacrifice O
the O
hearts O
of O
doxorubicin O
- O
treated O
animals O
were O
enlarged O
and O
the O
atria O
were O
hypertrophic B
. O

Milk B
- I
alkali I
syndrome I
induced O
by O
1 O
, O
25 O
( O
OH O
) O
2D O
in O
a O
patient O
with O
hypoparathyroidism B
. O

Milk B
- I
alkali I
syndrome I
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic B
ulcer I
disease I
with O
large O
amounts O
of O
calcium O
and O
alkali O
. O

Although O
with O
current O
ulcer B
therapy O
( O
H O
- O
2 O
blockers O
, O
omeprazole O
, O
and O
sucralfate O
) O
, O
the O
frequency O
of O
milk B
- I
alkali I
syndrome I
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia B
, O
alkalosis B
, O
and O
renal B
impairment I
remains O
the O
hallmark O
of O
the O
syndrome O
. O

Milk B
- I
alkali I
syndrome I
can O
present O
serious O
and O
occasionally O
life O
- O
threatening O
illness O
unless O
diagnosed O
and O
treated O
appropriately O
. O

This O
article O
presents O
a O
patient O
with O
hypoparathyroidism B
who O
was O
treated O
with O
calcium O
carbonate O
and O
calcitriol O
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk B
- I
alkali I
syndrome I
. O

This O
illustrates O
intravenous O
pamidronate O
as O
a O
valuable O
therapeutic O
tool O
when O
milk B
- I
alkali I
syndrome I
presents O
as O
hypercalcemic B
emergency I
. O

Encephalopathy B
during O
amitriptyline O
therapy O
: O
are O
neuroleptic B
malignant I
syndrome I
and O
serotonin B
syndrome I
spectrum O
disorders O
? O

This O
patient O
could O
have O
been O
diagnosed O
as O
having O
either O
neuroleptic B
malignant I
syndrome I
( O
NMS B
) O
or O
serotonin B
syndrome I
( O
SS B
) O
. O

Genetic O
separation O
of O
tumor B
growth O
and O
hemorrhagic B
phenotypes O
in O
an O
estrogen O
- O
induced O
tumor B
. O

Chronic O
administration O
of O
estrogen O
to O
the O
Fischer O
344 O
( O
F344 O
) O
rat O
induces O
growth O
of O
large O
, O
hemorrhagic B
pituitary B
tumors I
. O

Surprisingly O
, O
the O
F1 O
hybrid O
tumors B
were O
not O
hemorrhagic B
and O
had O
hemoglobin O
content O
and O
outward O
appearance O
identical O
to O
that O
of O
BN O
. O

Increased O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
in O
bladder O
afferent O
pathways O
following O
chronic O
bladder B
irritation I
. O

Immunocytochemical O
techniques O
were O
used O
to O
examine O
alterations O
in O
the O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
( O
NOS O
) O
in O
bladder O
pathways O
following O
acute O
and O
chronic O
irritation B
of I
the I
urinary I
tract I
of O
the O
rat O
. O

Effects O
of O
a O
new O
calcium O
antagonist O
, O
CD O
- O
832 O
, O
on O
isoproterenol O
- O
induced O
myocardial B
ischemia I
in O
dogs O
with O
partial O
coronary B
stenosis I
. O

Effects O
of O
CD O
- O
832 O
on O
isoproterenol O
( O
ISO O
) O
- O
induced O
myocardial B
ischemia I
were O
studied O
in O
dogs O
with O
partial O
coronary B
stenosis I
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine O
or O
diltiazem O
. O

In O
the O
presence O
of O
coronary B
artery I
stenosis I
, O
3 O
- O
min O
periods O
of O
intracoronary O
ISO O
infusion O
( O
10 O
ng O
/ O
kg O
/ O
min O
) O
increased O
heart O
rate O
and O
maximal O
rate O
of O
left O
ventricular O
pressure O
rise O
, O
which O
resulted O
in O
a O
decrease O
in O
percentage O
segmental O
shortening O
and O
ST O
- O
segment O
elevation O
of O
the O
epicardial O
electrocardiogram O
. O

The O
effect O
of O
recombinant O
human O
insulin O
- O
like O
growth O
factor O
- O
I O
on O
chronic O
puromycin O
aminonucleoside O
nephropathy B
in O
rats O
. O

We O
recently O
demonstrated O
that O
recombinant O
hGH O
exacerbates O
renal O
functional O
and O
structural O
injury O
in O
chronic O
puromycin O
aminonucleoside O
( O
PAN O
) O
nephropathy B
, O
an O
experimental O
model O
of O
glomerular B
disease I
. O

Therefore O
, O
we O
examined O
whether O
recombinant O
human O
( O
rh O
) O
IGF O
- O
I O
is O
a O
safer O
alternative O
for O
the O
treatment O
of O
growth B
failure I
in O
rats O
with O
chronic O
PAN O
nephropathy B
. O

rhIGF O
- O
I O
improved O
weight O
gain O
by O
14 O
% O
( O
p O
< O
0 O
. O
05 O
) O
, O
without O
altering O
hematocrit O
or O
blood O
pressure O
in O
rats O
with O
renal B
disease I
. O

Urinary O
protein O
excretion O
was O
unaltered O
by O
rhIGF O
- O
I O
treatment O
in O
rats O
with O
chronic O
PAN O
nephropathy B
. O

After O
12 O
wk O
, O
the O
inulin O
clearance O
was O
higher O
in O
rhIGF O
- O
I O
- O
treated O
rats O
, O
0 O
. O
48 O
+ O
/ O
- O
0 O
. O
08 O
versus O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
06 O
mL O
/ O
min O
/ O
100 O
g O
of O
body O
weight O
in O
untreated O
PAN O
nephropathy B
animals O
, O
p O
< O
0 O
. O
05 O
. O

The O
improvement O
in O
GFR O
was O
not O
associated O
with O
enhanced O
glomerular B
hypertrophy I
or O
increased O
segmental O
glomerulosclerosis B
, O
tubulointerstitial B
injury I
, O
or O
renal O
cortical O
malondialdehyde O
content O
. O

In O
rats O
with O
PAN O
nephropathy B
, O
administration O
of O
rhIGF O
- O
I O
increased O
IGF O
- O
I O
and O
GH O
receptor O
gene O
expression O
, O
without O
altering O
the O
steady O
state O
level O
of O
IGF O
- O
I O
receptor O
mRNA O
. O

In O
normal O
rats O
with O
intact O
kidneys O
, O
rhIGF O
- O
I O
administration O
( O
n O
= O
4 O
) O
did O
not O
alter O
weight O
gain O
, O
blood O
pressure O
, O
proteinuria B
, O
GFR O
, O
glomerular O
planar O
area O
, O
renal O
cortical O
malondialdehyde O
content O
, O
or O
glomerular O
or O
tubulointerstitial B
damage I
, O
compared O
with O
untreated O
animals O
( O
n O
= O
4 O
) O
. O

We O
conclude O
that O
: O
1 O
) O
administration O
of O
rhIGF O
- O
I O
improves O
growth O
and O
GFR O
in O
rats O
with O
chronic O
PAN O
nephropathy B
and O
2 O
) O
unlike O
rhGH O
, O
long O
- O
term O
use O
of O
rhIGF O
- O
I O
does O
not O
worsen O
renal O
functional O
and O
structural O
injury O
in O
this O
disease O
model O
. O

Nefiracetam O
is O
a O
novel O
pyrrolidone O
derivative O
which O
attenuates O
scopolamine O
- O
induced O
learning B
and I
post I
- I
training I
consolidation I
deficits I
. O

Prevention O
and O
treatment O
of O
endometrial B
disease I
in O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

The O
treatment O
regimens O
are O
described O
in O
74 O
patients O
with O
endometrial B
disease I
among O
850 O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

4 O
cases O
of O
endometrial B
carcinoma I
referred O
from O
elsewhere O
demonstrated O
the O
problems O
of O
inappropriate O
and O
unsupervised O
unopposed O
oestrogen O
therapy O
and O
the O
difficulty O
in O
distinguishing O
severe O
hyperplasia B
from O
malignancy B
. O

Cyclical O
low O
- O
dose O
oestrogen O
therapy O
with O
7 O
- O
- O
13 O
days O
of O
progestagen O
does O
not O
seem O
to O
increase O
the O
risk O
of O
endometrial B
hyperplasia I
or O
carcinoma B
. O

Lamivudine O
is O
effective O
in O
suppressing O
hepatitis B
B I
virus O
DNA O
in O
Chinese O
hepatitis O
B O
surface O
antigen O
carriers O
: O
a O
placebo O
- O
controlled O
trial O
. O

Lamivudine O
is O
a O
novel O
2 O
' O
, O
3 O
' O
- O
dideoxy O
cytosine O
analogue O
that O
has O
potent O
inhibitory O
effects O
on O
hepatitis B
B I
virus O
replication O
in O
vitro O
and O
in O
vivo O
. O

All O
36 O
patients O
receiving O
lamivudine O
had O
a O
decrease O
in O
hepatitis B
B I
virus O
( O
HBV O
) O
DNA O
values O
of O
> O
90 O
% O
( O
P O
< O
. O
001 O
compared O
with O
placebo O
) O
. O

There O
was O
no O
change O
in O
the O
hepatitis B
B I
e O
antigen O
status O
or O
in O
aminotransferase O
levels O
. O

Population O
- O
based O
study O
of O
risk O
of O
venous B
thromboembolism I
associated O
with O
various O
oral O
contraceptives O
. O

BACKGROUND O
: O
Four O
studies O
published O
since O
December O
, O
1995 O
, O
reported O
that O
the O
incidence O
of O
venous B
thromboembolism I
( O
VTE B
) O
was O
higher O
in O
women O
who O
used O
oral O
contraceptives O
( O
OCs O
) O
containing O
the O
third O
- O
generation O
progestagens O
gestodene O
or O
desogestrel O
than O
in O
users O
of O
OCs O
containing O
second O
- O
generation O
progestagens O
. O

All O
women O
who O
had O
a O
recorded O
diagnosis O
of O
deep B
- I
vein I
thrombosis I
, O
venous B
thrombosis I
not O
otherwise O
specified O
, O
or O
pulmonary O
embolus O
during O
the O
study O
period O
, O
and O
who O
had O
been O
treated O
with O
an O
anticoagulant O
were O
identified O
as O
potential O
cases O
of O
VTE B
. O

Of O
the O
83 O
cases O
of O
VTE B
associated O
with O
use O
of O
combined O
OCs O
, O
43 O
were O
recorded O
as O
deep B
- I
vein I
thrombosis I
, O
35 O
as O
pulmonary O
thrombosis B
, O
and O
five O
as O
venous B
thrombosis I
not O
otherwise O
specified O
. O

MK O
- O
801 O
augments O
pilocarpine O
- O
induced O
electrographic O
seizure B
but O
protects O
against O
brain B
damage I
in O
rats O
. O

The O
authors O
examined O
the O
anticonvulsant O
effects O
of O
MK O
- O
801 O
on O
the O
pilocarpine O
- O
induced O
seizure B
model O
. O

Intraperitoneal O
injection O
of O
pilocarpine O
( O
400 O
mg O
/ O
kg O
) O
induced O
tonic B
and I
clonic I
seizure I
. O

Scopolamine O
( O
10 O
mg O
/ O
kg O
) O
and O
pentobarbital O
( O
5 O
mg O
/ O
kg O
) O
prevented O
development O
of O
pilocarpine O
- O
induced O
behavioral O
seizure B
but O
MK O
- O
801 O
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
did O
not O
. O

An O
electrical O
seizure B
measured O
with O
hippocampal O
EEG O
appeared O
in O
the O
pilocarpine O
- O
treated O
group O
. O

Scopolamine O
and O
pentobarbital O
blocked O
the O
pilocarpine O
- O
induced O
electrographic O
seizure B
, O
MK O
- O
801 O
treatment O
augmented O
the O
electrographic O
seizure B
induced O
by O
pilocarpine O
. O

Brain B
damage I
was O
assessed O
by O
examining O
the O
hippocampus O
microscopically O
. O

Pilocarpine O
produced O
neuronal B
death I
in O
the O
hippocampus O
, O
which O
showed O
pyknotic O
changes O
. O

Pentobarbital O
, O
scopolamine O
and O
MK O
- O
801 O
protected O
the O
brain B
damage I
by O
pilocarpine O
, O
though O
in O
the O
MK O
- O
801 O
- O
treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

These O
results O
indicate O
that O
status B
epilepticus I
induced O
by O
pilocarpine O
is O
initiated O
by O
cholinergic O
overstimulation O
and O
propagated O
by O
glutamatergic O
transmission O
, O
the O
elevation O
of O
which O
may O
cause O
brain B
damage I
through O
an O
excitatory O
NMDA O
receptor O
- O
mediated O
mechanism O
. O

Paclitaxel O
, O
5 O
- O
fluorouracil O
, O
and O
folinic O
acid O
in O
metastatic O
breast B
cancer I
: O
BRE O
- O
26 O
, O
a O
phase O
II O
trial O
. O

5 O
- O
Fluorouracil O
plus O
folinic O
acid O
and O
paclitaxel O
( O
Taxol O
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast B
cancer I
patients O
. O

We O
performed O
a O
phase O
II O
trial O
of O
paclitaxel O
175 O
mg O
/ O
m2 O
over O
3 O
hours O
on O
day O
I O
followed O
by O
folinic O
acid O
300 O
mg O
over O
1 O
hour O
before O
5 O
- O
fluorouracil O
350 O
mg O
/ O
m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
TFL O
) O
in O
women O
with O
metastatic O
breast B
cancer I
. O

TFL O
is O
an O
active O
, O
well O
- O
tolerated O
regimen O
in O
metastatic O
breast B
cancer I
. O

Eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary B
artery I
disease I
, O
and O
20 O
with O
dilated B
cardiomyopathy I
) O
with O
inducible O
sustained O
ventricular B
tachycardia I
or O
ventricular B
fibrillation I
received O
oral O
d O
, O
l O
- O
sotalol O
to O
prevent O
induction O
of O
the O
ventricular B
tachyarrhythmia I
. O

Those O
patients O
in O
whom O
d O
, O
l O
- O
sotalol O
prevented O
induction O
of O
ventricular B
tachycardia I
or O
ventricular B
fibrillation I
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+ O
/ O
- O
18 O
months O
. O

One O
female O
patient O
with O
stable O
cardiac B
disease I
had O
recurrent O
torsades B
de I
pointes I
after O
2 O
years O
of O
successful O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

Treatment O
- O
related O
disseminated O
necrotizing O
leukoencephalopathy B
with O
characteristic O
contrast O
enhancement O
of O
the O
white O
matter O
. O

This O
report O
describes O
unique O
contrast O
enhancement O
of O
the O
white O
matter O
on O
T1 O
- O
weighted O
magnetic O
resonance O
images O
of O
two O
patients O
with O
disseminated O
necrotizing O
leukoencephalopathy B
, O
which O
developed O
from O
acute B
lymphoblastic I
leukemia I
treated O
with O
high O
- O
dose O
methotrexate O
. O

Necropsy O
of O
the O
first O
case O
revealed O
loss B
of I
myelination I
and O
necrosis B
of O
the O
white O
matter O
. O

Possible O
mechanisms O
causing O
such O
a O
leukoencephalopathy B
are O
discussed O
. O

Thrombotic B
complications O
in O
acute B
promyelocytic I
leukemia I
during O
all O
- O
trans O
- O
retinoic O
acid O
therapy O
. O

A O
case O
of O
acute B
renal I
failure I
, O
due O
to O
occlusion B
of I
renal I
vessels I
in O
a O
patient O
with O
acute B
promyelocytic I
leukemia I
( O
APL B
) O
treated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
ATRA O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

We O
report O
a O
case O
of O
acute B
renal I
failure I
in O
an O
APL B
patient O
treated O
with O
ATRA O
alone O
. O

After O
10 O
days O
of O
treatment O
, O
he O
developed O
acute B
renal I
failure I
that O
was O
completely O
reversible O
after O
complete O
remission O
of O
APL B
was O
achieved O
and O
therapy O
discontinued O
. O

The O
baby O
died O
of O
cerebral B
and I
pulmonary I
hemorrhage I
. O

The O
baby O
showed O
warfarin O
- O
induced O
embryopathy B
with O
nasal B
hypoplasia I
and O
stippled B
epiphyses I
( O
chondrodysplasia B
punctata I
) O
. O

Nasal B
hypoplasia I
with O
or O
without O
stippled B
epiphyses I
has O
now O
been O
reported O
in O
11 O
infants O
born O
to O
mothers O
treated O
with O
warfarin O
during O
the O
first O
trimester O
, O
and O
a O
causal O
association O
is O
probable O
. O

Effect O
of O
D O
- O
Glucarates O
on O
basic O
antibiotic O
- O
induced O
renal B
damage I
in O
rats O
. O

Dehydrated B
rats O
regularly O
develop O
acute B
renal I
failure I
following O
single O
injection O
of O
aminoglycoside O
antibiotics O
combined O
with O
dextran O
or O
of O
antibiotics O
only O
. O

Oral O
administration O
of O
2 O
, O
5 O
- O
di O
- O
O O
- O
acetyl O
- O
D O
- O
glucaro O
- O
1 O
, O
4 O
- O
6 O
, O
3 O
- O
dilactone O
protected O
rats O
against O
renal B
failure I
induced O
by O
kanamycin O
- O
dextran O
. O

D O
- O
Glucarates O
were O
effective O
against O
renal B
damage I
induced O
by O
peptide O
antibiotics O
as O
well O
as O
various O
aminoglycoside O
antibitocis O
. O

With O
a O
D O
- O
glucarate O
of O
a O
fixed O
size O
of O
dose O
, O
approximately O
the O
same O
degree O
of O
protection O
was O
obtained O
against O
renal B
damages I
induced O
by O
different O
basic O
antibiotics O
despite O
large O
disparities O
in O
administration O
doses O
of O
different O
antibiotics O
. O

D O
- O
Glucarates O
had O
the O
ability O
to O
prevent O
renal B
damage I
but O
not O
to O
cure O
it O
. O

Rats O
excreted O
acidic O
urine O
when O
they O
were O
spared O
from O
renal B
lesions I
by O
monosaccharides O
. O

A O
41 O
- O
year O
- O
old O
woman O
with O
a O
strong O
history O
of O
postoperative B
nausea I
and I
vomiting I
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron O
prophylaxis O
had O
been O
used O
. O

She O
had O
developed O
a O
severe O
acute O
major B
depression I
disorder I
almost O
immediately O
thereafter O
, O
possibly O
related O
to O
the O
use O
of O
a O
serotonin O
antagonist O
. O

Anaesthesia O
with O
a O
propofol O
infusion O
and O
avoidance O
of O
serotonin O
antagonists O
provided O
a O
nausea B
- O
free O
postoperative O
course O
without O
exacerbation O
of O
the O
depression B
disorder I
. O

The O
incidence O
of O
cardiac B
dysrhythmias I
was O
similar O
between O
groups O
. O

The O
following O
factors O
appear O
to O
predispose O
to O
the O
development O
of O
this O
complication O
: O
abnormal O
cerebrospinal O
dynamics O
related O
to O
the O
presence O
of O
central B
nervous I
system I
leukemia I
, O
and O
epidural O
cerebrospinal O
leakage O
; O
elevated O
cerebrospinal O
fluid O
methothexate O
concentration O
related O
to O
abnormal O
cerebrospinal O
fluid O
dynamics O
and O
to O
inappropriately O
high O
methotrexate O
doses O
based O
on O
body O
surface O
area O
calculations O
in O
older O
children O
and O
adults O
; O
the O
presence O
of O
neurotoxic B
preservatives O
in O
commercially O
available O
methotrexate O
preparations O
and O
diluents O
; O
and O
the O
use O
of O

The O
role O
of O
methotrexate O
contaminants O
, O
local O
folate B
deficiency I
, O
and O
cranial O
irradiation O
in O
the O
pathogenesis O
of O
intrathecal O
methotrexate O
toxicity B
is O
unclear O
. O

The O
incidence O
of O
neurotoxicity B
may O
be O
reduced O
by O
employing O
lower O
doses O
of O
methotrexate O
in O
the O
presence O
of O
central B
nervous I
system I
leukemia I
, O
in O
older O
children O
and O
adults O
, O
and O
in O
the O
presence O
of O
epidural O
leakage O
. O

Hyperosmolar B
nonketotic I
coma I
precipitated O
by O
lithium O
- O
induced O
nephrogenic B
diabetes I
insipidus I
. O

A O
45 O
- O
year O
- O
old O
man O
, O
with O
a O
10 O
- O
year O
history O
of O
manic B
depression I
treated O
with O
lithium O
, O
was O
admitted O
with O
hyperosmolar B
, I
nonketotic I
coma I
. O

After O
recovery O
from O
hyperglycaemia B
, O
he O
remained O
polyuric B
despite O
normal O
blood O
glucose O
concentrations O
; O
water O
deprivation O
testing O
indicated O
nephrogenic B
diabetes I
insipidus I
, O
likely O
to O
be O
lithium O
- O
induced O
. O

We O
hypothesize O
that O
when O
this O
man O
developed O
type B
2 I
diabetes I
, O
chronic O
polyuria B
due O
to O
nephrogenic B
diabetes I
insipidus I
was O
sufficient O
to O
precipitate O
hyperosmolar O
dehydration B
. O

BACKGROUND O
: O
In O
dogs O
, O
a O
large O
amount O
of O
intravenous O
cocaine O
causes O
a O
profound O
deterioration B
of I
left I
ventricular I
( I
LV I
) I
systolic I
function I
and O
an O
increase O
in O
LV O
end O
- O
diastolic O
pressure O
. O

CONCLUSIONS O
: O
In O
humans O
, O
the O
intracoronary O
infusion O
of O
cocaine O
sufficient O
in O
amount O
to O
achieve O
a O
high O
drug O
concentration O
in O
coronary O
sinus O
blood O
causes O
a O
deterioration B
of I
LV I
systolic I
and I
diastolic I
performance I
. O

Recorded O
were O
dose O
- O
limiting O
adverse O
events O
: O
hyper B
- I
or I
hypotension I
( O
three O
) O
, O
severe O
abdominal B
pain I
( O
0 O
) O
, O
vomiting B
( O
0 O
) O
and O
retained B
placenta I
( O
four O
) O
. O

Serious O
adverse O
events O
occurred O
in O
seven O
women O
: O
six O
cases O
with O
blood B
loss I
> O
or O
= O
1000 O
ml O
, O
four O
cases O
of O
manual O
placenta O
removal O
, O
five O
cases O
of O
additional O
oxytocics O
administration O
and O
five O
cases O
of O
blood O
transfusion O
. O

Maximum O
blood B
loss I
was O
greatest O
at O
the O
upper O
and O
lower O
dose O
levels O
, O
and O
lowest O
in O
the O
70 O
- O
125 O
microg O
dose O
range O
. O

Four O
out O
of O
six O
cases O
with O
blood B
loss I
> O
or O
= O
1000 O
ml O
occurred O
in O
the O
200 O
microg O
group O
. O

Heparin O
- O
induced O
thrombocytopenia B
, O
paradoxical O
thromboembolism B
, O
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

Important O
untoward O
effects O
of O
heparin O
therapy O
including O
heparin O
- O
induced O
thrombocytopenia B
, O
heparin O
- O
associated O
osteoporosis B
, O
eosinophilia B
, O
skin B
reactions I
, O
allergic B
reactions I
other O
than O
thrombocytopenia B
and O
alopecia B
will O
be O
discussed O
in O
this O
article O
. O

OBJECTIVE O
: O
We O
describe O
the O
unique O
CT O
features O
of O
ureteric B
calculi I
in O
six O
HIV B
- I
infected I
patients O
receiving O
indinavir O
, O
the O
most O
commonly O
used O
HIV O
protease O
inhibitor O
, O
which O
is O
associated O
with O
an O
increased O
incidence O
of O
urolithiasis B
. O

Images O
may O
need O
to O
be O
obtained O
using O
i O
. O
v O
. O
contrast O
material O
to O
enable O
diagnosis O
of O
ureteric B
stones I
or I
obstruction I
in O
patients O
with O
HIV B
infection I
who O
receive O
indinavir O
therapy O
. O

Ischemic B
colitis I
and O
sumatriptan O
use O
. O

Cases O
have O
been O
published O
of O
coronary B
vasospasm I
, O
myocardial B
ischemia I
, O
and O
myocardial B
infarction I
occurring O
after O
sumatriptan O
use O
. O

We O
report O
on O
the O
development O
of O
8 O
serious O
cases O
of O
ischemic B
colitis I
in O
patients O
with O
migraine B
treated O
with O
sumatriptan O
. O

51 O
patients O
with O
medically O
refractory O
Parkinson B
' I
s I
disease I
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
August O
1993 O
and O
February O
1997 O
for O
treatment O
of O
bradykinesia B
, O
rigidity B
, O
and O
L O
- O
DOPA O
- O
induced O
dyskinesias B
. O

Clinical O
assessment O
as O
well O
as O
blinded O
ratings O
of O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
( O
UPDRS O
) O
scores O
were O
carried O
out O
pre O
- O
and O
postoperatively O
. O

Gamma O
Knife O
pallidotomy O
is O
as O
effective O
as O
radiofrequency O
pallidotomy O
in O
controlling O
certain O
of O
the O
symptoms O
of O
Parkinson B
' I
s I
disease I
. O

This O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
guanethidine O
( O
5 O
mg O
) O
, O
hexamethonium O
( O
10 O
mg O
) O
or O
phentolamine O
( O
5 O
mg O
) O
, O
and O
conversely O
, O
potentiated O
by O
i O
. O
v O
. O
desmethylimipramine O
( O
0 O
. O
3 O
mg O
) O
, O
while O
propranolol O
( O
0 O
. O
5 O
mg O
) O
i O
. O
v O
. O
selectively O
inhibited O
the O
enlargement B
of I
pulse I
pressure I
and O
the O
tachycardia B
following O
i O
. O
c O
. O
carbachol O
( O
1 O
mug O
) O
. O

Neuroleptic B
malignant I
syndrome I
and O
methylphenidate O
. O

A O
1 O
- O
year O
- O
old O
female O
presented O
with O
neuroleptic B
malignant I
syndrome I
probably O
caused O
by O
methylphenidate O
. O

She O
had O
defects O
in O
the O
supratentorial O
brain O
including O
the O
basal O
ganglia O
and O
the O
striatum O
( O
multicystic B
encephalomalacia I
) O
due O
to O
severe O
perinatal O
hypoxic B
- I
ischemic I
encephalopathy I
, O
which O
was O
considered O
to O
be O
a O
possible O
predisposing O
factor O
causing O
neuroleptic B
malignant I
syndrome I
. O

This O
is O
the O
first O
reported O
patient O
with O
neuroleptic B
malignant I
syndrome I
probably O
caused O
by O
methylphenidate O
. O

Long O
- O
term O
efficacy O
and O
adverse O
event O
of O
nifedipine O
sustained O
- O
release O
tablets O
for O
cyclosporin O
A O
- O
induced O
hypertension B
in O
patients O
with O
psoriasis B
. O

Thirteen O
psoriatic B
patients O
with O
hypertension B
during O
the O
course O
of O
cyclosporin O
A O
therapy O
were O
treated O
for O
25 O
months O
with O
a O
calcium O
channel O
blocker O
, O
sustained O
- O
release O
nifedipine O
, O
to O
study O
the O
clinical O
antihypertensive O
effects O
and O
adverse O
events O
during O
treatment O
with O
both O
drugs O
. O

The O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin O
A O
and O
nifedipine O
included O
an O
increase O
in O
blood O
urea O
nitrogen O
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival B
hyperplasia I
in O
2 O
of O
the O
13 O
patients O
. O

Our O
findings O
indicate O
that O
sustained O
- O
release O
nifedipine O
is O
useful O
for O
hypertensive B
psoriatic B
patients O
under O
long O
- O
term O
treatment O
with O
cyclosporin O
A O
, O
but O
that O
these O
patients O
should O
be O
monitored O
for O
gingival B
hyperplasia I
. O

